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introdUction
background
Asthma is the most common chronic disease in childhood. Worldwide, 14% of all children 
aged 6 to 14 years report asthmatic symptoms in the last year.1 In the Netherlands, the 
estimated cumulative asthma prevalence in children aged 5-18 years is 8.1%.2 Severe 
childhood asthma is associated with an up to 32-fold increased risk of chronic obstruc-
tive pulmonary disease (COPD) in later life.3 Asthma and COPD account for 6% of global 
mortality.4
Asthma is an inflammatory disease that most commonly develops in childhood and 
affects both the large and small airways. Children with asthma have periods of general-
ized airway obstruction, caused by smooth-muscle spasms, increased mucus secretion 
and inflammation of the airways.5 Clinical presentation of childhood asthma comprises 
periods of combined coughing, wheezing and breathlessness, which are reported in 39% 
of all children on the day before an asthma exacerbation.6 In most cases, the first asthma-
symptoms occur from a young age onwards7, and symptom severity and lung function 
deficits track with age.8 Lower lung function or asthma in childhood might predispose for 
chronic obstructive respiratory diseases, including COPD, in adolescence and adult life.9, 10
The strongest predictor of asthma is chronic airflow limitation.11, 12 Children are able to 
perform spirometry from approximately 6 years onwards.13 Spirometry measurements 
in children with asthma show airway obstruction characterized by lower expiratory 
airflow rates with a lower forced expiratory volume in 1 second (FEV1) and FEV1/forced 
vital capacity (FVC).14 The measurement of respiratory resistance using the interrupter 
technique (Rint) is a method that could successfully be applied to children below age 
6 years. The Rint-technique has good repeatability and biological validity for the detec-
tion of airway obstruction.15 Additionally, markers of inflammation could be measured 
in exhaled air of children of all ages. Fractional Exhaled Nitric Oxide (FeNO) is a marker of 
eosinophilic inflammation in the airways, and is one of the strongest single biomarkers 
associated with childhood wheezing and asthma.16, 17 Although effective treatments 
are available for asthma symptoms, the morbidity of asthma and COPD remains high. 
The lack of curative options is mainly due to the largely unknown pathophysiological 
mechanisms.5 Therefore, it is important to identify risk factors and mechanisms which 
may lead to lower lung function, predisposing the individual for an increased risk of 
chronic obstructive respiratory diseases across the life course.
Over the past decades, multiple factors in early life, such as growth, environmental 
exposures and genetic susceptibility have been associated with respiratory symptoms 
in early childhood, and asthma and COPD at older ages.18 Epigenetic mechanisms, which 
refer to changes in gene expression that does not involve changes to the underlying 
DNA-sequence, have been suggested as a potential underlying mechanism.18, 19
18
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growth
Children born extremely preterm or with a low birth weight have high rates of neonatal 
respiratory diseases, such as infant respiratory distress syndrome and bronchopulmo-
nary dysplasia.20 Recent prospective studies in children suggest that also preterm birth, 
small size for gestational age at birth, and accelerated weight growth in the first months 
of infancy are associated with increased risks of childhood wheezing and asthma.21 The 
associations of early growth characteristics with chronic obstructive respiratory diseases 
might be explained by developmental adaptations of the lungs and airways, leading 
to relatively small airways and hence a reduction in expiratory flows reflected by lower 
lung function values.18 Previous studies examining associations between early growth 
characteristics and childhood lung function have reported inconsistent results.22-24 To 
further understand the causal pathways between early growth characteristics and child-
hood asthma, it is important to unravel whether lower lung function measures explain 
these associations.
Birth weight is the result of fetal weight growth, and the starting point for infant 
weight growth. Detailed information about growth throughout pregnancy and infancy 
enables identification of periods in early life, which might be critical for development of 
respiratory morbidity in later life.18 Most studies that focused on the associations of fetal 
growth with childhood lung function or asthma did not take infant growth into account, 
and vice versa. This limits conclusions because fetal and infant growth are correlated.25 
Studies focused on combined fetal and infant growth patterns in relation to childhood 
respiratory morbidity are scarce, limited to young ages only and differ in definitions of 
fetal and infant growth patterns or asthma-related outcomes.26, 27 Additionally, children’s 
current body mass index (BMI) and atopy might affect associations of fetal and infant 
growth with childhood lung function and asthma. This warrants further studies.
Early growth characteristics are associated with an increased risk of obesity in later life 
28 and obesity is hypothesized to be associated with asthma.29 An increased BMI could 
reduce the pulmonary vital capacity by mechanical pressure, and increase obstruction-
related respiratory resistance and the risk of asthma symptoms.29 Alternatively, a higher 
BMI could lead to an increased production of systemic pro-inflammatory mediators by 
fat tissue, with subsequent airway inflammation.29 The major limitation of BMI is that 
it does not distinguish fat mass from free-fat mass, while it is suggested that specific 
fat mass distribution is more strongly associated with adverse health risks. Studies that 
assessed detailed adiposity measures are scarce and are mainly performed in adult 
populations. Further understanding of the associations of childhood BMI and detailed 
body fat measures with childhood lung function and asthma will provide further insight 
on pathophysiological mechanisms.
By exploration of potential pathways explaining the associations between early 
growth characteristics with childhood asthma, identification of specific growth periods 
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in early life which might be critical for development of respiratory morbidity in later 
life, and the effects of body composition in later life, we will expand current knowledge 
on the pathophysiological mechanisms linking growth and development of childhood 
lung function and asthma.
environmental exposures
The knowledge on the role of environmental exposures in the developmental origins 
of health and disease emerges quickly.30 Insight into environmental exposures during 
pregnancy and early childhood that affect lung development and asthma provides an 
opportunity for interventions at the time when they have their greatest effect. Maternal 
smoking during pregnancy is strongly associated with fetal growth retardation, preterm 
birth and lower birth weight.31, 32 Evidence suggests that fetal tobacco smoke exposure 
might also have a direct effect on lung development, which may include suboptimal 
development of the respiratory tract, resulting in impaired lung growth with smaller 
airway diameters leading to a higher respiratory resistance.33 Maternal smoking during 
pregnancy has been associated with wheezing up to age 4 years.34, 35 Previous studies on 
the adverse effect of maternal smoking during pregnancy on childhood lung function 
and asthma at older ages are inconsistent.36, 37 Furthermore, it is unknown whether as-
sociations could be explained by early growth characteristics.
Folic acid supplement use during pregnancy is recommended to prevent neural tube 
defects.38 Folic acid supplement use and related folate concentrations in blood, but also 
vitamin B12 and homocysteine, are involved in the one-carbon metabolism, necessary 
for multiple physiological processes, including biosynthesis, amino acid homeostasis 
and epigenetic changes to the DNA.39, 40 The genetic variant C677T in the methylenetet-
rahydrofolate reductase gene (MTHFR) is known to affect circulating folate, vitamin B12 
and homocysteine concentrations.41 Increased intake of folic acid supplements during 
pregnancy has been associated with increased risks of asthma and allergic diseases in 
the offspring in animal studies.42 Human studies show conflicting results 43, and the 
modifying effects of maternal or child’s MTHFR-C677T variants on the associations of 
maternal folic acid supplement use, folate, vitamin B12 and homocysteine blood concen-
trations during pregnancy with lung function and asthma are unclear.44-46
Prolonged and exclusive breastfeeding have been suggested to be associated with 
a decreased risk of asthma symptoms in early childhood with a possible diminishing 
effect over time.47 Underlying mechanisms for the association of breastfeeding with 
asthma symptoms might include secretory factors in breast milk that stimulate the 
neonatal immune system, and change the balance between pro- and anti-inflammatory 
mechanisms.48 This might lead to altered airway inflammation or airway resistance. 
Previous studies suggest a potential mediating role of inhalant allergies and respiratory 
tract infections.47 More detailed asthma phenotyping and use of objective measure-
20
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ments, such as asthma related lung function tests, might improve the understanding of 
the potential protective effect of breastfeeding. Furthermore, observing dose-response 
relationships based on breastfeeding duration or exclusivity would support the causal-
ity of the association of breastfeeding with childhood asthma.
Thus, exploration of the associations of maternal tobacco smoke exposure during 
pregnancy, use of folic acid supplements during pregnancy and lack of breastfeed-
ing might provide new insights on pathophysiological pathways of environmental 
exposures on development of childhood lung function and asthma, and could enable 
targeted interventions.
genetic susceptibility
Family studies have shown that lung function is a heritable trait for 30-50% 49, and 
asthma for up to 75%.50 However, the role of genetic factors on respiratory morbidity 
on an individual population-based level is unclear. In the past decade a methodology 
has been introduced to study the genetics of complex non-Mendelian diseases, the 
genome-wide association (GWA) study. GWA studies test associations between a large 
number (~10 million) of genetic variants and predefined phenotypes in a hypothesis-
free manner. Recent GWA studies identified many common genetic variants associated 
with asthma-related outcomes, including childhood onset asthma 51, 52, adult asthma 
52-54, impaired lung function 55-57 and atopy.58-60 Overall, current studies have identified 
313 different genetic variants associated with asthma (Figure 1.1). However, asthma is 
unlikely to be a single disease but rather a series of complex, overlapping individual 
diseases or phenotypes, each defined by its unique interaction between genetic and 
environmental factors.61 This suggests that a more detailed defined phenotype might 
represent a specific pathogenic mechanism, and thus, focusing on a more specific phe-
notype may increase the power of genetic studies. As individuals with severe asthma-
exacerbations at young age are highly susceptible to lower lung function and increased 
risk of chronic obstructive respiratory diseases in later life 3, identification of genetic 
variants associated with severe asthma exacerbations in childhood will provide new 
knowledge on the genetic mechanisms affecting respiratory morbidity and mortality 
across the life course.
Previously, three meta-analyses of GWA studies have identified 35 genetic variants 
to be associated with lung function in adults of European ancestry.55-57, 62 Adult asthma 
and COPD are partly the result of lung development in childhood and adolescence, in 
which the pattern of lung function growth and decline is an important determinant of 
lung function and respiratory health in adulthood.10 Both reduced growth resulting in a 
low maximal level of lung function and early decline are associated with the subsequent 
development of chronic airflow obstruction.10 It is not known whether the identified 
genetic variants associated with adult lung function already affect lung function in 
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childhood, thereby predisposing the individual for chronic obstructive respiratory 
diseases at an older age.
epigenetics
Asthma is explained by both environmental exposures and genetic susceptibility.63 
Pathways of environmental exposures, such as tobacco smoke exposure during preg-
nancy, lack of breastfeeding and folic acid that affect lung development and risk of 
chronic obstructive respiratory diseases might be modified by genetic susceptibility. 
Identified genetic variants associated with childhood asthma in large-scale GWA studies 
only account for a low fraction of variance, up to 7.5%.64 Epigenetic mechanisms could 
link the role of environmental exposures with the unexplained heritability for childhood 
asthma.65, 66 The term epigenetics literally translates into “outside conventional genetics”, 
and refers to changes in DNA structure that does not involve changes to the underlying 
DNA-sequence.19 Multiple epigenetic mechanisms, including DNA-methylation, histone 
modification, and non-coding RNA-associated gene silencing are considered to initiate 
and sustain epigenetic changes.67 Current advances in assays to assess DNA-methylation 
have enabled the study of methylation status of >480,000 sites (CpGs) in the genome 
with a good genomic coverage and requirement of low amounts of DNA, making it ideal 
for use in large cohorts. DNA-methylation of genetic regions could modify the expres-
sion of nearby genes.68
DNA-methylation occurs by the addition of a methyl-group to DNA and is a natural 
occurrence, but is also influenced by several environmental exposures, such as tobacco 
smoke and folic acid.69 Folate provides methyl groups for a range of biochemical mecha-
nisms, including DNA-methylation.70 Fetal development is characterized by high rates of 
DNA-methylation changes and rapid organ development.18 Whether periconceptional 
maternal folate levels may alter fetal DNA-methylation levels reflected at birth needs to 
be studied.
Subsequently, altered DNA-methylation at birth may affect gene expression and 
related respiratory tract development, predisposing individuals for obstructive airway 
diseases in later life.9, 71 Studies that examined associations of DNA-methylation with 
lung function, asthma or COPD are scarce, limited to candidate genes or high-risk popu-
lations and lack replication. Identification of genomic regions with altered DNA-meth-
ylation levels related to lung function and respiratory diseases across the life course is 
important to understand underlying mechanisms of environmental and genetic factors 
that influence the development of lower lung function and risk of respiratory diseases.
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HYPotHesis
The hypothesis of this thesis is that early growth and adverse environmental exposures 
in fetal life and infancy, in combination with genetic susceptibility, lead to structural and 
functional adaptations in early lung development, and eventually lower lung function 
and higher risk of chronic obstructive respiratory diseases in later life (Figure 1.2). These 
pathways might be explained by epigenetic mechanisms.
obJectiVes
The major aims of this thesis are:
1. To identity which fetal, birth, infant, and child’s growth or body composition charac-
teristics are associated with childhood lung function and asthma.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENETIC SUSCEPTIBILIBY 
Single Nucleotide Polymorphisms 
Genome-wide associations 
Genetic risk scores 
GROWTH 
Fetal and infant growth 
Low birth weight, preterm birth 
Child’s adiposity 
LOWER LUNG FUNCTION  
IN CHILDHOOD 
CHRONIC OBSTRUCTIVE RESPIRATORY DISEASES  
IN CHILD- AND ADULTHOOD 
ENVIRONMENTAL FACTORS 
Fetal exposures 
Maternal smoking, supplement use  
Infant’s exposures 
Breastfeeding 
EPIGENETICS 
DNA-methylation 
figure 1.2. Overview of the early origins of chronic obstructive respiratory diseases and its potential un-
derlying early growth, environmental and (epi)genetic mechanisms studies in this thesis.
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2. To assess whether early life environmental exposures, including maternal tobacco 
smoking, folate, vitamin B12 and homocysteine concentrations, and child’s breast-
feeding, are related to childhood lung function and asthma.
3. To identify genetic and epigenetic variants related to childhood lung function and 
asthma, and epigenetics variants explaining the associations of environmental expo-
sures with chronic obstructive respiratory disease outcomes across the life course.
generAl design
The studies presented in this thesis were embedded in a population-based prospective 
cohort study, the Generation R Study, and international collaboration projects.
the generation r study
The Generation R Study is a population-based prospective cohort study in Rotterdam, 
the Netherlands, following pregnant women and their children from fetal life onwards 
(www. generationr.nl). The study is designed to identify early environmental and genetic 
causes and causal pathways leading to normal and abnormal growth, development and 
health during fetal life, childhood and adulthood. Enrolment was aimed in first trimester, 
but was allowed until birth of the child (Figure 1.3). In total, 9,778 mothers with a de-
livery date from April 2002 until January 2006 were enrolled in the study, and response 
at baseline was 61%.72 Data collection for the current thesis included fetal ultrasounds 
examinations during each trimester of pregnancy for fetal growth, detailed infant physi-
cal examinations, questionnaires for environmental exposures, and biological samples 
including cord blood for DNA and DNA- methylation.73
Child’s DNA and DNA-methylation was extracted from white cells in cord blood. DNA 
Samples were genotyped using Illumina Infinium II HumanHap610-660 Quad Arrays 
following standard manufacturer’s protocols. Bisulfite conversion in DNA-methylation 
samples was performed using the EZ-96 DNA Methylation kit (Zymo Research Corpora-
tion, Irvine, USA), after which samples were processed with the Infinium HumanMeth-
ylation450 BeadChip (Illumina Inc., San Diego, USA) followed quality control, probe 
exclusion and data normalization.
Information on birth characteristics was obtained from midwife and hospital regis-
tries. During the preschool years (from birth until the age of 4 years) information was 
mainly obtained from postal questionnaires including questions adapted from the 
International Study on Asthma and Allergy in Childhood (ISAAC). Growth data was 
collected at community health centers. At the age of 6 years, asthma diagnosis was 
obtained by questionnaire. Additional detailed hands-on assessments were performed 
in a dedicated research center to measure length, weight, body composition and body 
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fat distribution, Fractional exhaled Nitric Oxide (FeNO) and airway resistance (Rint). 
At age 10 years, length and weight were measured, lung function was assessed using 
spirometry according to the American Thoracic Society / European Respiratory Society 
(ATS/ERS) guidelines, and inhalant allergic sensitization was measured using skin prick 
testing. Furthermore, parental questionnaires provided information on ever physician-
Enrolment 
From early pregnancy until after birth 
Fetal period 
Physical examinations, including repeated ultrasounds 
for fetal growth, parental anthropometrics. 
Questionnaires on parental health, life style habits 
Maternal blood samples 
Birth 
Information on birth obtained from midwives and 
hospital records 
Cord blood collection for DNA extraction, genotyping, 
and assessment of DNA-methylation 
Preschool period (0-4 years) 
Visits to child health care centers for anthropometrics 
Questionnaires on child’s life style and health, including 
wheezing 
Childhood period (5-6 years)  
Hands on assessments for body composition, Rint, FeNO 
Questionnaires on child’s life style and health, including 
wheezing and asthma 
Childhood period (9-10 years) 
Hands on assessments for anthropometrics, spirometry 
Biological samples in children 
Questionnaires on child’s lifestyle and health, including 
wheezing and asthma 
figure 1.3. Design and data collection in the Generation R Study.
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diagnosed asthma, and respiratory symptoms and use of inhalant medication in the 
past 12 months (Figure 1.3). With the available data in Generation R, we assessed the 
associations of early growth, early environmental exposures in fetal life and early child-
hood, and genetics and epigenetics with childhood lung function and asthma outcomes 
at ages 6 and 10 years.
cHicos consortium
We conducted a meta-analysis focused on the associations of early growth characteristics 
with childhood lung function and asthma with partners participating in the framework 
of the European consortium CHICOS (Child Cohort Research Strategy for Europe, www.
chicosproject.eu). The overall aim of CHICOS is to improve child health across Europe 
by developing an integrated strategy for mother-child cohort research in Europe. Euro-
pean population-based birth- and mother-child cohorts were able to participate if they 
included children born between 1989 and 2011, had information available on at least 
gestational age and weight at birth and lung function measurements and asthma in 
childhood (until age 18 years), and were willing and able to exchange original data. We 
selected cohorts from both the CHICOS Consortium and other existing collaborations or 
birth cohorts (www.birthcohorts.net).
PAce consortium
We conducted two Epigenome Wide Association Studies (EWAS) with partners collabo-
rating in the Pregnancy and Child Epigenetics (PACE) Consortium. The aim of the PACE 
consortium is to facilitate joint analyses of DNA-methylation data in relation to a wide 
range of exposures and outcomes pertinent to health in pregnancy and childhood by 
bringing together researchers and by leveraging existing knowledge, skills and data. 
We first assessed the association of maternal folate levels during pregnancy with DNA-
methylation in cord blood in collaboration with a Norwegian cohort and investigators 
of the National Institute of Environmental Health Sciences (NIEHS). Next, we assessed 
the associations of DNA-methylation in cord blood with lung function in childhood. 
Population-based birth- and mother-child cohorts were able to participate in the meta-
analysis if they had information available on DNA-methylation in cord blood assessed 
with the Illumina Infinium HumanMethylation450 BeadChip array and lung function 
measurements in childhood (until age 18 years). Replication of the findings in older 
subjects, associations with asthma and COPD and differential expression was sought in 
existing collaborations with infant-, adolescent- and adult cohorts.
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oUtline of tHis tHesis
chapter 2 focuses on associations of early growth with childhood lung function and 
asthma. Chapter 2.1. presents a meta-analysis on the associations of preterm birth, birth 
weight and infant growth with childhood lung function and asthma. In Chapter 2.2, 
the associations of fetal and infant growth patterns with lung function and school-age 
respiratory morbidity are presented. The associations of detailed body fat measures 
with lung function, wheezing and asthma at age 6 years are explored in Chapter 2.3. 
In chapter 3, the effect of early exposures on childhood lung function and asthma are 
described. Chapter 3.1 presents the influence of maternal smoking during pregnancy on 
lung function, wheezing and asthma at school-age. The associations of maternal folic 
acid supplement use, and folate, vitamin B12 and homocysteine levels in pregnancy and 
at birth with lung function and asthma in childhood are presented in Chapter 3.2. The 
associations of breastfeeding duration and exclusivity with lung function, wheezing and 
asthma at school-age are reported in Chapter 3.3. chapter 4 focuses on associations 
of genetic variants with lung function and asthma in childhood, and the role of DNA-
methylation on the association of environmental exposures and genetic variants with 
lung function and chronic obstructive respiratory diseases. In Chapter 4.1, the discovery 
of a new genetic locus associated with severe childhood asthma is described. Chapter 
4.2 presents the associations of a genetic risk score based on genetic variants for adult 
lung function with childhood lung function and asthma. Chapter 4.3 presents the as-
sociations of maternal folic acid levels during pregnancy with child’s epigenome-wide 
DNA-methylation status at birth, measured in cord blood. In Chapter 4.4, the associations 
of epigenome-wide DNA-methylation at birth with lung function and chronic obstruc-
tive respiratory diseases throughout the life course is described. The main findings and 
implications described in this thesis are discussed in the general discussion in chapter 
5, followed by a English and Dutch summary in chapter 6.
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AbstrAct
background Children born preterm or with a small-size-for-gestational-age are at 
increased risk for childhood asthma.
objective To assess the hypothesis that these associations are explained by reduced 
airway patency.
methods We used individual participant data of 24,938 children from 24 birth cohorts to 
examine and meta-analyze the associations of gestational age, size-for-gestational-age, 
and infant weight gain with childhood lung function and asthma (age range 3.9 – 19.1 
years). Second, we explored whether these lung function outcomes mediated the as-
sociations of early growth characteristics with childhood asthma.
results Children born with a younger gestational age had a lower forced expiratory 
volume in 1 second (FEV1), FEV1/forced vital capacity (FEV1/FVC), and forced expiratory 
volume after exhaling 75% of vital capacity (FEF75), whereas those born with a smaller 
size-for-gestational-age at birth had lower FEV1 but higher FEV1/FVC (p-values<0.05). 
Greater infant weight gain was associated with higher FEV1, but lower FEV1/FVC and 
FEF75 in childhood (p-values<0.05). All associations were present across the full range 
and independent of other early life growth characteristics. Preterm birth, low birth 
weight and greater infant weight gain were associated with an increased risk of child-
hood asthma (pooled odds ratio (95% CI): 1.34 (1.15, 1.57), 1.32 (1.07, 1.62) and 1.27 
(1.21, 1.34), respectively). Mediation analyses suggested that FEV1, FEV1/FVC and FEF75 
may explain 7 (2, 10)% to 45 (15, 81)% of the associations between early growth charac-
teristics and childhood asthma.
conclusions Younger gestational age, smaller size-for-gestational-age, and greater 
infant weight gain were across the full ranges associated with childhood lung function. 
These associations explain to a substantial extent the risk of childhood asthma.
Early growth characteristics and the risk of reduced lung function and asthma
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.1
introdUction
Children born extremely preterm or with a low birth weight have high rates of neonatal 
respiratory diseases such as infant respiratory distress syndrome and bronchopulmonary 
dysplasia.1 An accumulating body of evidence suggests that these children also have an 
increased risk of chronic obstructive respiratory diseases in adulthood.2 More recent, 
prospective studies in children suggest that preterm birth and small size for gestational 
age at birth increase the risk of childhood asthma.3 Recent results of a meta-analysis of 
individual participant data of 147,000 children participating in prospective birth cohort 
studies showed consistent associations of younger gestational age at birth and greater 
infant weight gain with childhood asthma.4 The associations of lower birth weight 
with childhood asthma seem to be largely explained by gestational age at birth.4 The 
mechanisms underlying the associations of early growth characteristics with childhood 
asthma are not known yet. Airway caliber is a key determinant of total airway resistance. 
A reduced airway caliber could result in airway obstruction that predisposes to asthma 
and chronic obstructive pulmonary diseases.5-7 Therefore, we hypothesized that the as-
sociations of early growth characteristics with childhood asthma might be explained by 
developmental adaptations of the lungs and airways, leading to relatively small airways 
and, hence, a reduction in expiratory flows reflected by lower lung function values.8 Thus 
far, previous studies focused on the associations of birth weight and infant weight gain 
with childhood lung function have reported inconsistent results.9-16 These inconsistent 
results might be due to the different ages at which spirometry was performed, and not 
taking other early growth characteristics or potential confounders into account.
To test the hypothesis that the associations of early life growth characteristics with 
childhood asthma are explained by reduced airway patency, we performed an individual 
participant data meta-analysis of 24,938 children from 24 birth cohort studies. We exam-
ined the strength, consistency, and independence of the associations of gestational age 
at birth, birth weight and infant weight gain with lung function outcomes in childhood 
and whether these lung function outcomes explain the previously reported associations 
of early growth characteristics with risk of childhood asthma.
metHods
sources of data
European population-based birth- and mother-child cohorts participated if they 
included children born between 1989 and 2011, had information available on at least 
gestational age and weight at birth and lung function measurements in childhood 
(until age 18 years), and were willing and able to exchange original data.4 We identi-
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fied 50 European cohorts selected from existing collaborations on childhood health or 
asthma-related outcomes (www.chicosproject.eu, www.birthcohortsenrieco.net, www.
ga2len.org, and www.birthcohorts.net) accessed until May 29, 2012). In total, 24 cohorts, 
comprising data on 24,938 children, fulfilled the criteria (S-figure 2.1.1).
Information about gestational age and weight at birth and weight in the first year of 
life was obtained by measurements, medical registries or parental questionnaires (S-
table 2.1.1). We created gestational age-adjusted birth weight standard deviation scores 
(birth weight SDS) based on European reference values.17 Infant weight gain in the first 
year was defined as the difference between weight at age 1 year (range 6-18 months) 
and weight at birth, divided by the number of months between these two measure-
ments. Standard deviation scores (SDS) for age-specific infant weight gain were derived 
by intra-cohort means and standard deviations.18 Cohort specific growth characteristics 
are given in the Supplemental Material (S-table 2.1.2).
All cohorts obtained lung function measurements by spirometry, of which 22 accord-
ing to the recent guidelines of the American Thoracic Society / European Respiratory So-
ciety (ATS/ERS)19-21, and 2 according to earlier guidelines of the ATS 22 or ERS and European 
Coal and Steel Community 23 (S-table 2.1.1). If cohorts had collected lung function data 
at multiple time points (n = 6 cohorts), we used the measurement closest to the mean 
age of children (8.5 years) in the full meta-analysis. Variables for analyses were forced 
vital capacity (FVC), forced expiratory volume in 1 second (FEV1), forced mid-expiratory 
flow (FEF25–75) and forced expiratory flow after exhaling 75% of the vital capacity (FEF75). 
We mainly focused on FEV1, FEV1/FVC, and FEF75, which reflect reduced airway patency 
in obstructive lung diseases such as asthma or bronchopulmonary dysplasia due to 
preterm birth or low birth weight.24, 25 All lung function variables were converted into 
sex-, height-, age-, and ethnicity (Caucasian versus non-Caucasian) -adjusted Z-scores 
based on the Global Lung Initiative reference values.26 Asthma (yes / no) was defined as 
ever physician diagnosed asthma, and was obtained by medical registries (2 cohorts) or 
parental questionnaires adapted from the International Study on Asthma and Allergy 
in Childhood (ISAAC) 27 (22 cohorts) at the age of spirometry (S-table1). Cohort specific 
characteristics of lung function measurements and asthma are given in the Supplemen-
tal Material (S-table 2.1.3).
We included covariates based on known associations with childhood lung function 
from previous studies.28, 29 Information on covariates was mainly assessed by question-
naires (S-table 2.1.1). Potential confounders included maternal educational level, smok-
ing during pregnancy, smoking during infancy of their offspring, history of asthma or 
atopy, child’s sex, siblings, day care attendance in the first 2 years of life, breastfeeding, 
lower respiratory tract infections in the first 2 years of life, eczema, inhalant allergies, and 
body mass index (BMI) at the moment of lung function measurement. Cohort specific 
characteristics of all covariates are given in the Supplemental Material (S-tables 2.1.4-5).
Early growth characteristics and the risk of reduced lung function and asthma
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statistical analysis
First, we conducted 1-stage random effect regression analyses to study the separate and 
combined associations of gestational age, birth weight and infant weight gain with FEV1, 
FVC, FEV1/FVC, FEF25-75 and FEF75. For these analyses, individual participant data from 
all cohorts were combined and modeled simultaneously taking into account clustering 
of participants within studies.30 To prevent multicollinearity in our regression models, 
we initially assessed the separate associations of gestational age and birth weight with 
lung function. Thereafter, we assessed whether the associations of birth weight with 
lung function was driven by gestational age by creating gestational age adjusted birth 
weight standard deviation scores. The models focused on the associations of infant 
weight gain with lung function outcomes were adjusted for gestational age and weight 
at birth. For these analyses, we used early growth characteristics as continuous variables 
in the models providing p-values for trend. To test non-linear and dose-response associa-
tions, we categorized gestational age, birth weight SDS and infant weight gain SDS. As 
a sensitivity analysis, we conducted a 2-stage random effect meta-analysis to study the 
associations of gestational age, birth weight, and infant weight gain, and dichotomized 
preterm birth and low birth weight with each lung function outcome. For this analysis, 
we used linear regression models per cohort, after which pooled regression coefficients 
(β’s) from the per cohort effect estimates were calculated. We tested for heterogeneity 
between effect estimates using I2.31, 32 For all analyses, the first model was adjusted for 
child’s sex (crude model), the second model was additionally adjusted for potential con-
founders (full model). To determine interactive effects between gestational age, birth 
weight and infant weight gain we added the corresponding multiplicative terms in the 
full model. Since we used Northern-European reference curves for birth weight SDS, 
we performed a sensitivity analysis to explore whether the associations were different 
in North-Western European subjects only. Numbers were too small to perform these 
analyses separately in other European regions. To assess differences in results related to 
pubertal growth changes, we repeated our analyses is strata of children aged < 11 years 
and ≥11 years.33 We also performed a complete-case sensitivity analysis to explore any 
differences between complete and non-complete-case analyses, and sensitivity analyses 
in which we excluded cohorts that used parental report of early growth characteristics 
or that did not perform spirometry measurements according to the ATS/ERS guidelines.
Second, we conducted a 1-stage random effect regression analysis to assess the as-
sociations of early growth characteristics with asthma, and observed whether changes 
in the effect estimates occurred after additional adjustment for lung function measures 
(FEV1, FVC, FEV1/FVC, FEF25-75 and FEF75 ) as potential mediators (mediator model). The 
difference between the original effect estimates and the effect estimates after ad-
ditional adjustment for potential mediators was expressed as percentage change. The 
percentage change was calculated by the formula: 100 x (effect estimatemediator - effect 
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estimateoriginal model)/( effect estimateoriginal model- 1). A 95% confidence interval for the per-
centage change of the effect estimate was calculated using a bootstrap method with 
1,000 resamplings.34-36
For all analyses, missing values in covariates were used as an additional group in the 
categorical variables to prevent exclusion of non-complete cases. Statistical analyses 
were performed with R version 3.0.0 (libraries rmeta and metafor; The R foundation for 
Statistical Computing), and Comprehensive Meta-Analysis (Biostat, US).
resUlts
subject characteristics
Information about the main characteristics of the cohorts are given in Table 2.1.1. De-
tailed information about determinants, outcomes and covariates is given in the Supple-
mental Material (S-tables 2.1.1-5). Of all participants, 8.2% (n = 2,053) was born preterm 
(<37 weeks of gestational age), and 4.8% (n = 1,191) was born with a low birth weight 
(<2,500 gram). The mean age at which spirometry assessments were performed was 8.5 
(range 3.9 - 19.1) years. The proportion of children aged ≥11 years was 11.9% (n = 2,972).
early growth measures and lung function outcomes
Results from the 1-stage random effect models showed that younger gestational age at 
birth was, across the full range, associated with lower FEV1, FEV1/FVC and FEF75 in child-
hood (p-values for trend <0.01) (Figures 2.1.1A-C). A smaller size-for-gestational-age at 
birth across the full range was associated with lower FEV1 and higher FEV1/FVC (p-values 
for trend <0.01) (Figures 2.1.1D-E). Small size-for-gestational-age at birth was not associ-
ated with FEF75 (Figure 2.1.1F). Greater infant weight gain was associated with a higher 
FEV1, but with a lower FEV1/FVC and FEF75 (p-values for trend <0.01; Figures 2.1.1G-I). 
Most associations showed a linear trend, except for the associations of birth weight with 
FEV1/FVC and infant weight gain with FEV1 and FEV1/FVC which were non-linear (Figures 
2.1.1E, G, H).
To explore the combined effects of gestational age, birth weight SDS and infant weight 
gain SDS, we performed tests for interaction between these early growth characteristics. 
These tests for interaction were significant for gestational age and birth weight SDS in 
relation to FEV1, FEV1/FVC, FEF25-75 and FEF75 (p-values for interaction <0.01; Figure 2.1.2, 
S-table 2.1.9). Stratified analyses showed that a lower birth weight was associated with 
lower FEV1 and FEV1/FVC among children born after ≥ 32 weeks only, whereas higher 
birth weight was associated with FEF75 only among term born children (p-values for 
strata <0.05).
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figure 2.1.3. Forest Plots of the Associations between Preterm Birth and Low Birth Weight with FEV1, FEV1/
FVC and FEF75.
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figure 2.1.3. Forest Plots of the Associations between Preterm Birth and Low Birth Weight with FEV1, FEV1/
FVC and FEF75. (continued)
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figure 2.1.3. Forest Plots of the Associations between Preterm Birth and Low Birth Weight with FEV1, FEV1/
FVC and FEF75. (continued)
Values are pooled Z-score differences (95% confidence interval) from random effect meta-analysis for the 
associations of preterm birth vs. term birth (A, B, C) and low birth weight vs. normal birth weight (D, E, F) 
with lung function outcomes. Lung function outcomes are forced expiratory volume in 1 second (FEV1), 
FEV1/forced vital capacity (FVC) ratio, and forced expiratory flow at 75% of the exhaled FVC (FEF75). Models 
are adjusted for maternal education, smoking during pregnancy, smoking during childhood, atopy, asthma 
and child’s sex, number of siblings, daycare attendance, breastfeeding, respiratory tract infections, child-
hood eczema, inhalant allergies and body mass index. Low birth weight was adjusted for gestational age.
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No differences in results were observed when we used 2-stage random effect models 
of combined effect estimates (S-tables 2.1.6-7). Also, the results from the sensitivity 
analyses showed similar results when we used cohorts with North-Western European 
subjects only, when we excluded cohorts that did not perform spirometry measurements 
according to the recent ATS/ERS guidelines, when we performed stratified analyses for 
children aged < 11 years or ≥ 11 years (S-table 2.1.8), or when we excluded cohorts that 
used parental report of early growth characteristics (data not shown).
Figure 2.1.3 shows that compared to term born children, those born preterm had a 
lower FEV1, FEV1/FVC and FEF75, (pooled Z-score (95% CI): -0.20 (-0.26, -0.14), -0.15 (-0.21, 
-0.09) and -0.19 (-0.27, -0.11), respectively). Also, compared to normal birth weight chil-
dren, those with a low birth weight had lower FEV1, FEV1/FVC and FEF75 (-0.29 (-0.38, -0.21) 
and -0.16 (-0.25, -0.08) and -0.17 (-0.26, -0.08) respectively), independent of gestational 
age. Results of associations of growth characteristics with all lung function outcomes, 
including FVC and FEF25-75 are given in the Supplemental Material: S-tables 2.1.6-8.
early growth, lung function and asthma
Preterm birth, low birth weight and greater weight gain were all associated with an in-
creased risk of childhood asthma (OR (95% CI): 1.34 (1.15, 1.57), 1.32 (1.07, 1.62) and 1.27 
(1.21, 1.34), respectively. Mediation analyses suggested that FEV1, FEV1/FVC and FEF75 
may explain 7 (2, 10)% to 45(15, 81)%. Specifically, after additional adjustment for FEV1, 
FEV1/FVC or FEF75, the associations of preterm birth with asthma attenuated with -7 (-19, 
-1)%, -14 (-40, -3)% and -39 (-69, -3)%, respectively. Similarly, the associations of low 
birth weight with asthma attenuated with -19 (-37, -12)%, -22 (-47, -11)% and -222 (-47, 
-11)%, respectively (Table 2.1.2). The strongest mediating effect was observed for FEF75 
for the association between gestational age and asthma (-45 (-81, -15)%). Similar trends 
were observed for greater weight gain, although the associations did not attenuate into 
non-significant.
discUssion
In this meta-analysis of individual participant data of 24,938 children from 24 birth 
cohorts, we observed that lower gestational age, smaller size at birth and greater infant 
weight gain were all associated with lower childhood FEV1. The positive associations of 
birth weight and infant weight gain with FVC were larger than the positive associations 
of birth weight and infant weight gain with FEV1. This combination resulted in associa-
tions of higher birth weight and infant weight gain with lower FEV1/FVC. Also, a lower 
gestational age at birth was associated with a lower FEF75 in childhood, suggesting 
persistent reduction of small airways patency. A greater infant weight gain was associ-
Early growth characteristics and the risk of reduced lung function and asthma
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ated with lower FEF75. Remarkably, these associations were present across the full-range 
of early growth and not restricted to clinically diagnosed preterm- or low birth weight 
children. Also, the observed associations of the early life growth characteristics with 
lung function outcomes were independent of each other. Stratified analyses showed 
that children born very preterm with a relatively low birth weight had the lowest FEV1 
and FEV1/FVC. The associations of early growth characteristics with childhood asthma 
were partly explained by lung function adaptations.
Whereas lung growth continues until the early adulthood, the most rapid develop-
ment of airways and alveoli occurs in early life.37 Developmental adaptations in fetal life 
and infancy due to early life adverse exposures might result in impaired lung growth 
with smaller airways, decreased lung volume, and subsequently to an increased risk of 
bronchopulmonary dysplasia, asthma or COPD.9, 14, 38 Previous studies suggest that chil-
dren with asthma already have a reduced lung function in the first months of life, and 
that this deficit progresses into childhood and early adulthood.39, 40 Airway caliber is a 
key determinant of total airway resistance and reduced caliber is a prominent feature of 
asthma and chronic obstructive pulmonary diseases.5-7 Lower lung function in early life 
is likely to lead to lower peak lung function in early adulthood, and the natural decline in 
FEV1 from that point onwards will be accelerated by any additional adverse exposures.41 
Thus, lung function during the life course seems to be programmed at least partly in 
early life.
Children born preterm or with a very low birth weight are at increased risk of neonatal 
respiratory diseases.1 We observed that children born at a younger gestational age had 
a lower FEV1, even after taking FVC into account, and a lower FEF75 in childhood. These 
associations were not only present among children born very preterm, but across the 
full range of gestational age at birth. Moreover, the associations of preterm birth with 
childhood asthma were partly explained by lung function. These findings are in line 
with previous studies showing persistent lung function adaptions in children and adults 
born preterm. A recent meta-analysis of 28 published studies showed that children born 
between 24 and 36 weeks had a lower FEV1 at ages 5 up to 23 years.42 These and other 
studies suggest that preterm birth has adverse effects on lung function, persisting into 
adulthood.42-44
In the present study, a lower birth weight was associated with lower FEV1 in child-
hood. This suggests that a lower birth weight leads to a persistent reduction of airway 
patency. A previous study analyzed 10 studies examining the associations of birth 
weight with FEV1 in adults (range 19 – 70 years).10 The authors reported a modest posi-
tive association between FEV1 and birth weight. Two recent studies from longitudinal 
birth cohorts among adults reported strong positive associations of birth weight with 
FEV1 and FEF25-75 in young adults aged 21 and 31 years.9, 11 The effect of birth weight was 
independent of preterm birth in both studies. However, studies among children showed 
Early growth characteristics and the risk of reduced lung function and asthma
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conflicting results.12, 13 We observed an association of lower birth weight with lower FEV1, 
independent of gestational age at birth. We previously reported that the effect of lower 
birth weight on asthma was largely explained by gestational age.4 Therefore, although 
gestational age-adjusted birth weight is associated with lower lung function this seems 
not related to the risk of clinically manifest childhood asthma.
Previous studies examining associations between infant weight gain and childhood 
lung function have reported inconsistent results.14-16 Differences might be due to dif-
ferent ages at which spirometry was performed, not taking other weight characteristics 
into account, such as birth weight or current body mass index, and possible hidden bias 
due to the use of mL instead of Z-scores for lung function.45 In line with the findings for 
birth weight, we observed that lower infant weight gain was associated with a lower 
childhood FEV1 (p-value for trend <0.01). Alternatively, a greater infant weight gain was 
associated with a higher childhood FEV1. This association was fully explained by FVC. 
These results suggest dysanapsis, in which FVC was higher relative to FEV1 as a result of 
possible disproportional growth of lung volume and airways. Dysanapsis is commonly 
used to indicate relatively narrow airways for lung volume, but here a relatively higher 
lung volume for airways applies.46 Greater infant weight gain was also associated with 
a lower FEF75, which is in line with previous studies reporting associations of body mass 
index or adiposity with reduced expiratory flows and asthma.47, 48 A suggested mecha-
nism is leptin release from adipose tissue, which might have pro-inflammatory effects in 
the airways 49, or a direct effect of increased body weight on lung function.50 However, 
our analyses were adjusted for childhood body mass index. Further studies are needed 
to explore whether the associations of infant weight gain with end-expiratory flows are 
explained by specific adiposity-related measures or biomarkers.
To the best of our knowledge this is the first study that examines the individual and 
combined associations of the main early growth characteristics with childhood lung 
function outcomes, and whether lung function adaptations explain the previously 
reported associations of early growth characteristics with childhood asthma. Our results 
suggest that respiratory consequences of preterm birth and a low birth weight present 
across the full range. This observation might have important population effects, since 
the largest majority of children are in the less extreme ranges of gestational age and 
weight at birth. Furthermore, our results suggest that the associations of gestational 
age, birth weight and infant weight gain with childhood asthma are at least partly ex-
plained by adaptions in airway caliber. We observed strong effect estimates with wide 
confidence intervals which limit the precision. Therefore, these mediation effects should 
be interpreted carefully. The effect estimates for the observed associations could be 
considered as small and without clinical relevance for individuals. However, the associa-
tions may be important from an etiological respiratory developmental perspective and 
may be important on a population-level. The associations of early growth characteristics 
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with lung function outcomes seemed already established before the pubertal growth 
spurt. The largest lung and airway growth occurs before pubertal growth spurt 37, 51, 
with FVC increasing proportionately more than the FEV1.33 Lung and airway growth is 
proportionally less after start of the pubertal growth spurt 33, which might explain the 
similar effect estimates before and after the pubertal growth spurt. Further studies are 
needed to identify the developmental adaptations of the lungs and immune system 
that might explain the mediating effect of lung function on the associations of early 
growth characteristics with childhood asthma. Identification of modifiable exposures 
may lead to development of future preventive strategies.
Some methodological limitations need to be discussed. We used data from 24 ongoing 
cohort studies. Missing values always occur in these studies. Since we did not have ad-
ditional data on patterns of missing values in all 24 cohorts, we were not able to perform 
multiple imputation. Data on childhood asthma was mainly obtained by parental ques-
tionnaires adapted from the International Study on Asthma and Allergy in Childhood 
(ISAAC).27 This questionnaire has been validated in various age groups in many countries 
against measurements of bronchial hyperresponsiveness and doctor-diagnosed asthma, 
and is widely accepted in epidemiological studies. We did not have information on use 
of asthma medication, which might have influenced the lung function values in asth-
matic patients. This missing information on asthma medication may have influenced our 
effect estimates. We would expect that asthmatic children who use asthma medication 
would in general have had a higher lung function values in case of good adherence 
and inhaler technique. We used GLI reference data to convert lung function values into 
Z-scores. These prediction equations were based on 74,187 individuals including 31,840 
individuals aged <20 years, of whom 58% were assessed before, and 42% were assessed 
during pubertal growth spurt.26 To date, the GLI normal values are considered the most 
accurate reference values for all age ranges, and have been adopted by both the ATS and 
ERS. For the covariates, we imputed missing values as additional category to prevent 
exclusion of non-complete cases. No differences in results were observed in complete 
case analyses. No direct clinical and laboratory information about pubertal growth was 
available. Also, although we took major potential confounders into account, residual 
confounding may still be an issue. No information was available about e.g. exposure to 
environmental micro-organisms or asthma severity. Exploring mediation of lung func-
tion for the association of early growth characteristics with asthma using the method 
proposed by Baron and Kenny might have been limited by misclassification of lung 
function measurements or asthma diagnosis although we aimed to reduce this issue by 
multi-level modelling.52 Most of the participating studies had measured childhood lung 
function and asthma at the same age. Therefore, further follow-up studies with longitu-
dinally measured detailed data on lung function and asthma or related symptoms from 
birth onwards are needed to disentangle the direction of causality.
Early growth characteristics and the risk of reduced lung function and asthma
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in conclusion, younger gestational age, lower birth weight and lower infant weight gain 
were independently associated with persistent changes in childhood lung function. 
These associations were present across the full spectrum of these early growth charac-
teristics. Stratified analyses showed that children born very preterm with a relatively low 
birth weight had the lowest FEV1 and FEV1/FVC. Our results suggest that associations of 
early growth with the risk of childhood asthma were partly explained by lung function 
adaptations. Thus, fetal and infant growth patterns may persistently affect lung func-
tion, and thereby contribute to the risk of respiratory diseases in later life.
Detailed acknowledgements and online resources can be found in the published article 
online: http://www.sciencedirect.com/science/article/pii/S0091674915013615
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AbstrAct
background Obesity and asthma often coexist. We hypothesized that detailed body fat 
distribution measures might be more strongly associated with childhood asthma than 
body mass index (BMI).
objective We examined the associations of total body and abdominal fat measures 
with respiratory resistance (Rint), fractional exhaled nitric oxide (FeNO), and the risks of 
wheezing and asthma in school-aged children.
methods In a population-based prospective cohort study among 6,178 children aged 
6 years, we measured BMI, fat mass index, android/gynoid ratio and pre-peritoneal and 
subcutaneous fat mass by physical examinations, Dual-energy X-ray absorptiometry 
and ultrasound, respectively. We performed Rint and FeNO measurements, and assessed 
physician-diagnosed wheezing and asthma by questionnaires.
results A higher BMI was associated with a higher Rint (Z-score (95% CI): 0.06 (0.01, 
0.12)) and increased risk of wheezing (OR (95% CI): 1.07 (1.00, 1.14), per Z-score BMI 
increase), but not with FeNO or asthma. A high fat mass index was associated with a 
higher Rint (Z-score (95% CI): 0.40 (0.13, 0.68)). A high android/gynoid fat mass ratio 
was associated with a lower FeNO (Sym% (95% CI): -9.8 (-16.3, -3.4)), whereas a high pre-
peritoneal fat mass was associated with a higher FeNO (Sym% (95% CI): 6.5 (0.1, 12.9)). 
Subcutaneous fat mass was not associated with any respiratory outcome.
conclusion Studying detailed body fat distribution measures might provide better 
insight of the obesity-asthma paradigm.
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introdUction
Asthma and obesity are two of the leading chronic childhood morbidities in developed 
countries with reported prevalences up to 10% and 25%, respectively.1,2 It has been 
hypothesized that obesity leads to asthma. A proposed underlying mechanism is that a 
higher body mass index (BMI) leads to an increased production of systemic pro-inflam-
matory mediators by fat tissue, with subsequent airway inflammation and an increased 
risk of asthma.3 Alternatively, an increased BMI might lead to increased intrathoracic and 
abdominal fat deposition. This might reduce the pulmonary vital capacity and increase 
obstruction-related respiratory resistance and the risk of asthma symptoms.3 Most stud-
ies that assessed the obesity-asthma link use BMI as a proxy for body fat and body com-
position. The major limitation of BMI is that it does not distinguish fat mass from free-fat 
mass 4, while it is suggested that fat mass distribution is more strongly associated with 
adverse health risks.5 Higher visceral fat mass has been associated with cardiometabolic 
diseases, which might be due to an increased secretion of leptin.3, 6 Therefore, more 
detailed measurements of total and abdominal fat mass distribution might be better 
predictors for the development of asthma.4 Studies that assessed detailed adiposity 
measures are scarce, are mainly performed in adults and show inconsistent results. The 
use of dual-energy X-ray absorptiometry (DXA) and ultrasound allows a more accurate, 
fast and precise measurement of body fat composition, including regional fat measure-
ments 7, and has been proven to be highly reproducible in children.8
To test the hypothesis that fat mass distribution leads to higher obstruction related 
respiratory resistance and airway inflammation, and subsequently increased risk of 
childhood asthma, we assessed the associations of BMI, total body and abdominal fat 
mass measures with respiratory resistance (Rint), fractional exhaled nitric oxide (FeNO), 
wheezing and asthma among 6,178 school-aged children participating in a population-
based prospective cohort study.
metHods
This study was embedded in the Generation R Study, a population-based prospective 
cohort study of pregnant women and their children from fetal life onwards in Rotterdam, 
The Netherlands.9 The study protocol was approved by the Medical Ethical Committee 
of the Erasmus Medical Centre, Rotterdam (MEC-2007-413-NL21545.078.0), and written 
informed consent of parents / legal guardians of participants was obtained.
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childhood body fat profile
At age 6 years, height and weight were measured. Body fat distribution was measured 
with a DXA scanner (GE-Lunar, 2008, Madison, WI, USA), and analyzed with enCORE 
v.12.6.10 Total body fat mass (kg) was calculated as percentage of total body weight (kg) 
measured by DXA. Fat mass index (total body fat mass/height²) and android/gynoid fat 
mass ratios were calculated and used as total and regional fat measures, respectively. 
The android/gynoid fat ratio reflects the central body fat mass distribution in the ab-
dominal (android) and hip (gynoid) region, and is generally used as a marker for waist/
hip fat mass distribution.11 Abdominal ultrasounds were used to measure subcutaneous 
fat and pre-peritoneal fat, a measure of visceral abdominal fat, as described in detail 
before.7 We constructed Z-scores [(observed value – mean)/standard deviation] for all 
body fat measures, using known prevalences of overweight and obesity in children aged 
6 years in the Netherlands (12.7% and 2.9%, respectively) 12 and to enable comparison of 
the effect sizes of different outcome measures. To examine non-linear associations and 
for clinical interpretation, we categorized body fat measures Z-score into “low” (Z-score 
< -1.00), “normal” (Z-score ≥-1.00 and ≤1.00) and “high” (Z-score >1.00), which reflect the 
16th and 84th percentiles. Categorization of body fat measures into tertiles resulted in 
similar results (data not shown). Additional information on body fat profile measures is 
provided in the Supplemental Material.
childhood lung function, wheezing and asthma
At age 6 years, lung function measurements were performed according to European 
Respiratory Society (ERS) and American Thoracic Society (ATS) recommendations.13, 14
Rint was measured during expiration with occlusion of the airway at peak expiratory 
flow, and converted into sex- and height-adjusted Z-scores.15 Fractional exhaled nitric 
oxide (FeNO) was measured using the NIOX Flex chemiluminescence analyser (Aerocrine 
AB, Solna, Sweden). Additional information on Rint and FeNO-measures is provided in 
the Supplemental Material. Information on the prevalences of wheezing in the past 12 
months (no; yes) and ever physician-diagnosed asthma (no; yes) was collected by ques-
tionnaires adapted from the International Study on Asthma and Allergy in Childhood 
(ISAAC).16
covariates
Potential covariates included early growth, and socio-economic and lifestyle factors. In 
detail, maternal characteristics included age (years), pre-pregnancy BMI (kg/m2), edu-
cational level (low; middle; high), history of asthma and atopy (no; yes), psychological 
distress during pregnancy (no; yes), parity (nulli-; multiparous), and maternal smoking 
during pregnancy (no; yes), and were obtained from questionnaires during pregnancy. 
Maternal psychological distress in the second trimester of pregnancy was defined using 
Body fat mass distribution and asthma at school-age
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the global severity index (GSI), a measure of current level or depth of the symptoms, 
and denotes overall psychological distress.17 High scores represent an increased occur-
rence of overall distress, based on Dutch cut-offs.17 We used parity as a proxy for siblings, 
and the correlation between those variables was high (κ = 0.87). Sex (female; male), 
gestational age (weeks) and birth weight (grams) of the children were obtained from 
midwife and hospital registries at birth. Information about ethnicity (European; non-
European, and pet keeping (no; yes, cat, dog or bird) in the first year were obtained by 
questionnaires. Postal questionnaires at 6 and 12 months provided information about 
ever breastfeeding (no; yes). Information on ever physician diagnosed inhalant allergy 
(no; yes, pollen, house dust mite, or pets), physical activity (hours per day) and lower 
respiratory tract infections (no; yes, but not physician attended; yes, physician attended 
for bronchitis and/or pneumonia) was obtained by parental questionnaires at age 6 
years.
statistical analysis
We used linear and logistic regression models to examine the associations of body fat 
profile measures with Rint, FeNO, wheezing and asthma in children aged 6 years. We 
constructed age- and sex-adjusted Z-scores for BMI using Dutch reference data (Growth 
Analyzer 3.5, Dutch Growth Research Foundation). Sex-specific weights were classified 
by the International Obesity Task Force cut offs into underweight, normal, overweight 
and obesity.18 Due to low numbers of underweight children (n=55), we excluded these 
individuals from the analyses. First, models were adjusted for child’s sex only. Second, to 
assess the influence of possible confounders, models were adjusted for growth related 
factors (maternal pre-pregnancy BMI, child’s gestational age at birth and birth weight) 
and socio-economic and lifestyle related factors (maternal age, educational level, ma-
ternal smoking during pregnancy, history of asthma and atopy, psychological distress 
during pregnancy, parity, child’s sex, ethnicity, breastfeeding, pet keeping, physical 
activity and lower respiratory tract infections). Confounders were included in our mod-
els based on the literature, if they were associated with both the determinant and the 
outcome and were not in the causal pathway, or if they changed the effect estimates 
with ≥10%. Additionally, associations of total body and abdominal fat mass measures 
with Rint, FeNO, wheezing and asthma were adjusted for BMI. Missing data were <25%, 
except for maternal stress during pregnancy (26.5%). To reduce potential bias due to 
missing data on covariates, we performed multiple imputation generating 10 datasets 
by Markov Chain Monte Carlo and used the pooled estimates.19 We log-transformed 
FeNO due to skewed distribution and present those results in sympercents (sym%).20 All 
other measures of association are presented as odds ratios (OR) or Z-score differences 
with their corresponding 95% Confidence Intervals (95% CI). Statistical analyses were 
performed using SPSS version 21.0 for Windows (SPSS Inc).
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table 2.3.1. Maternal and Child Characteristics.
subjects
n = 6,178
never asthma-
diagnosed
(n = 4,140)
ever asthma-
diagnosed
(n = 298)
maternal characteristics
Age (years)# 30.6 (5.1) 31.4 (4.7) 31.2 (5.1)
Pre-pregnancy body mass index (kg/m2)‡ 23.8 (18.9,36.0) 23.4 (4.0) 23.6 (4.5)
Education (higher) 46.0 (2,843) 53.8 (2,228) 44.3 (132)
History of asthma or atopy (yes) 42.8 (2,645) 41.2 (1,706) 54.4 (162)
Maternal psychological distress (yes) 10.1 (625) 7.6 (313) 12.1 (36)
Parity (≥1) 43.6 (2,695) 41.1 (1,701) 45.6 (136)
Smoking during pregnancy (yes) 26.8 (1,658) 23.4 (968) 27.9 (83)
birth and infant characteristics
Sex (female) 50.0 (3,090) 50.4 (2,088) 39.6 (118)
Gestational age at birth (weeks)‡ 40.1 (35.7, 42.3) 40.1 (36.0, 42.3) 39.9 (33.1, 42.0)
Birth weight (gram)# 3,428 (556) 3,453 (553) 3,359 (624)
Ethnicity (European) 65.7 (4,061) 73.2 (3,032) 66.8 (199)
Breastfeeding (ever ) 91.8 (5,674) 92.1 (3,815) 87.2 (260)
Pet keeping 1st year (yes) 37.9 (2,342) 38.5 (1,595) 39.9 (119)
school-age characteristics
Age at follow-up measurements (years) # 6.2 (0.5) 6.2 (0.5) 6.3 (0.5)
Physical activity per day (hours)‡ 1.4 (0.1, 4.5) 1.4 (0.0, 4.3) 1.4 (0.1, 4.6)
Lower respiratory tract infections age 6 years (yes) 5.8 (358) 3.2 (133) 25.5 (76)
Current height (cm)# 119.5 (6.0) 119.1 (5.6) 119.2 (6.2)
 Missing 0.1 (7) 0.1 (6) -
Current weight (kg)# 22.3 (17.3, 33.5) 22.6 (3.7) 23.0 (4.0)
 Missing 1.4 (88) 1.3 (54) 1.7 (5)
Body mass index (kg/m²)‡ 15.7 (13.4, 20.9) 15.6 (13.4, 20.2) 15.8 (13.4, 21.7)
 Underweight 0.9 (55) 0.9 (35) 1.0 (3)
 Normal weight 83.6 (5,079) 85.5 (3,484) 81.6 (239)
 Overweight 12.0 (728) 10.3 (418) 13.3 (39)
 Obese 4.5 (271) 3.4 (139) 4.1 (12)
 Missing 1.6 (100) 1.6 (64) 1.7 (5)
Total body and regional fat mass
 Fat mass index (kg/cm2)‡ 0.37 (0.24, 0.79) 0.37 (0.23, 0.74) 0.38 (0.24, 0.81)
 Missing 1.5 (94) 1.5 (60) 1.7 (5)
 Android/Gynoid ratio‡ 0.24 (0.16, 0.42) 0.24 (0.16, 0.40) 0.24 (0.14, 0.48)
 Missing 1.4 (87) 1.3 (54) 1.7 (5)
Abdominal fat mass
 Subcutaneous area (mm²)‡ 48.0 (18.0, 191.9) 46.0 (17.0, 171.0) 46.0 (14.2, 201.8)
 Pre-peritoneal area (mm²)‡ 39.0 (16.0,120.0) 38.0 (16.0, 109.6) 38.0 (13.2, 111.5)
Body fat mass distribution and asthma at school-age
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resUlts
general
A total of 6,178 children were included for the current analyses (S-Figure 2.3.1). Loss 
to follow-up was mainly due to non-response to questionnaires, and due to technical 
issues for Rint and FeNO. Maternal and child characteristics are presented in Table 2.3.1 
and S-Table 2.3.1. Of all children, 83.6% had a normal weight, 12.0% had overweight, 
and 4.5% were obese. Of all children, 9.4% wheezed in the past year, and 6.1% were ever 
diagnosed by a physician with asthma. All characteristics, except for maternal history of 
asthma or atopy and parity, and child’s sex and breastfeeding, differed between subjects 
included and those lost to follow-up (S-Table 2.3.2).
body mass index, lung function and asthma
In the full model, a higher BMI was associated with a higher Rint and increased risk 
of wheezing (Z-score (95% CI) 0.06 (0.01, 0.12)), and OR (95% CI) 1.07 (1.00, 1.14)), re-
spectively, per Z-score increase in BMI) but not with FeNO or asthma (Figures 2.3.1A-D). 
Compared with normal weight, overweight was associated with a higher Rint (Z-score 
(95% CI): 0.36 (0.07, 0.65)) (Figure 2.3.1A). Obesity was associated with an increased risk 
of wheezing (OR (95% CI): 2.09 (1.22, 3.57)) (Figure 2.3.1C). Underweight was not associ-
ated with Rint (S-Table 2.3.3).
table 2.3.1. Maternal and Child Characteristics. (continued)
subjects
n = 6,178
never asthma-
diagnosed
(n = 4,140)
ever asthma-
diagnosed
(n = 298)
 Missing 18.3 (1,131) 18.7 (773) 17.7 (52)
Rint (kPa.L-1.s) 0.84 (0.29) 0.85 (0.29) 0.92 (0.30)
 Missing 29.0 (1,794) 31.4 (1,301) 30.1 (89)
FeNO (ppb) 7.3 (2.8, 30.5) 7.2 (2.7, 26.4) 8.3 (2.9, 40.2)
 Missing 36.0 (2,221) 37.9 (1,570) 38.2 (113)
Wheezing (yes) 9.4 (426) 6.3 (254) 54.1 (160)
 Missing 26.3 (1,626) 0.8 (32) 0
Asthma (yes) 6.1 (298) - -
 Missing 28.2 (1,745) - -
Values are #means (SD), ‡medians (2.5-97.5th percentile) or percentages (absolute numbers) based on mul-
tiple imputation except for main risk factors and outcomes under study (Current height and weight, body 
mass index, total body and regional fat mass, abdominal fat mass, Rint, FeNO, wheezing and asthma).
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total and abdominal fat measures, lung function and asthma
Fat mass index was not linearly associated with Rint, FeNO, wheezing or asthma. When 
categorized, we observed that a high fat mass index was associated with a higher Rint 
(Z-score 0.40 (0.13, 0.68)), compared to a normal fat mass index. Continuous regional an-
droid/gynoid fat mass ratio was associated with a lower FeNO (sym% difference: -2.8 (-4.9, 
-0.6) per Z-score increase of android/gynoid fat mass ratio), but not with Rint, wheezing 
or asthma. A high android/gynoid fat mass ratio, compared with normal android/gynoid 
fat mass ratio, was associated with a lower FeNO (sym% -9.8 (-16.3, -3.4)). Subcutaneous 
fat area was not associated with any asthma-related outcome (Table 2.3.2). Also, we 
 
figure 2.3.1. Association of Body Mass Index in Categories and Continuously with Rint, FeNO, Wheezing 
and Asthma in Children at Age 6 Years.
Values are changes in Z-score for Rint (A) or in sympercent for FeNO (B), and odds ratios for wheezing (C) 
and asthma (D) (95% confidence interval presented as error bars) of overweight and obesity compared with 
normal weight or per kg/m2 increase of BMI, from logistic or linear regression models, *p < 0.05 and **p < 
0.01. Models were adjusted for maternal age, pre-pregnancy BMI, educational level, history of asthma and 
atopy, psychological distress during pregnancy, parity, smoking during pregnancy, and child’s sex, gesta-
tional age at birth, birth weight, ethnicity, breastfeeding, pet keeping, physical activity, lower respiratory 
tract infections and current height.
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did not observe associations of pre-peritoneal fat area with Rint, wheezing or asthma. 
Higher pre-peritoneal fat area was associated with a higher FeNO (sym% difference: 2.6 
(0.3, 5.0) per Z-score increase of pre-peritoneal fat area. When categorized in 3 groups, 
high pre-peritoneal fat area was associated with higher FeNO (sym% difference: 6.5 (0.1, 
12.9)) compared with normal pre-peritoneal fat area. When we additionally adjusted the 
associations of total body and abdominal fat mass measures with Rint, FeNO, wheezing 
and asthma for BMI, only the association of fat mass index with Rint attenuated (Z-score 
(95%CI): 0.30 (-0.05, 0.65) (S-Table 2.3.4). When we mutually adjusted for android/gynoid 
ratio and pre-peritoneal fat area and their associations with FeNO, the size and the direc-
tions of the effect estimates remained (Z-scores (95% CI): 4.4 (1.7, 7.1) and -3.9 (-6.6, -1.2), 
respectively).
table 2.3.2. Association of Total Body and Abdominal Fat Mass Measures with Rint, FeNO, Wheezing and 
Asthma in Children at Age 6 Years.
rint feno wheezing Asthma
Z-score
(95% ci)
sym%
(95% ci)
odds ratio
(95% ci)
odds ratio
(95% ci)
n = 4,384 n = 3,957 n = 4,554 n = 4,433
fat mass index
(Z-score)
N 4,283 3,896 417 / 4,484 264 / 4,375
Basic model -0.03 (-0.12, 0.07) 0.5 (-1.6, 2.6) 1.17 (1.05, 1.30)** 1.16 (1.00, 1.34)
Full model 0.08 (-0.02, 0.19) -1.4 (-3.8, 0.1) 1.09 (0.96, 1.25) 1.09 (0.92, 1.29)
 Low 0.15 (-0.12, 0.42)
(n = 605)
-4.3 (-10.0, 1.6)
(n = 557)
1.07 (0.78, 1.46)
(n = 65 / 679)
0.90 (0.60, 1.35)
(n = 38 / 665)
 Normal Reference
(n = 3,030)
Reference
(n = 2,767)
Reference
(n = 290 / 3,246)
Reference
(n = 193 / 3,220)
 High 0.40 (0.13, 0.68)**
(n = 648)
-5.8 (-12.0, 0.4)
(n = 572)
1.20 (0.84, 1.70)
(n = 62 / 559)
1.09 (0.69, 1.72)
(n = 33 / 490)
Android/gynoid fat mass ratio
(Z-score)
N 4,279 3,897 418 / 4,486 264 / 4,376
Basic model 0.03 (-0.07, 0.12) -1.7 (-3.9, 0.5) 1.14 (1.01, 1.27)* 1.04 (0.89, 1.21)
Full model 0.06 (-0.03, 0.15) -2.8 (-4.9, -0.6)* 1.07 (0.94, 1.21) 0.97 (0.82, 1.15)
 Low -0.15 (-0.44, 0.15)
(n = 444)
-3.1 (-10.0, 3.2)
(n = 436)
1.05 (0.74, 1.51)
(n = 51 / 543)
0.99 (0.63, 1.56)
(n = 32 / 538)
 Normal Reference
(n = 3,299)
Reference
(n = 2,996)
Reference
(n = 314 / 3,429)
Reference
(n = 207 / 3,375)
 High 0.10 (-0.19, 0.38)
(n = 536)
-9.8 (-16.3, -3.4)*
(n = 465)
1.00 (0.70, 1.44)
(n = 53 / 518)
0.85 (0.52, 1.39)
(n = 25 / 463)
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discUssion
We observed that a higher BMI was associated with a higher Rint and an increased risk of 
wheezing in school-aged children. Detailed assessment of total body fat mass distribu-
tion showed that a higher fat mass index was associated with a higher Rint, whereas a 
higher android/gynoid fat mass ratio was associated with a lower FeNO. A higher pre-
peritoneal fat mass, a measure of visceral abdominal fat, was associated with a higher 
table 2.3.2. Association of Total Body and Abdominal Fat Mass Measures with Rint, FeNO, Wheezing and 
Asthma in Children at Age 6 Years. (continued)
rint feno wheezing Asthma
Z-score
(95% ci)
sym%
(95% ci)
odds ratio
(95% ci)
odds ratio
(95% ci)
n = 4,384 n = 3,957 n = 4,554 n = 4,433
subcutaneous area
(Z-score)
N 3,503 3,363 355 / 3,729 225 / 3,606
Basic model -0.05 (-0.15, 0.06) 2.1 (-0.1, 4.4) 1.02 (0.91, 1.15) 1.04 (0.88, 1.21)
Full model 0.06 (-0.14, 0.26) 2.7 (-1.6, 7.0) 1.08 (0.85, 1.37) 1.04 (0.77, 1.41)
 Low -0.02 (-0.30, 0.26)
(n = 536)
-3.6 (-10.0, 2.8)
(n = 450)
0.97 (0.70, 1.36)
(n = 58 / 590)
0.91 (0.60, 1.40)
(n = 44 / 599
 Normal Reference
(n = 2,454)
Reference
(n = 2,408)
Reference
(n = 245 / 2,662)
Reference
(n = 154 / 2,622
 High 0.10 (-0.19, 0.39)
(n = 542)
1.8 (-4.5, 8.1)
(n = 530)
1.14 (0.78, 1.67)
(n = 52 / 477)
0.97 (0.59, 1.61)
(n = 27 / 385)
Pre-peritoneal area
(Z-score)
N 3,466 3,363 353 / 3,704 223 / 3,593
Basic model -0.11 (-0.21, -0.01)* 4.0 (1.8, 6.2)** 1.01 (0.89, 1.13) 1.03 (0.87, 1.21)
Full model -0.03 (-0.14, 0.08) 2.6 (0.3, 5.0)* 0.96 (0.84, 1.09) 0.98 (0.83, 1.16)
 Low -0.17 (-0.45, 0.11)
(n = 528)
-4.9 (-11.2, 1.4)
(n = 462)
1.10 (0.80, 1.52)
(n = 64 / 602)
1.23 (0.83, 1.83)
(n = 43 / 595)
 Normal Reference
(n = 2,455)
Reference
(n = 2,413)
Reference
(n = 247 / 2,648)
Reference
(n = 154 / 2,617)
 High -0.27 (-0.57, 0.03)
(n = 483)
6.5 (0.1, 12.9)*
(n = 488)
0.84 (0.56, 1.26)
(n = 42 / 454)
1.15 (0.69, 1.91)
(n = 26 / 381)
Values are changes in Z-score for Rint or in sympercent for FeNO, and odds ratios for wheezing and asthma 
(95% confidence interval) from linear and logistic regression models, *p < 0.05 and **p < 0.01. “n =” repre-
sents number of total group (Rint, FeNO) or number of cases per total group (wheezing, asthma). Z-score 
was categorized into “low” (Z-score < -1.00), “normal” (Z-score ≥-1.00 and ≤1.00) and “high” (Z-score >1.00). 
Full models were adjusted for maternal age, pre-pregnancy BMI, educational level, history of asthma and 
atopy, psychological distress during pregnancy, parity, smoking during pregnancy, and child’s sex, gesta-
tional age at birth, birth weight, ethnicity, breastfeeding, pet keeping, physical activity, lower respiratory 
tract infections and current height.
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FeNO. No other associations of specific childhood body fat mass measures with Rint, 
FeNO, wheezing or asthma were observed.
comparison with previous studies
A recent meta-analysis of 6 cohort studies comprising 25,000 children aged 5-14 years 
examined the association between obesity and physician-diagnosed asthma, at least 
one year after BMI assessment, and observed that overweight and obese children had a 
1.35 and 1.50-fold increased risk of asthma , respectively.21 The use of BMI as Z-scores led 
to weaker and non-significant effect estimates. We observed no associations between 
overweight and obesity with childhood asthma. This difference might be explained by 
the young age of our subjects and our broad definition of ever asthma, which might 
have comprised multiple asthma phenotypes including those with asthma symptoms 
at a young age due to respiratory infections. A recent multi-center cross-sectional study 
comprising 10,652 children aged 8 – 12 years reported that overweight and obese 
children had a 1.14 and 1.67 fold increased risk of wheezing, respectively.22 We observed 
similar effect sizes, and additionally took growth and socio-economic and lifestyle-
related factors into account.
Previous studies that examined the association of BMI with lung function obtained 
by spirometry in children reported inconsistent results. Among 8-12 year-old children, 
cross-sectional analyses showed that childhood obesity was associated with a 2.5% 
lower Forced Expiratory Volume in 1 second / Forced Vital Capacity (FEV1/FVC).22, 23 Oth-
ers reported that obesity was not associated with changes in FVC24, or with higher FEV1 
and FVC.25, 26 In the latter studies the effect estimates for the association of obesity with 
FEV1 was twice smaller than with FVC, which implies that higher BMI was associated with 
more obstruction if FEV1/FVC was used.25, 26 These results are in line with our observed 
association of BMI with increased respiratory resistance when we used Rint.
Studies that examined associations between adiposity and FeNO are scarce and 
showed that higher BMI, percent body fat and waist circumference were associated 
with an increased risk of current asthma in individuals with a low to normal FeNO 25, or 
showed no associations between BMI and FeNO.27, 28 Differences in results with our study 
might be explained by the limitations of BMI, which does not distinguish fat mass from 
free-fat mass, the use of different obesity measures such as waist circumference, and age 
at time of measurement.
Of the specific body fat mass measures, we observed that a high fat mass index and a 
high android/gynoid fat mass ratio were associated with a higher Rint and lower FeNO, 
respectively. In contrast with the android/gynoid fat mass ratio, a measure of waist-hip 
ratio, a high pre-peritoneal fat mass was not associated with Rint, but was with a high 
FeNO. When we mutually adjusted android/gynoid ratio and pre-peritoneal fat area and 
their associations with FeNO the size and the directions of the effect estimates remained, 
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suggesting independent opposite effects of android/gynoid fat mass ratio and pre-
peritoneal fat. Also, we did not observe any interaction between physician-diagnosed 
inhalant allergies of the child and any fat measure for the associations with Rint, FeNO, 
wheezing and asthma. Several studies assessed the associations of specific body fat 
measures with lung function and asthma. In a study among 327 asthmatic children 
aged 10 years and 351 matched controls in Puerto Rico, a higher BMI was associated 
with a higher FEV1 and FVC, and increased risk of asthma (OR (95%CI): 1.27 (1.1-1.5), per 
z-score increase in BMI).29 A greater waist-hip ratio, waist circumference and percentage 
body fat were associated with a higher FVC, and a greater waist circumference with a 
lower FEV1/FVC. Three central obesity indicators (waist-hip ratio, waist circumference 
and waist-to-height ratio) consistently showed stronger dose-dependent associations 
with active asthma in a population of 2,758 schoolchildren than BMI.30 Besides age of 
participants, differences in study designs and methods of fat mass distribution measure-
ments could explain differences with our results. We additionally assessed associations 
of pre-peritoneal and subcutaneous fat mass with lung function and asthma.
interpretation of results
We observed that higher BMI was associated with higher Rint and increased risk of 
wheezing, high fat mass index with higher Rint, and android/gynoid fat mass ratio and 
pre-peritoneal fat mass with lower and higher FeNO, respectively. A higher BMI and obe-
sity were also associated with current wheezing, but not with ever physician diagnosed 
asthma. This difference could be explained by the differences in definition of current 
wheezing and ever physician diagnosed asthma. Current wheezing reflects obstructive 
respiratory symptoms most commonly due to asthma at age 6 years, whereas ever 
physician diagnosed asthma could partly reflect respiratory symptoms due to recurrent 
lower respiratory tract infections in early life. Respiratory symptoms due to recurrent 
lower respiratory tract infections are difficult to clinically distinguish from respiratory 
symptoms due to asthma at younger ages.
Because of the observational design of our study, we cannot draw conclusions about 
causality. However, support for our findings comes from animal studies, which have 
shown that inflammatory adipokines, mainly leptin and adiponectin, are secreted by 
adipose tissue.31 Leptin increases airway inflammation and responsiveness 32, whereas 
adiponectin reduces airway hyperreactivity and inflammation.33 Leptin is a member 
of the interleukin (IL)-6 family of cytokines and elevated levels affect allergen-induced 
T-cells and bronchial epithelial cells through TNF-α related IL-4 an IL-5 34, and histamine 
release.35 Leptin decreases the airway diameter in mice through the inhibition of central 
cholinergic tone 36, a parasympathetic effect. Visceral fat, as opposed to subcutane-
ous fat, exhibits relatively higher levels of adiponectin production in lean animals.37 
Higher adiponectin levels lead to lower inflammatory responses reflected by decreased 
Body fat mass distribution and asthma at school-age
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neutrophil recruitment and lower expression of inflammatory markers in mice when 
exposed to ozone.38 Obese mice have reduced serum adiponectin levels and increased 
eosinophil levels in bronchoalveolar lavage fluids and the peribronchovascular space.39 
Thus, animal studies show that adiposity could affect airway obstruction and inflamma-
tion. Human studies on the adiposity-asthma relation through leptin and adiponectin 
are scarce, mostly performed in adults, and show conflicting results. A recent study in 
mainly asthmatic children aged 8 years showed that higher leptin plasma concentra-
tions were associated with a lower FEV1, but not with FeNO and sputum eosinophils.40
We observed that regional fat measures were associated with changes in FeNO. An 
underlying mechanism could be that larger fat depots lead to an increase of arginase 
relative to L-arginine concentration, and lower FeNO. This is because NO is produced 
from L-arginine by the NO synthase (NOS) family of enzymes and arginase is a biologi-
cal competitor with NOS for L-arginine, which could lead to changes in FeNO levels, as 
known in children with asthma.41, 42 In humans, an increase in BMI has been associated 
with lower FeNO.43, 44 Also, lower arginine levels and higher arginase activity have been 
associated with lower FEV1, FEV1/FVC and FeNO.45
We observed that a higher pre-peritoneal fat area was associated with a lower Rint 
and higher FeNO, whereas subcutaneous fat area was not associated with any outcome. 
Visceral fat is known to be a better marker for inflammatory status, and risk factor for 
metabolic and cardiovascular outcomes, than subcutaneous fat mass.46 Also, animal 
studies showed that increased nutrient-intake in lean rats increased expression of leptin 
more in visceral fat and plasma than in subcutaneous fat.47 In a study among 799 11-year 
old children, a higher trunk-to-extremity fat ratio, which is a surrogate of visceral fat, was 
associated with lower serum adiponectin levels.47 In a study amongst 394 adults both 
leptin and adiponectin were associated with higher central body fat distribution, and se-
rum adiponectin concentrations seemed determined predominantly by the visceral fat 
compartment.48 Regarding the L-arginine metabolism, a recent study showed that the 
addition of arginase in subcutaneous fat deposits of morbid obese individuals reduced 
vasodilation, whereas this was not observed in the visceral tissues of these individuals. 
Furthermore, their visceral fat tissue exerted greater expression of pro-inflammatory 
oxidative-stress related, hypoxia-induced and proangiogenic genes with increased 
macrophage populations. This suggests that the visceral microenvironment, as opposed 
to subcutaneous fat tissue, may affect systemic health.49 Also, in mice models, L-arginine 
decreased fat accumulation in visceral fat 50, even in rats with high BMI.51 Thus, a lo-
cal fat depot-specific expression of adipokines and increased arginase levels might be 
contributing to the pathogenesis of asthma.
The different directions for the associations of android/gynoid fat mass ratio and 
abdominal pre-peritoneal fat area with FeNO could be explained by their different loca-
tions. The android area contains both pre-peritoneal and subcutaneous fat deposits. The 
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android/gynoid ratio, a proxy of waist-hip ratio, is a practical index of central adipose 
tissue distribution.11 In a study amongst 30 girls, waist-hip ratio was not associated with 
visceral or subcutaneous fat deposits.52 In adults, waist-hip ratio is a poor predictor of 
the distribution of adipose tissues among several fat compartments in the abdominal 
region.53 Waist-hip ratio does not account for large variations in the level of total fat 
and abdominal visceral adipose tissues.54 Among children, pre-peritoneal fat mass rep-
resents less than 10% of total abdominal fat. Therefore, android/gynoid fat mass ratio 
reflects fat depositions of different locations in the body, whereas the pre-peritoneal and 
subcutaneous fat areas reflect the effects of two different fat tissue types localized in the 
abdomen. Thus, our results suggest that the associations between obesity and asthma 
might be driven by local fat deposits, and not by general adiposity. Specific underlying 
pathophysiological mechanisms for differences in direction of android/gynoid fat mass 
ratio and abdominal pre-peritoneal fat area with FeNO need to be explored.
An alternative hypothesis proposes that a higher central body fat mass distribution 
exerts mechanical effects on the lungs, such as diminished tidal lung volumes, due to 
deposition of adipose tissue in the chest and abdomen, and around the airways, which 
might result in lower functional vital capacity.55 In the present study, a higher total fat 
mass index was associated with a higher respiratory resistance. We did not observe as-
sociations of a higher android/gynoid fat mass ratio with higher respiratory resistance. 
Studies focused on persistent or increasing total and abdominal fat mass and the risk 
of higher respiratory resistance and subsequently risk of wheezing or asthma among 
children in later life are needed.
strengths and limitations
A strength of this cross-sectional study in a population-based cohort is the use of 
detailed respiratory outcomes and adjustment for many relevant growth, socio- demo-
graphic and lifestyle covariates. However, some methodological considerations need to 
be discussed. Biased effect estimates in longitudinal studies mainly occur due to loss 
to follow-up. We observed that children lost to follow-up more often had unfavorable 
growth, socio-economic and lifestyle factors, which suggests that follow-up was selec-
tive. We did not have data on forced oscillation which is suggested to provide a more 
reliable evaluation of bronchial obstruction compared to the interrupter technique.56 
We used the interrupter technique to assess bronchial patency, as this is one of the very 
few methods that can successfully be applied to young children in the setting of an epi-
demiological study. When used in a standardized way according to recommendations, 
the expiratory interrupter resistance has good feasibility, repeatability and biological 
validity for the detection of airways obstruction 57, and appropriate reference data for 
commercial Rint devices are available.58 Its diagnostic value compared to forced oscilla-
tion and multiple breath washout, two other techniques that can be used in young chil-
Body fat mass distribution and asthma at school-age
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dren, is still debated as very few comparative studies have been published, that widely 
differ in patient selection criteria.59 Although the use of ISAAC-based questionnaires is a 
standardized and widely accepted method to identify children at risk for asthma, report-
ing bias might have occurred16, resulting in either overestimations or underestimations 
of the true associations. When absolute values of BMI (kg/m2) and Rint (kPa.L-1.s) were 
used, an increase of 1 kg/m2 in BMI was associated with an increase of 0.005 (95%CI: 
0.001, 0.010) kPa.L-1.s in Rint. This effect estimate is small and replication studies using 
Rint as outcome at this age are therefore needed. Also, the prevalence of children with 
underweight and obesity was low (0.9 and 4.5%, respectively), which could have af-
fected the power of our study. We categorized fat measures to assess possible non-linear 
associations and for easier clinical interpretation, although methods of cut-offs and the 
use of categorization could be argued.60 We additionally adjusted associations of total 
body and abdominal fat mass measures with Rint, FeNO, wheezing and asthma for BMI. 
The correlation between total body and abdominal fat mass measures and BMI was 
moderate (Pearson correlation 0.46 to 0.63) and might have introduced multicollinear-
ity. Despite this, most effect estimates remained similar in size and direction. Last, we 
assessed both body fat profile and Rint, FeNO, wheezing and asthma in a cross-sectional 
setting, and therefore we cannot distinguish the direction of causation between body 
fat profile measures, Rint, FeNO, wheezing and asthma.
in conclusion, a higher BMI was associated with higher Rint and increased risk of 
wheezing in school-age children. Abdominal body fat mass distribution may affect 
Rint and FeNO. Detailed body fat distribution measures might be better measures to 
understand the obesity-asthma paradigm.
Detailed acknowledgements and online resources can be found in the published article 
online: http://www.sciencedirect.com/science/article/pii/S009167491630625X
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AbstrAct
background Tobacco smoke exposure has been associated with early childhood asthma 
symptoms. We assessed the associations of tobacco smoke exposure during pregnancy 
and childhood with wheezing patterns, asthma, airway interrupter resistance (Rint) 
and Fractional exhaled Nitric Oxide (FeNO) in school-age children, and whether birth 
characteristics explained the associations.
methods This study was embedded in a population-based prospective cohort study 
among 6,007 children. Paternal and maternal smoking during pregnancy (never, first 
trimester only, continued), secondhand tobacco smoke exposure during childhood, 
wheezing patterns and asthma were prospectively assessed by questionnaires. Wheez-
ing patterns were defined as never, early (≤3 years only), late (>3 years only) and per-
sistent (≤3 and >3 years) wheezing. Rint and FeNO were measured at age 6 years. Birth 
characteristics were available from registries.
results Continued maternal smoking during pregnancy was associated with increased 
risks of early and persistent wheezing (OR: 1.24 (1.01, 1.52); 1.48 (1.13, 1.95)), and asthma 
(1.65 (1.07, 2.55), for ≥5 cigarettes per day), but not with Rint or FeNO. Birth character-
istics did not explain these associations. Childhood tobacco smoke exposure was as-
sociated with higher Rint (difference Z-score 0.45 (0.00, 0.90)), but this effect attenuated 
after adjustment for birth characteristics. Maternal smoking during first trimester only 
or paternal smoking during pregnancy was not associated with Rint, FeNO, wheezing or 
asthma.
conclusion Continued maternal smoking during pregnancy was associated with in-
creased risks of asthma outcomes in school-age children, whereas childhood tobacco 
smoke exposure was associated with higher Rint. Birth characteristics may explain part 
of these associations.
Tobacco smoke exposure, airway resistance and asthma in school-age children
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introdUction
Toxic environmental exposures in fetal life and infancy, including secondhand to-
bacco smoke exposure, are associated with an increased risk of childhood asthma.1-6 
Recently, we have observed that continued maternal smoking throughout pregnancy 
was associated with an increased risk of preschool wheezing.7 These associations were 
independent of paternal smoking, smoke exposure in childhood and being small for 
gestational age, and suggest a direct adverse effect of fetal tobacco smoke exposure 
on lung development. Direct intrauterine mechanisms in response to fetal smoke 
exposure may include suboptimal development of the respiratory tract system, which 
results in impaired lung growth with smaller airways and airway diameters leading to a 
higher airway resistance.7-9 Previous studies on the adverse effect of maternal smoking 
during pregnancy on childhood asthma at older ages are inconsistent.1,10-13 This might 
be due to socio-economic or life style related factors, or to not taking current tobacco 
smoke exposure in childhood or important birth outcomes such as gestational age 
and weight at birth into account.14 To disentangle the effects of direct intra-uterine 
adaptation mechanisms from unknown socio-economic, or life style related factors on 
childhood asthma, information on paternal smoking during pregnancy of the mother 
can be used.15 If stronger associations of maternal smoking during pregnancy with 
asthma or related outcomes is observed than for paternal smoking, taking secondhand 
tobacco smoke exposure in childhood into account, this would support the hypothesis 
that intra-uterine adaptation mechanisms underlie the observed associations. Similar 
associations for maternal and paternal smoking with asthma or related outcomes would 
suggest that common and shared socio-economic or life style related factors within 
families explain these associations.15-17 Additionally, the effects of secondhand tobacco 
smoke exposure in childhood on airway resistance and asthma outcomes, and the roles 
of being born early or small for gestational age in the association of maternal smoking 
during pregnancy with childhood asthma are not clear.7,18,19
Therefore, we first aimed to examine the associations of maternal and paternal 
smoking in different periods of pregnancy with airway resistance, airway inflammation, 
wheezing patterns and physician-diagnosed asthma in school-aged children participat-
ing in a large population-based prospective cohort study. Second, we examined the as-
sociations of secondhand tobacco smoke exposure during childhood with lung function 
and asthma outcomes, taking account for parental smoke exposure during pregnancy. 
Third, we examined whether the associations of tobacco smoke exposure with the lung 
function and asthma outcomes were modified by gestational age and weight at birth 
or atopy.
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mAteriAls And metHods
general design
This study was embedded in the Generation R Study, a population-based prospective 
cohort study of pregnant women and their children in Rotterdam, The Netherlands. 
In each trimester of pregnancy assessments were performed, including physical ex-
amination, fetal ultrasound examination, and questionnaires.20,21 All children were born 
between April 2002 and January 2006. Of all eligible children in the study area, 61% 
participated in the study at birth.20 The study protocol was approved by the Medical 
Ethical Committee of the Erasmus Medical Center, Rotterdam (MEC 217.595/2002/20). 
Written informed consent was obtained from all participants. A total of 6,007 children 
were included for the current analyses (Figure 3.1.1).
n = 6,976 
Children with any smoking data available 
n = 6,007 
Children with any asthma outcome data 
available 
 
Rint   n = 3,816 
FeNO   n = 3,463 
Wheezing patterns n = 3,750 
Asthma   n = 4,404  
n = 969 
Missing data on all asthma outcomes 
excluded 
n = 1,157 
Data on twins (n=172) and missing 
data on maternal smoking during 
pregnancy (n=1,157) excluded 
n = 8,305 
Cohort with consent for follow up until age 
6 years    
figure 1. Flowchart of Participants.
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fetal and childhood smoke exposure
As previously described in detail 7, mothers reported their active tobacco use by 3 ques-
tionnaires during pregnancy. We grouped mothers’ tobacco use into three categories 
based on the first questionnaire: 1) never during pregnancy, 2) first trimester only, and 
3) continued during pregnancy. Reported tobacco use in the second and third trimester 
were used to reclassify maternal smoking, when appropriate. Active paternal smoking 
was assessed in the first questionnaire by asking the mother whether the father smoked 
during her pregnancy (n=5,411). The number of cigarettes smoked daily was classified as 
none, ≤4 cigarettes per day, and ≥5 cigarettes per day. Information about any in-house 
secondhand tobacco smoke exposure in childhood at age 6 years, irrespective whether 
this source was the mother, father or anyone else, was obtained by a questionnaire at 
the age of 6 years (response rate 76%;” Was the child exposed to any in-house tobacco 
smoke (never / yes, ≤ 1 time per week / yes, ≥ 2 times per week”).
childhood asthma outcomes
At age 6 years, airway interrupter resistance (Rint) was measured in kPa/L (MicroRint, 
MicroMedical, Rochester, Kent, UK) during tidal expiration, with occlusion of the airway 
at peak expiratory flow, according to ERS and ATS guidelines. Fractional exhaled nitric 
oxide (FeNO) in ppb was measured using the NIOX chemiluminescence analyzer (Aero-
crine AB, Solna, Sweden) according to ERS and ATS guidelines. FeNO levels were natural 
log-transformed to obtain normality. Wheezing was reported by parental questionnaires 
annually from birth to age 4 years and at age 6 years. Wheezing patterns were defined in 
4 categories as previously proposed 22 and commonly used in epidemiological studies: 
1) no wheezing: no recorded wheezing at any age; 2) early wheezing: at least 1 wheez-
ing episode during the first 3 years of life but no wheezing episodes at 4 and 6 years 
of age; 3) late wheezing: no wheezing episodes during the first 3 years of age but at 
least 1 wheezing episode at 4 or 6 years of age; and 4) persistent wheezing: at least 1 
wheezing episode in the first 3 years of life and 1 episode of wheezing at 4 or 6 years of 
age.22,23 Physician-diagnosed ever asthma was assessed using questions adapted from 
the International Study on Asthma and Allergy in Childhood (ISAAC) at age 6 years.24
covariates
We obtained information on maternal age, anthropometrics, socio-economic status, 
history of asthma and atopy, parity, child’s ethnicity and pet keeping by questionnaires, 
completed by the mother at enrollment. Data on gestational age and birth weight was 
obtained by midwife and hospital registries. Detailed information on fetal and child-
hood smoke exposure, childhood asthma outcomes, and covariates, including child’s 
inhalant allergies, is provided in the Supplemental Material.
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statistical analysis
First, we used multivariate logistic and linear regression analyses to examine the associa-
tions of maternal and paternal smoking during pregnancy, including reported number 
of cigarettes, with Rint, FeNO and increased risk of asthma at age 6 years. These models 
were adjusted for maternal age, pre-pregnancy body mass index, educational level, his-
tory of asthma or atopy, psychological distress during pregnancy, parity, and child’s sex, 
ethnicity, breastfeeding, pet keeping, and secondhand tobacco smoke exposure at age 
6 years (see Supplemental Material). Differences in prevalences of wheezing patterns 
in strata of maternal and paternal smoking during pregnancy were tested using uni-
variate and multivariate polynomial regression models, with “no maternal smoking” and 
“never wheezing” as reference. The associations of paternal smoking with Rint, FeNO, 
wheezing patterns and asthma were assessed among mothers who did not smoke dur-
ing pregnancy (n = 4,504). Second, we used similar regression analyses to examine the 
associations of secondhand tobacco smoke exposure, including secondhand tobacco 
smoke exposure per week, with Rint, FeNO and asthma at age 6 years. These associations 
were adjusted the same covariates as the maternal model, and maternal and paternal 
smoking during pregnancy. Third, to assess whether these were explained by birth 
outcomes, we additionally adjusted the models for gestational age and weight at birth 
(birth outcome model). Also, we additionally adjusted models for atopy (inhalant allergy 
or eczema) at age 6 years to assess the potential confounding or mediating roles of 
atopy (Supplemental Material). Finally, we categorized tobacco smoke exposure into 
4 categories (never, smoke exposure during pregnancy only, smoke exposure in child-
hood only, smoke exposure during pregnancy and in childhood) and examined their 
associations with Rint, FeNO, wheezing and asthma using the birth outcome model.
Additional information on used methods is provided in the Supplemental Material. 
Measures of association are presented in Odds Ratios (ORs) for wheezing and asthma, 
in sympercents (symmetric percentage difference = regression coefficients of elog 
transformed FeNO*100%) for FeNO measurements 25 and in standardized z-score differ-
ences for Rint measurements, all with their 95% Confidence Interval (95% CI). Statistical 
analyses were performed using SPSS version 21.0 for Windows software (SPSS Inc).
resUlts
Of the population for the current analysis, 67.6% (n = 4,063) was of European origin. 
Those of non-European ethnicity were mainly of Turkish (7.3%), Surinamese (6.8%), 
Moroccan (5.1%) or Dutch Antilles (2.5%) origin. Mean maternal age at inclusion was 
30.6 years. Of all mothers, 25.0% (n = 1,503) reported to smoke during pregnancy of 
which 8.8% (n = 528) smoked during the first trimester only, and 16.2% (n = 975) smoked 
Tobacco smoke exposure, airway resistance and asthma in school-age children
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continuously during pregnancy (Table 3.1.1). Of all fathers, 44% (n = 2,383) smoked dur-
ing pregnancy of their partners. Children were classified as never wheezing (45.6%, n = 
2,149), early wheezing (28.6%, n = 1,266), late wheezing (7.4%, n = 324), and persistent 
wheezing (18.5%, n = 765). At age 6 years of the children, average airway resistance 
(Rint) was 0.84 (SD 0.29) kPa/L/s, and median FeNO was 7.5 (SD 8.5) ppb. Current wheez-
ing was reported for 8.7% (n = 305), and physician-diagnosed asthma for 6.5% (n = 213) 
of the children. Other characteristics of parents and their children are given in Table 3.1.1 
and S-Table 3.1.1. Participants without follow-up data at age 6 years had younger, lower 
educated, more smoking parents, mothers with a higher pre-pregnancy body mass 
index, and higher prevalence of parity and psychological distress, and had a lower birth 
weight and more often were of non-European ethnicity than those participants with 
follow-up data (S-Table 3.1.2).
smoking exposure and rint, feno, wheezing patterns and asthma
As compared with no maternal smoking, maternal smoking in the first trimester only 
was not associated with a higher mean Rint and FeNO, or increased risks of wheezing 
patterns and asthma in childhood (Table 3.1.3, confounder model).
Continued maternal smoking during pregnancy was not associated with Rint or FeNO. 
Continued maternal smoking of ≥ 5 cigarettes per day was associated with an increased 
risk of physician diagnosed asthma (OR 1.65 (1.07, 2.55)). The effect estimate did not 
materially change when we additionally adjusted for gestational age and birth weight 
(Table 3.1.3, birth outcome model). The effect estimate became stronger after adjust-
ment for inhalant allergies and eczema (OR 1.77 (1.13, 2.79) (S-Table 3.1.3). The distribu-
tion of wheezing patterns was not different between children from mothers who did or 
did not smoke during first trimester only. As compared with children from mothers who 
did not smoke, those from mothers who continued smoking during pregnancy showed 
a higher prevalence of early wheezing (29.9% vs. 28.1%, respectively) and persistent 
wheezing (25.2% vs. 17.0%, respectively). Similarly, continued maternal smoking dur-
ing pregnancy showed increased odds for early and persistent wheezing when taking 
confounders and birth outcomes into account (Table 3.1.2).
Among children of mothers who did not smoke during pregnancy, paternal smoking 
was not associated with childhood Rint or FeNO (Z-score difference -0.4 (-0.34, 0.26) and 
sympercent change -0.2 (-6.9, 6.5), respectively). In contrast to maternal smoking of ≥ 
5 cigarettes per day, paternal smoking of ≥ 5 cigarettes per day during pregnancy was 
not associated with physician diagnosed asthma (OR 1.01 (0.58, 1.75); Table 4). No differ-
ences in risk for wheezing patterns were observed between children from fathers who 
did not smoke or fathers who smoked during pregnancy (Table 3.1.2).
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table 3.1.1. Characteristics of Parents and their Children
maternal smoking during pregnancy (n = 6,007)
no smoking
n = 4,504 (75.0%)
first trimester 
only smoking
n = 528 (8.8%)
continued 
smoking
n = 975 (16.2%)
maternal characteristics
Age (years) 31.0 (4.8) 30.3 (5.0) 29.2 (5.8)
Pre-pregnancy body mass index (kg/m2) 24.6 (4.2) 24.4 (4.1) 25.1 (4.6)
Education, higher (%) 53.3 (2,401) 47.0 (248) 23.6 (230)
History of asthma or atopy (%) 38.3 (1,716) 34.7 (183) 36.3 (354)
Psychological distress during pregnancy (%) 16.5 (745) 16.7 (88) 25.7 (251)
Parity ≥1 (%) 45.0 (2,029) 32.0 (169) 44.0 (429)
Paternal characteristics
Age (years) 33.5 (5.4) 32.9 (5.8) 32.0 (6.0)
Education, higher (%) 58.7 (2,685 ) 49.6 (282) 27.9 (241 )
History of asthma or atopy (%) 34.4 (1,597) 34.2 (190) 25.6 (208)
Smoking during pregnancy of partner (%) 34.9 (1,428) 65.4 (320) 76.6 (635)
child characteristics
Sex, female (%) 50.6 (2,281) 52.1 (275) 45.3 (442)
Gestational age at birth (weeks) 39.9 (1.7) 39.9 (0.6) 39.7 (1.9)
Birth weight (grams) 3,466 (549) 3,466 (188) 3,285 (557)
Ethnicity, non-European (%) 34.0 (1,532) 23.5 (124) 37.7 (368)
Breastfeeding until 1stt year (%) 92.2 (4,151) 90.3 (477) 83.9 (818)
Pet keeping until 1stt year (%) 31.1 (1,399) 40.7 (215) 44.2 (431)
Inhalant allergies age 6 years (%) 12.4 (557) 12.3 (65) 13.1 (128)
Eczema ever until 6 year (%) 21.7 (976) 21.8 (115) 24.4 (975)
Secondhand tobacco smoke exposure age 6 years (%)
 No 92.7 (3,271) 83.9 (324) 49.9 (308)
 Yes, ≤ 1 time / week 2.4 (86) 4.9 (19) 9.1 (56)
 Yes, ≥ 2 times / week 4.8 (171) 11.1 (43) 41.0 (253)
Wheezing patterns until 6 years (%)
 Never 47.7 (2,149) 43.6 (230) 36.7 (358)
 Early 28.1 (1,266) 30.1 (159) 29.7 (290)
 Late 7.2 (324) 7.8 (41) 8.3 (81)
 Persistent 17.0 (765) 18.6 (98) 25.2 (246)
Rint age 6 years (kPa/L/s) 0.84 (0.29) 0.81 (0.28) 0.86 (0.31)
FeNO age 6 years(ppb) 9.5 (8.5) 8.6 (6.0) 8.9 (7.4)
Asthma age 6 years (%) 6.2 (213) 5.3 (20) 8.8 (53)
Values are means (SD), medians (2.5-97.5th percentile) or percentages (absolute numbers) based on imput-
ed data. Missing data on paternal smoking during pregnancy (9.9%), secondhand tobacco smoke exposure 
(22.3%), child’s Rint (36.5%), FeNO (23.1%), and asthma (26.7%) were not imputed.
Tobacco smoke exposure, airway resistance and asthma in school-age children
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Compared with children not exposed to secondhand tobacco smoke , those who were 
exposed had a higher Rint (difference in Z-score 0.45 (0.00, 0.90)), but no difference in 
FeNO, or increased risk of asthma (Table 3.1.5). Additional adjustment for gestational 
age and size at birth did attenuate the size of the effect estimate for Rint (0.41 (-0.03, 
0.86).
We observed no statistical significant interactions between gestational age or size 
at birth with maternal of paternal smoking during pregnancy, or secondhand tobacco 
smoke exposure in childhood (all p-values for interaction > 0.05).
When we used the combined tobacco smoke exposure variable, we observed that 
smoke exposure during pregnancy only was associated with persistent wheezing (OR 
1.32 (1.00, 1.74) (S-Table 3.1.4). We did not observe associations of smoke exposure in 
childhood only or smoke exposure both during pregnancy and in childhood with Rint, 
FeNO and asthma (S-Table 3.1.4).
discUssion
We observed, in a large population-based prospective cohort study from early preg-
nancy onwards, that children of mothers who continued smoking ≥5 cigarettes per day 
during pregnancy had an increased risk of early and persistent wheezing, and asthma 
at school-age. These associations were not explained or modified by gestational age or 
birth weight. Maternal smoking during first trimester only and paternal smoking were 
not associated with childhood Rint, FeNO, or asthma. This implies that the observed 
associations are due to continued intra-uterine adverse effects, and not by unmeasured 
socio-economic, behavioral or genetic factors. Associations of smoke exposure with 
airway resistance were present for childhood secondhand tobacco smoke exposure, 
independently of any tobacco smoke exposure during pregnancy. This association 
seemed partly explained by gestational age and weight at birth.
comparison of main findings with other studies
Many previous studies suggest a direct adverse effect of tobacco smoke exposure on 
lung development, although disentanglement of exposure to maternal smoking dur-
ing pregnancy and secondhand tobacco smoke remains difficult.1-3,7,26,27 Our study is a 
follow-up of a study previously performed in the same population at younger age, in 
which we observed that fetal exposure to continued maternal smoking is associated 
with increased risks of wheezing in preschool children.7 We do now show that the ad-
verse effects of maternal smoking during pregnancy on wheezing patterns and asthma 
extends into school-age, independent of paternal smoking, smoke exposure in child-
hood and birth characteristics. A large meta-analysis performed by Burke et al. observed 
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that postnatal passive smoke exposure was associated with a 30% to 70% increased 
risk of incident wheezing and that prenatal maternal smoking was associated with a 
21% to 85% increase in incidence of asthma in children aged ≤2 years.1 A recent pooled 
analysis focused on wheezing and asthma at older ages, and showed an 1.4 and 1.6-fold 
independent effect of maternal smoking during pregnancy on wheezing and asthma in 
children aged 4 to 6 years who were not exposed to secondhand tobacco smoke in their 
first year of life.2 Also, a linear dose-dependent association of maternal daily cigarette 
consumption during pregnancy with wheezing and asthma was observed. The sizes 
of these effect estimates were similar to those observed in our study. We additionally 
took other important confounders such as parental history of asthma and atopy into 
account.28 Younger gestational age and weight at birth might be associated with smaller 
airways and could subsequently lead to lower lung function, in particular lower airway 
patency.29, 30 It is known that these birth characteristics play an important role in the 
development of respiratory symptoms and lower lung function in childhood and adult-
hood.19,30,31 We observed that the associations between maternal smoking with wheez-
ing and asthma were not explained by gestational age and birth weight. We additionally 
observed that socio-economic or life style related factors, using the paternal smoking 
during pregnancy as a proxy15, did not explain the associations of maternal smoking 
during pregnancy with Rint, wheezing and asthma.
Burke et al. observed that secondhand tobacco smoke exposure in childhood was 
associated with childhood asthma (age 5 to 18 years) with approximately similar effect 
estimates (OR 1.20 (0.98-1.46)) as maternal smoke exposure during pregnancy.1 We only 
observed an association of secondhand tobacco smoke exposure with a higher Rint. 
This is consistent with earlier studies 32,33, although these studies did not take smoke 
exposure during pregnancy into account, did not use asthma as a separate outcome or 
were performed in asthma-suspected children only. Additionally, we explored the role 
of birth characteristics and observed that the association between secondhand tobacco 
smoke exposure and Rint was partly explained by gestational age and size at birth.
interpretation of results
We observed that the associations of maternal smoking during pregnancy with Rint, 
FeNO, wheezing patterns and physician diagnosed asthma were not explained or modi-
fied by gestational age or weight at birth. Thus, despite the strong associations between 
maternal smoking during pregnancy with birth characteristics, the pathways leading 
from fetal smoke exposure to physician diagnosed asthma might be independent of 
early body growth. The effects of maternal smoking during pregnancy on airway remod-
eling, hyper-responsiveness and inflammation in offspring was recently assessed in mice 
models.34 Smoking during pregnancy induced airway remodeling including increased 
airway smooth muscle layer, collagen III deposition and house dust mite-induced goblet 
Tobacco smoke exposure, airway resistance and asthma in school-age children
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cell numbers, which may contribute to increased methacholine responsiveness. This 
remodeling was irrespective of allergen exposure, although allergen exposure resulted 
in higher methacholine responsiveness in house dust mite-exposed offspring from 
smoking mothers when compared to non-smoking mothers. Other pathways that have 
been suggested are adverse effects of nicotine leading to a reduced blood flow and 
decreased delivery of oxygen and nutrients to the fetus, a reduction in fetal breathing 
movements or a reduction in number and metabolism of alveolar type II cells, which 
can affect abnormal growth and maturation of the airways and lungs independent of 
body size.35-37 However, we did not observe associations of maternal smoking during 
pregnancy with Rint. Alternatively, recent studies propose that maternal smoking dur-
ing pregnancy changes the expression of asthma susceptibility genes by a reduction of 
histone deacetylase activity and changes in methylation patterns.38-40 Thus far it is not 
known to what extent these epigenetic changes persist throughout life course or which 
specific critical periods for epigenetic changes are important to have an effect on the 
risk of later lung disease.
strengths and weaknesses
The major strength of this study is that we used a population-based prospective cohort 
design, with detailed information about maternal and paternal smoking during preg-
nancy, and secondhand tobacco smoke exposure in childhood. Some methodological 
considerations need to be discussed. First, follow-up data was available in 70% of our 
original study population. This non-response could have led to biased effect estimates, if 
associations of Rint, wheezing patterns or asthma would be different between children 
included and not included in the analyses. Second, information about parental smoking 
during pregnancy was prospectively collected. Reporting bias by underreporting of 
the participants might have occurred although assessing smoke exposure by question-
naires is valid in epidemiologic studies.41 Assessing smoke exposure by biomarkers 
(cotinine, nicotine) in urine, blood and air has not been proven to enhance the quality 
of smoking data when studying asthma or asthma-related outcomes.41,42 We had no ob-
jectively measured data on inhalant allergy such as specific IgE sensitization measured 
with serum or skin prick tests. Third, we did not have data on spirometry, the preferred 
measure in asthma assessment. Since lung function measurements using spirometry 
in children aged 6 years are only successful in approximately 50%, we did not perform 
these measurements at this age.43 The Rint technique showed a high feasibility in this 
age group, and is known to detect small changes in proximal and more distal airway 
function with good within- and between-occasion reproducibility.44 Previous studies 
have shown that Rint is able to identify differences in baseline and change in airway 
caliber. The discriminating capacity of Rint to identify asthma was found to be useful 
with positive predictive values of 82%.44-46 Also, Rint is associated with clinically relevant 
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endpoints including asthma diagnosis or wheezing and is able to distinguish between 
groups of symptomatic and healthy young children.46 Fourth, asthma is a difficult 
diagnosis in young children. Both wheezing patterns and asthma were self-reported 
outcome measures. Although using validated questionnaires based on international 
guidelines24, underreporting or over-reporting might have occurred, which might have 
led to misclassification of the outcomes resulting in either overestimations or underes-
timations of the true associations. Finally, although we took account for many potential 
confounders, residual confounding might still be an issue, as in any observational study.
in conclusion, our results suggest that maternal smoking during pregnancy leads to 
increased risks of early and persistent wheezing and asthma in school-aged children. 
Secondhand tobacco smoke exposure in childhood is associated with higher Rint but 
this effect is partly explained by gestational age and weight at birth.
Detailed acknowledgements and online resources can be found in the published article 
online: http://www.sciencedirect.com/science/article/pii/S0012369215506387
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AbstrAct
background: Breastfeeding is associated with a lower risk of asthma symptoms in early 
childhood, but its effect at older ages remains unclear. We examined the associations 
of duration and exclusiveness of breastfeeding with asthma outcomes in children aged 
6 years, and whether these associations were explained by atopic or infectious mecha-
nisms.
methods: We performed a population-based prospective cohort study among 5675 
children. Information about breastfeeding was collected by questionnaires. At age 
6 years, we measured interrupter resistance (Rint) and fractional exhaled nitric oxide 
(FeNO). Information about wheezing patterns (early (≤3 years only), late (>3 years only), 
persistent (≤3 and >3 years)), and current asthma at 6 years was derived from repeated 
questionnaires.
results: Compared to children who were ever breastfed, those who were never breastfed 
had lower FeNO levels (sympercent (95% CI): -16.0 (-24.5, -7.5)) and increased risks of late 
and persistent wheezing (OR(95% CI): 1.69 (1.06, 2.69) and 1.44 (1.00, 2.07), respectively). 
Shorter duration of breastfeeding was associated with early wheezing and current 
asthma (1.40 (1.14, 1.73) and 2.19 (1.29, 3.71), respectively). Less exclusive breastfeeding 
was associated with early wheezing (1.28 (1.08, 1.53)). Breastfeeding duration and exclu-
siveness were not associated with FeNO or Rint. The associations were not explained by 
inhalant allergies, partly by lower respiratory tract infections in early life, and to a lesser 
extent by lower respiratory tract infections in later life.
conclusions: Breastfeeding patterns may influence wheezing and asthma in childhood, 
which seems to be partly explained by infectious mechanisms.
Duration and exclusiveness of breastfeeding and outcome in asthma
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introdUction
Breastfeeding may influence the development of childhood asthma.1 Prolonged and 
exclusive breastfeeding has been associated with a decreased risk of asthma symptoms 
in early childhood with a possible diminishing effect over time.2-5 Underlying mecha-
nisms might involve secretory IgA, cytokines, and long-chain fatty acids in breast milk 
that stimulate the immune system 6 and change the balance between pro- and anti-
inflammatory mechanisms.7 This might lead to altered airway inflammation or airway 
resistance. Previous studies suggest a potential mediating role of inhalant allergies and 
respiratory tract infections.8
In a recent meta-analysis using data of 775,718 children from 117 observational stud-
ies 5, breastfeeding was associated with a decreased risk of asthma, regardless of asthma 
definition or the age at which asthma was measured (0–2 years, 3–6 years, or 7 years and 
older). The authors observed a large heterogeneity, which might partly be explained 
by the high variability of the asthmatic phenotypes used by the individual studies.9 
Furthermore, in a randomized trial amongst 13,889 children followed up until age 6.5 
years receiving an experimental breastfeeding intervention, no differences in allergic 
symptoms or asthma prevalence were observed.3 More detailed asthma phenotyping 
and use of objective measurements, such as lung function tests, might improve the 
understanding of the protective effect of breastfeeding. Furthermore, observing dose-
response relationships based on breastfeeding duration or exclusivity would support 
the causality of the association of breastfeeding with childhood asthma.
Therefore, we aimed to examine among 5,675 children participating in a population-
based prospective cohort study the associations of breastfeeding duration and exclu-
siveness with airway resistance, airway inflammation, and the risks of wheezing and 
asthma in children up to age 6 years, and to explore whether these associations were 
mediated by atopic or infectious mechanisms.
metHods
design and cohort
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from fetal life until young adulthood in Rotterdam, The Netherlands. A 
detailed description of the study design has been published previously.10 The study pro-
tocol was approved by the Medical Ethical Committee of the Erasmus Medical Centre, 
Rotterdam (MEC-2007-413-NL21545.078). Written informed consent was obtained from 
all participants. A total of 5,675 children were included for the current analyses (S-Figure 
3.3.1).
168
Chapter 3.3
breastfeeding duration and exclusiveness
In the Netherlands, use of breastfeeding until age 6 months is encouraged and sup-
ported. Detailed information about breastfeeding was collected using questionnaires 
administered at 2, 6 and 12 months after birth. Children were classified as ‘never 
breastfed’ and ‘ever breastfed’. Duration of breastfeeding was categorized into 4 groups: 
‘<2 months’, ‘2-4 months’, 4-6 months and ‘≥6 months’. Exclusivity of breastfeeding was 
defined by at which age infant formula, other drinks or food was introduced. Exclusivity 
of breastfeeding was categorized into ‘non-exclusive breastfeeding for 4 months’, and 
‘exclusive breastfeeding for 4 months’.
Asthma outcomes
Children visited the research center at a mean age of 6.1 (SD 0.4) years. Lung function 
tests were performed according to international guidelines.11,12 Airway resistance (Rint) 
was measured in kPa/L (MicroRint, MicroMedical, Rochester, Kent, UK) during tidal 
expiration, and sex- and height-adjusted z-scores were calculated.12 We corrected for a 
stepwise variation due to technical issues that required replacement of the Rint device. 
Fractional exhaled Nitric Oxide (FeNO) was used as a measure of eosinophilic airway 
inflammation and measured online (NIOX chemiluminescence analyzer; Aerocrine AB, 
Solna, Sweden). Questionnaires adapted from the International Study on Asthma and 
Allergy in Childhood (ISAAC) provided information on wheezing (no, yes) at ages 1 to 4 
and 6 years.13 Wheezing patterns were characterized by time of onset and subsequent 
absence or persistence into ‘never’, ‘early’ (wheezing ≤3 years only), ‘late’ (wheezing >3 to 
6 years only), or ‘persistent wheezing (wheezing ≤3 years and >3 to 6 years) in children 
with information on wheezing for at least two time points.13 We defined ‘current asthma’ 
(no, yes) based on information on ever physician-diagnosed asthma (no, yes) and pres-
ence of wheezing in the past 12 months obtained at age 6 years.
covariates
We obtained information on maternal age, pre-pregnancy body mass index (BMI), 
educational level, parity, history of asthma or atopy, and pet keeping by questionnaires 
completed by the mother at enrolment. Information about active maternal smoking was 
obtained by postal questionnaires during the first, second and third trimester of preg-
nancy and combined into smoking during pregnancy (no, yes). Maternal psychological 
distress was defined using the global severity index (GSI), a measure of current level 
or depth of the symptoms, which denotes overall psychological distress.14,15 Midwife 
and hospital registries at birth provided information on sex, gestational age and birth 
weight. Ethnicity of the child was based on country of birth of the parents. Information 
on inhalant allergies (pollen, house dust mite, pets) and lower respiratory tract infections 
Duration and exclusiveness of breastfeeding and outcome in asthma
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(pneumonia, bronchitis) was obtained by questionnaire at age 6 years. More detailed 
information on covariates is provided in the Supplementary Material.
data analysis
We used multivariate regression models to examine the associations between duration 
and exclusiveness of breastfeeding with Rint, FeNO, wheezing patterns, and current 
asthma at 6 years. Detailed information on covariates is given in the supplementary 
material. Missing data of covariates and wheezing were imputed to reduce bias and 
improve efficiency. The final models were adjusted for maternal BMI, educational level, 
parity, smoking, and child’s sex, birth >37 weeks of gestation, birth weight and ethnicity. 
We additionally adjusted our models for inhalant allergies and respiratory tract infec-
tions as they are hypothesized to be within the causal pathway, and calculated the per-
centage change of the effect estimate by the formulas: 100x(effect estimatemediator-effect 
estimatemodel1)/(effect estimatemodel1) for Rint and FeNO, and 100x(effect estimatemediator-
effect estimatemodel1)/( effect estimatemodel1-1) for wheezing patterns and current asthma. 
A 95% confidence interval for the percentage change of the effect estimate was cal-
culated using a bootstrap method with 1,000 resamplings.16 FeNO levels were natural 
log-transformed to obtain normality and presented as sympercent difference (sym%), 
which represents the regression coefficient of elog transformed FeNO*100%, and can be 
interpret as percentage change.17 All measures of association are presented with their 
95% confidence intervals (95% CI). Statistical analyses were performed using the Statisti-
cal Package of Social Sciences version 21.0 (IBM Corp., Armonk, NY, USA), and R version 
3.0.0 (The R foundation for Statistical Computing).
resUlts
Detailed characteristics of children and their mothers are presented in Table 3.3.1 and S-
Table 3.3.1. Of the children, 92.2% were ever breastfed, 20.1% was breastfed <2 months, 
16.5% for 2-4 months, 9.4% for 4-6 months and 24.7% for ≥6 months. Mean Rint was 0.84 
(SD 0.29) kPa/l/s and median FeNO was 9.2 (range 0.10– 19) ppb. Of the children, 54.1% 
were categorized as never, 28.0% as early, 4.8% as late, and 13.0% as persistent wheeze. 
Current asthma was reported for 3.2%. Non-responders and participants without follow-
up data had younger, lower educated mothers with a higher pre-pregnancy BMI and 
higher prevalence of smoking and psychological distress. Children were more often 
non-from European ethnicity, born younger, had a lower birth weight, and more often 
had respiratory tract infections than those included in the study (S-Table 3.3.2).
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table 3.3.1. Characteristics of Mothers and Their Children.
imputed data
(n = 5,675)
maternal characteristics
Age (years) 31.1 (4.9)
Body mass index (kg/m2)
 <20 8.6 (487)
 20-25.0 55.0 (3,121)
 25-30.0 26.5 (1,504)
 ≥30 9.9 (562)
Higher educational level (%) 53.0 (3,009)
Multi-parous (%) 42.9 (2,431)
History of asthma or atopy (%) 37.8 (2,142)
Pet keeping (%) 32.9 (1,897)
Smoking during pregnancy (%) 14.3 (812)
Psychological distress during pregnancy (%) 7.8 (444)
child characteristics
Female sex (%) 50.1 (2,845)
Gestational age at birth (weeks) 40.1 (26.7, 42.9)
Birth weight (grams) 3,459 (545)
European ethnicity (%) 70.8 (4,018)
Inhalant allergy (%) 6.9 (391)
Lower respiratory tract infections at 6 years (%) 5.1 (290)
Breastfeeding ever (%) 92.2 (5,231)
Breastfeeding duration (%)
 Never 9.9 (444)
 <2 months 20.1 (1,140)
 2-4 months 16.5 (939)
 4-6 months 9.4 (531)
 ≥6 months 24.7 (1,404)
Breastfeeding exclusiveness (%)
 Never 9.6 (444)
 Non-exclusive for 4 months 65.0 (2,993)
 Exclusive for 4 months 25.4 (1,171)
Rint (kPa/L/s) 0.84 (0.29)
FeNO (ppb) 9.2 (0.1, 119)
Wheezing
 Never 54.1 (3,072)
 Early 28.0 (1,590)
 Late 4.8 (274)
 Persistent 13.0 (739)
Current asthma (%) 3.2 (132)
Values are means (SD), medians (range) or percentages (absolute numbers). Data on breastfeeding dura-
tion and exclusiveness, Rint, FeNO and current asthma were not imputed.
Duration and exclusiveness of breastfeeding and outcome in asthma
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breastfeeding and asthma outcomes
In crude analyses, breastfeeding was associated with FeNO, wheezing patterns and asth-
ma, but not with Rint (S-Tables 3.3.3). Results did not materially change after adjustment 
for confounders (Tables 2 and 3). Compared with children who were ever breastfed, those 
never breastfed had lower FeNO levels (sym% (95% CI): -16.0 (-24.5, -7.5) (Table 3.2.2). The 
duration and exclusivity of breastfeeding was not associated with FeNO. Never breast-
fed children had increased risks of late and persistent wheezing (Odds Ratio (OR) (95% 
CI): 1.69 (1.06, 2.69) and 1.44 (1.00, 2.07), respectively) (Table 3.3.3). Among breastfed 
children, those breastfed for <2 months had increased risks of early wheeze and current 
table 3.3.2. Associations of Breastfeeding with Childhood Rint and FeNO
rint feno
Z-score difference sympercent difference
n = 3,422 n = 3,150
breastfeeding (n = 5,675)
Never (n = 444) -0.11 (-0.51, 0.29)
n = 248
-16.0 (-24.5, -7.5)**
n = 241
Ever (n = 5,231) Reference
n = 3,174
Reference
n = 2,906
duration of breastfeeding
(n = 4,023)
0.1 - 2 months
(n = 1,138 )
-0.7 (-0.38, 0.25)
n = 677
-1.1 (-7.8, 5.6)
n = 621
2 - 4 months
(n = 941)
0.07 (-0.25, 0.40)
n = 556
-4.5 (-11.3, 2.4)
n = 535
4 - 6 months
(n = 540)
0.20 (-0.19, 0.59)
n = 320
0.20 (-4.3, -12.5, 3.9)
n = 304
≥6 months
(n = 1,404)
Reference
n = 848
Reference
n = 776
duration (per month)
(n = 4,023)
0.01 (-0.03, 0.04)
n = 2,401
0.2 (-0.5, 0.9)
n = 2,236
exclusivity of breastfeeding
(n = 4,164)
Non-exclusive for 4 months
(n = 2,993)
-0.10 (-0.37, 0.17)
n = 1,784
-2.8 (-8.7, 3.1)
n = 1,672
Exclusive for 4 months
(n = 1,171)
Reference
n = 718
Reference
n = 663
Values are z-scores differences (95% confidence intervals) or sympercent differences (95% confidence in-
tervals). “n =” represents number of total group. Models were adjusted for maternal body mass index, edu-
cational level, parity, smoking, and child’s sex, gestational age at birth, weight at birth and ethnicity. **p < 
0.01.
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asthma (OR (95% CI): 1.40 (1.14, 1.73) and 2.19 (1.29, 3.71), respectively) compared with 
those breastfed for ≥6 months. Longer duration of breastfeeding was associated with 
early wheezing and current asthma (OR (95% CI): 0.97 (0.94, 1.00) and 0.92 (0.87, 0.98), 
respectively) (Tables 3.3.2 and 3.3.3). Similarly, non-exclusively breastfed children had 
an increased risk of early wheezing (OR (95% CI): 1.28 (1.08, 1.53)), compared with those 
breastfed exclusively for 4 months. Additional adjustment for inhalant allergies did not 
materially change the effect estimates (S-Table 3.3.4a). After additional adjustment for 
table 3.3.3. Associations of Breastfeeding with Wheezing Patterns and Current Asthma.
wheezing patterns current asthma
early wheezing
odds ratio
late wheezing
odds ratio
Persistent 
wheezing
odds ratio
odds ratio
n = 1,590 n = 274 n = 739 n = 4,093
breastfeeding
(n = 5,675)
Never (n = 444) 1.31 (0.98, 1.75)
n = 141
1.69 (1.06, 2.69)*
n = 28
1.44 (1.00, 2.07)*
n = 76
1.57 (0.90, 2.74)
n = 17 / 317
Ever (n = 5,231) Reference
n = 1,449
Reference
n = 246
Reference
n = 663
Reference
n = 115 / 3,776
duration of breastfeeding
(n = 4,023)
0.1 - 2 months
(n = 1,138 )
1.40 (1.14, 1.73)**
n = 344
1.13 (0.72, 1.77)
n = 62
1.24 (0.94, 1.65)
n = 156
2.19 (1.29, 3.71)**
n = 41 / 806
2 - 4 months
(n = 941)
1.20 (0.97, 1.48)
n = 266
0.80 (0.49, 1.32)
n = 37
1.14 (0.86, 1.52)
n = 119
1.27 (0.69, 2.31)
n = 20 / 695
4 - 6 months
(n = 540)
1.14 (0.89, 1.46)
n = 153
0.55 (0.26, 1.14)
n = 15
0.90 (0.63, 1.30)
n = 53
0.86 (0.39, 1.93)
n = 8 / 420
≥6 months
(n = 1,404)
Reference
n = 355
Reference
n = 65
Reference
n = 157
Reference
n = 25 / 1,130
duration (per month)
(n = 4,023)
0.96 (0.94, 0.98)**
n = 1,118
0.99 (0.95, 1.04)
n = 179
0.97 (0.94, 1.00)*
n = 485
0.92 (0.87, 0.98)*
n = 94 / 3,051
exclusivity of breastfeeding
(n = 4,164)
Non-exclusive for 4 months
(n = 2,993)
1.28 (1.08, 1.53)**
n = 858
1.23 (0.81, 1.86)
n = 146
1.23 (0.97, 1.56)
n = 391
1.48 (0.89, 2.47)
n = 76 / 2,200
Exclusive for 4 months
(n = 1,171)
Reference
n = 295
Reference
n = 45
Reference
126
Reference
n = 20 / 941
Values are odds ratios (95% confidence intervals). “n =” represents number of cases (wheezing patterns) and 
number of cases per total group (current asthma). Models were adjusted for maternal body mass index, 
educational level, parity, smoking, and child’s sex, gestational age at birth, weight at birth and ethnicity. *p 
< 0.05, **p < 0.01
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early respiratory tract infections the effect estimates most prominently and significantly 
attenuated for children breastfed <2 months with early and persistent wheezing and 
current asthma, and for children non-exclusively breastfed for 4 months with early and 
persistent wheezing (range %change -8.8 to -66.4)). After additional adjustment for late 
respiratory tract infections, only the effect estimate for children breastfed <2 months 
with persistent wheezing attenuated (%change (95% CI): -33.5 (-82.8, -17.6)) (S-Table 
3.3.4b).
discUssion
We observed that children who were never breastfed had lower FeNO levels and in-
creased risks of late and persistent wheezing. Those who were shorter breastfed had 
increased risks of early wheezing and current asthma. Less exclusive breastfeeding was 
associated with an increased risk of early wheezing. The associations were partly ex-
plained by lower respiratory tract infections in early life, and to a lesser extent by lower 
respiratory tract infections in later life. Inhalant allergies did not explain the associations. 
Breastfeeding was not associated with Rint.
comparison of main findings with other studies
Recently, 117 studies that examined the associations between breastfeeding and asthma 
were meta-analysed.5 The effect of breastfeeding on asthma was most pronounced in 
children aged 0–2 years and decreased with age, but seemed still evident at school age. 
The size and the directions of our effect estimates were similar when we used the same 
definition of breastfeeding duration (ever vs. never, ≥3-4 months vs <3-4 months; and 
≥6 months vs < 6 months) (data not shown). It has also been reported that children 
who were breastfed longer 18-21 or more exclusive 19 had a higher forced expiratory 
volume in 1 second (FEV1) at ages 8-18 years, although not all studies observed positive 
effects.22 We observed no association between breastfeeding and Rint. Besides different 
lung function test, differences in results might be explained by different definitions of 
duration of exclusiveness of breastfeeding, the age at which lung function measure-
ments were performed, adjustment for confounders and sample sizes. Further studies 
on the associations between breastfeeding and lung function are needed. Only one 
study examined the association of breastfeeding duration with FeNO levels, and among 
asthmatic children only. Children who were never breastfed or breastfed for <6 months 
had no difference in FeNO level at age 8 years, compared with children who were breast-
fed ≥6 months.23 We observed that children who were never breastfed had lower FeNO 
levels, compared to children who were ever breastfed. The duration and exclusiveness 
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of breastfeeding was not associated with FeNO. Further studies are needed to replicate 
our findings before any strong conclusion might be drawn.
Previous studies suggested a mediating effect of allergies and respiratory tract 
infections.5, 19, 20, 24-26 We applied thorough mediation analyses, and observed that the 
associations were not explained by inhalant allergies. Lower respiratory tract infections 
in early life, and to a lesser extent lower respiratory tract infections in later life, did partly 
explain the associations. Other potential underlying mechanisms such as the impact of 
breastmilk on the microbiome need to be explored.
interpretation of results
Underlying mechanisms for the associations of breastfeeding and asthma might in-
clude secretory factors in breast milk such as IgA, cytokines, and long-chain fatty acids 
6 which stimulates the development of the infants immune system. Also, breastmilk 
stimulates the intestinal microbiota, which influences the developing immune system 
and activates T-regulatory cells.27 Opposite of expected, we observed that children who 
were never breastfed had lower FeNO levels than children who were longer or more 
exclusively breastfed, and thus might have less eosinophillic airway inflammation. 
Based on previous findings, we speculate that children who were never, shorter or less 
exclusively breastfed more often had respiratory tract infections in early life.28, 29 This is 
supported by our results that shorter or less exclusive breastfeeding was associated with 
increased risks of early wheezing, which is more commonly induced by respiratory tract 
infections 13. Respiratory tract infections usually lead to high amounts of neutrophillic 
granulocytes in the airways.30 The presence of numerous neutrophillic granulocytes 
might suppress the production of eosinophils 31, and lead to less eosinophillic airway 
inflammation. However, asthma phenotypes based on cell type might not be consistent 
over time.32 Furthermore, we observed that results changed less when we additionally 
adjusted for respiratory tract infections in later life, as compared to when respiratory 
tract infections in early life. This implies that the associations between breastfeeding and 
asthma-related outcomes are partly explained by the protective effect of breastfeeding 
on lower respiratory tract infections in early life. Finally, as the child develops, more 
factors influence respiratory morbidity, making it difficult to identify the specific role 
of breastfeeding. In later childhood, associations of atopic mechanisms with persistent 
wheezing and asthma seem stronger than the associations of infectious mechanisms 
with persistent wheezing and asthma.13, 33 The dose-dependent effect of breastfeeding 
on asthma in atopic children remains under debate as earlier studies observed more 26 
or no 34, 35 protective effects of breastfeeding on asthma in school-aged children. In the 
current study, the associations between breastfeeding and asthma-related outcomes 
were not mediated by inhalant allergies, which might be limited by the unavailability of 
objective allergy measures.
Duration and exclusiveness of breastfeeding and outcome in asthma
175
Ch
ap
te
r 3
.3
strengths and limitations
This study was embedded in a population-based prospective cohort study with detailed 
data on breastfeeding status, lung function and asthma outcomes. However, some 
limitations do apply. First, characteristics of non-responders at baseline and those lost 
to follow-up differed from those included in the study. This could have led to biased 
results if associations of breastfeeding status with asthma-related outcomes would be 
different between those included and not included. Second, we did not perform spi-
rometry. It is known that spirometry is feasible and acceptable for approximately 50% 
of children performing spirometry for the first time.36 Rint is more feasible at this age, 
and can detect small differences in airway resistance with good within- and between-
occasion reproducibility. The biological validity of increased airway resistance has been 
extensively demonstrated and airway resistance is associated with clinically relevant 
endpoints.37 Also, Rint can distinguish between groups of symptomatic and healthy 
young children.38 Third, exploring mediation using the method proposed by Baron and 
Kenny is limited by assumptions of causality, absence of mediator-outcome confound-
ing and absence of exposure-mediator interaction.39 Objective measures of inhalant 
allergies and respiratory tract infections were not available. Although questionnaires 
are efficient tools in epidemiological studies 40, 41, lack of objective measures could have 
affected our results. Further studies with longitudinally and objective measured data on 
inhalant allergies and respiratory tract infections are needed to disentangle the direc-
tion of causality and possible mediating effects. Current asthma was defined as ever 
physician-diagnosed asthma (5.9%) and presence of wheezing symptoms in the past 
12 months at age 6 years (9.0%), which led to a relatively low prevalence. This might 
have been an underestimation of true asthma cases, as asthmatic children with proper 
treatment might not have had any wheezing symptoms. Furthermore, the Generation R 
study is a multi-ethnic population–based birth cohort. Of the population for the current 
analysis, those of non-European ethnicity were mainly of Turkish (6.4%), Surinamese 
(6.2%), Moroccan (4.5%) or Dutch Antilles (2.2%) origin with current asthma prevalences 
of 3.7%, 4.8%, 3.4%, and 11.1%, respectively. Europeans (76.6%) had a current asthma 
prevalence of 3.1%. Last, as in any observational study, residual confounding due to 
unmeasured or insufficiently measured confounders might be an issue.
in conclusion, never breastfeeding was associated with lower FeNO levels, and 
increased risks of persistent wheezing. A shorter duration or non-exclusiveness of 
breastfeeding was associated with an increased risk of wheezing and asthma, providing 
evidence for a dose-response relationship. Results were independent of atopic mecha-
nisms, but were partly explained by infectious mechanisms in early life. Further studies 
using detailed information on allergies and respiratory tract infections throughout life 
are needed to explore the underlying pathophysiological mechanisms.
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AbstrAct
Asthma exacerbations are among the most frequent causes of hospitalization during 
childhood, but the underlying mechanisms are poorly understood. We performed 
a genome-wide association study of a specific asthma phenotype characterized by 
recurrent, severe exacerbations occurring between 2 and 6 years of age in a total of 
1,173 cases and 2,522 controls. Cases were identified from national health registries of 
hospitalization, and DNA was obtained from the Danish Neonatal Screening Biobank. 
We identified five loci with genome-wide significant association. Four of these, GSDMB, 
IL33, RAD50 and IL1RL1, were previously reported as asthma susceptibility loci, but the 
effect sizes for these loci in our cohort were considerably larger than in the previous 
genome-wide association studies of asthma. We also obtained strong evidence for a 
new susceptibility gene, CDHR3 (encoding cadherin-related family member 3), which is 
highly expressed in airway epithelium. These results demonstrate the strength of apply-
ing specific phenotyping in the search for asthma susceptibility genes.
A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations
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Acute asthma exacerbations are among the most frequent causes of hospitalization dur-
ing childhood and are responsible for large health-care expenditures.1-4 Available treat-
ment options for prevention and treatment of asthma exacerbations are inadequate 5, 
suggesting that asthma with severe exacerbations may represent a distinct subtype of 
disease and demonstrating a need for improved understanding of its pathogenesis.
Asthma heritability is estimated to be 70–90% 6, 7, but only a limited number of sus-
ceptibility loci have been verified in genome-wide association studies (GWAS).8-13 Larger 
GWAS may identify new susceptibility loci with smaller effects, but, owing to the large 
heterogeneity in asthma 14, an alternative strategy is to increase phenotype specificity 
in genome-wide analyses. A specific phenotype is likely to be more closely related to a 
specific pathogenic mechanism, and focusing on a particular phenotype may increase 
the power of genetic studies.
We aimed to increase understanding of the genetic background of early childhood 
asthma with severe exacerbations by conducting a GWAS of this particular asthma 
phenotype. We identified children with recurrent acute hospitalizations for asthma oc-
curring between 2 and 6 years of age (cases) from the Danish National Patient Register. 
We then extracted and amplified DNA from dried blood spot samples isolated from the 
Danish Neonatal Screening Biobank, as previously described 15, 16, before genome-wide 
array genotyping (Affymetrix Axiom CEU array). Case criteria were fulfilled for 2,029 of 
1.7 million children born in Denmark between 1982 and 1995 (1.1/1,000 children). The 
final case cohort (Copenhagen Prospective Studies on Asthma in Childhood exacerba-
tion cohort, COPSACexacerbation) after genotyping and quality control comprised 1,173 
children (S-Figure 4.1.1). Compared to the general population, cases were more often 
boys (67 versus 51%) and more often had mothers who smoked during pregnancy (32 
versus 15%) (S-Tables 4.1.1 and 4.1.2). Controls consisted of 2,511 individuals of Danish 
descent without asthma who were previously genotyped (Illumina Human610-Quad 
v1.0 BeadChip). We analyzed association between disease and 124,514 SNPs genotyped 
in both cases and controls, and we accounted for population stratification by multidi-
mensional scaling. The genomic inflation factor was 1.04. The genome-wide association 
analysis detected an excess of association signals beyond those expected by chance 
(S-Figure 4.1.2), and SNPs from five regions reached genome-wide significance (P < 5 
× 10−8; Figure 4.1.1 and S-Figure 4.1.3). The top SNPs from the five loci were rs2305480 
in GSDMB (odds ratio (OR) = 2.28, P = 1.3 × 10−48), rs928413 near IL33 (OR = 1.50, P = 
4.2 × 10−13), rs6871536 in RAD50 (OR = 1.44, P = 1.7 × 10−9), rs1558641 in IL1RL1 (OR = 
1.56, P = 6.6 × 10−9) and rs6967330 in CDHR3 (OR = 1.45, P = 1.4 × 10−8) (Table 4.3.1). 
Validation of results for the top SNPs by re-genotyping of cases and use of an alternative 
control population gave similar results (S-Tables 4.1.3 and 4.1.4). Association analyses in 
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the discovery cohort stratified on number of asthma- related hospitalizations showed 
higher OR with increasing number of hospitalizations for all five SNPs (Table 4.1.2). There 
was no significant interaction between the top SNPs and no effect modification by sex.
We first sought replication in the childhood-onset stratum (with onset before 16 years 
of age) from a previous GWAS of asthma including 14,503 individuals conducted by the 
GABRIEL Consortium11 (S-Table 4.1.5), which showed evidence of association for all 5 of 
the genome- wide significant loci reported here (Table 4.1.1). The CDHR3 locus was the 
only locus that had not previously been associated with asthma or any other atopic trait. 
We therefore followed up the top SNP from this locus (rs6967330) by further replication 
in a total of 3,975 children from 2 birth cohorts of European ancestry (COPSAC2000 and 
the Manchester Asthma and Allergy Study (MAAS)) and in 1 cohort with a population of 
mixed ancestry (Generation R). There was evidence for association with asthma before 
figure 4.1.1. Manhattan Plot for the Discovery Genome-wide Association Analysis. The Horizontal Line 
indicates the Genome-wide Significance Threshold (P < 5 × 10−8).
A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations
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the age of 6 years in combined analyses of the three birth cohorts and in the combined 
replication sets (Table 4.1.1 , S-Figure 4.1.4 and S-Table 4.1.6), as well as in a subsample 
including the 980 individuals with non-European ancestry (S-Table 4.1.6). Phenotype-
specific replication was possible in the COPSAC2000 and MAAS birth cohorts with 
prospective registration of acute asthma hospitalizations and exacerbations from birth 
to 6 years of age in a total of 1,091 children. The rs6967330 risk allele (A) was associated 
with greater risk of asthma hospitalizations (hazards ratio (HR) = 1.7 (95% confidence 
interval (CI) = 1.2–2.4), P = 0.002) and severe  exacerbations (HR = 1.4 (95% CI = 1.1–1.9), 
P = 0.007) in combined analyses (Figure 4.1.2, S-Figure 4.1.5 and S-Table 4.1.6).
In COPSAC2000, we observed a trend in the direction of increased neonatal bronchial 
responsiveness associated with the rs6967330 risk allele (P = 0.10) (S-Table 4.1.7). There 
was no association with eczema in any of the three birth cohorts, and data on allergic 
sensitization were inconsistent (S-Table 4.1.6).
figure 4.1.2. Cumulative Risk of Asthma Hospitalization during the First 6 Years of Life Stratified on CDHR3 
(rs6967330) Genotype.
Data are from combined analysis of the COPSAC2000 and MAAS birth cohorts (replication), including a total 
of 1,091 children, of whom 92 were hospitalized for asthma. Genotype distribution was as follows: AA, 30 
individuals; AG, 312 individuals; GG, 749 individuals. The P value for the association between genotype and 
risk of hospitalization was 0.002 (Cox regression analysis using an additive genetic model).
A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations
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The top SNP at the CDHR3 locus (rs6967330) is a nonsynonymous coding SNP, where 
the risk allele (A), corresponding to the minor allele, results in an amino acid change 
from cysteine to tyrosine at position 529. This SNP is the only known nonsynonymous 
variant in this linkage disequilibrium (LD) region, but there are other variants located 
within Encyclopedia of DNA Elements (ENCODE)-predicted regulatory regions that are 
in moderate to high LD (r2 > 0.5) with the sentinel SNP (S-Table 4.1.8). Two SNPs with 
partial LD (r2 = 0.71 and 0.58) were also associated with asthma in the discovery analysis 
but with less statistical significance. A similar association pattern with rs6967330 as the 
top SNP was observed in the GABRIEL (replication) study (S-Figure 4.1.6) and in the Gen-
eration R (replication) subsample of individuals with non-European ancestry (S-Figure 
4.1.7), suggesting that rs6967330 might be the causal gene variant at this locus.
We investigated the potential functional consequences of the top variant in CDHR3 
(rs6967330; p.Cys529Tyr) by generating an expression construct encoding tagged hu-
man CDHR3 and introducing the mutation encoding p.Cys529Tyr (A allele at rs6967330 
resulting in mutation of cysteine 529 to tyrosine) by site- directed mutagenesis. We 
transfected the constructs for wild-type and mutant CDHR3 into 293T cells. Consistent 
results from six independent experiments involving flow cytometry (n = 3) (S-Figure 
4.1.8) and immunofluorescence staining (n = 3) (S-Figure 4.1.9) showed that the wild-
type protein was expressed at very low levels at the cell surface, whereas the Cys529Tyr 
mutant showed a marked increase in cell surface expression (Supplementary Note). 
These results support the possibility that rs6967330 represents the causal variant at this 
locus. A recent study 17 reported that a SNP (rs17152490) in high LD (r2 = 0.69) with our 
top SNP was associated with lung expression of CDHR3, further supporting a functional 
role for this locus.
CDHR3 is a transmembrane protein with six extracellular cadherin domains. Protein 
structure modeling showed that the risk-associated alteration (p.Cys529Tyr) was located 
at the interface between two membrane-proximal cadherin domains, D5 and D6 (Figure 
4.1.3). Interestingly, Cys592 and Cys566, which are expected to form a disulfide bridge 
within D6, are close to Cys529 in D5, and the short distance between them could allow 
disulfide rearrangement (for the wild-type, non-risk cysteine variant). The location of 
the variant residue at the domain interface suggests that the variant residue may in-
terfere with interdomain stabilization, overall protein stability, folding or conformation, 
in agreement with the observation in our experimental studies of altered cell surface 
expression.
The biological function of CDHR3 is unknown, but it belongs to the cadherin family 
of transmembrane proteins involved in homologous cell adhesion and important for 
several cellular processes, including epithelial polarity, cell-cell interaction and differen-
tiation.18 Other members of the cadherin family have been associated with asthma and 
related traits, including E-cadherin 19 and protocadherin-1.20
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We demonstrated protein expression of CDHR3 in bronchial epithelium from adults and 
in fetal lung tissue (S-Figure 4.1.10). CDHR3 was previously found to be highly expressed 
in normal human lung tissue 21 and specifically in the bronchial epithelium.22CDHR3 
(probe 235650_at) was upregulated by tenfold in differentiating epithelial cells (with a 
rank of 123 out of more than 47,000 transcripts ranked by magnitude of upregulation)23 
and seems to be highly expressed in the developing human lung.24
There is an increasing focus on the role of the airway epithelium in asthma pathogen-
esis. Structural or functional abnormalities in the epithelium may increase susceptibility 
to environmental stimuli by exaggerating immune responses and structural changes in 
underlying tissues and increasing airway reactivity.25 Epithelial integrity is dependent 
on the interaction of proteins in cell-cell junction complexes, including adhesion mol-
ecules. Studies have shown impaired tight junction function 26 and reduced E-cadherin 
expression 27 in the airway epithelium of individuals with asthma. CDHR3 is a plausible 
candidate gene for asthma because of its high level of expression in the airway epithe-
lium and the known role of cadherins in cell adhesion and interaction. Most asthma 
exacerbations in children are caused by respiratory infections, predominantly common 
viral infections such as rhinovirus 28, but bacterial infection may also have a role 29, as 
well as exposure to air pollution.30 It is therefore plausible that CDHR3 variation increases 
figure 4.1.3. Overview of the CDHR3 Protein Model.
The model covers cadherin domains 2–6 (D2–D6) and is based on the structure of the entire mouse N-cad-
herin ectodomain (Protein Data Bank (PDB) 3Q2W; domains 1–5). The location of the alteration at position 
529 is indicated with a blue star. The distance between residue 529 and the disulfide bridge in D6 (between 
residues 566 and 592) is approximately 20 Å.
A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations
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susceptibility to respiratory infections or other airway irritants through impaired epithe-
lial integrity and/or disordered repair processes.
Interestingly, the CDHR3 asthma risk allele is the ancestral allele. Public data from pro-
tein databases suggest that humans are unique among 36 other vertebrate species in 
having the derived (non-risk) allele resulting in a cysteine at position 529 (S-Table 4.1.9), 
which is now the wild-type allele in most human populations (Human Genome Diversity 
Project (HGDP) selection browser). This finding suggests that the risk (ancestral) allele, 
associated with increased surface expression of CDHR3, may have been advantageous 
during early human evolution. This phenomenon in which the ancestral allele is the risk 
allele is known for other common diseases and may reflect a shift from a beneficial to a 
deleterious effect for a particular allele as a result of a changing environment.31
The CDHR3 variant seems to be associated with an asthma phenotype of early onset, 
as demonstrated by the strongest replication of association in the GABRIEL stratum with 
asthma onset before 16 years of age (S-Table 4.1.10) and in the second replication in-
cluding children with asthma onset before 6 years of age (Table 4.1.1). Increased risk was 
already demonstrated in the first year of life (Figure 4.1.2), particularly in children who 
were homozygous for the risk allele (A). This finding is in line with the tendency toward 
association of increased airway reactivity in neonates with the risk allele and findings 
of CDHR3 expression in the fetal lung. CDHR3 variation also seems to be more strongly 
associated with an asthma phenotype with exacerbations (Supplementary Table 4.1.6), 
particularly with recur-rent exacerbations (Table 4.1.2 and S-Table 4.1.6).
The top locus in this study, on chromosome 17q12-21, has consistently been associ-
ated with childhood-onset asthma.11, 13 The effect size in the present study is remarkably 
high, with an OR of 2.3 that increases to 2.7 for the children with the highest number 
of exacerbations. This finding suggests a key role for this locus in severe exacerbations 
in early childhood, in line with a previous report from the COPSAC2000 birth cohort 
study.32
Genome-wide significant association with asthma has previously been shown for 
variants in or near IL33, RAD50-IL13 and IL1RL1.11, 33 The fact that the top loci in our study 
were generally shared with previous GWAS of asthma suggests that early-onset asthma 
with severe exacerbations is at least partly driven by multiple common variants in the 
same genes that contribute to asthma without severe exacerbations.
The sample size of the present GWAS was less than one-fifth that of the largest pub-
lished GWAS of asthma (GABRIEL) 11, and, yet, we found a similar number of genome-wide 
significant loci, similar statistical significance and considerably larger effect estimates. 
Further increasing phenotypic specificity by stratified analysis in the 358 children with 
the highest number of exacerbations resulted in an additional increase in effect esti-
mates, with ORs between 1.6 and 2.7 per risk allele, and strong statistical significance. 
Effect estimates were also higher than previously reported when replicating the exact 
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top SNP from the GABRIEL study (S-Table 4.1.11). This finding demonstrates that specific 
phenotyping is a helpful approach in the search for asthma susceptibility genes. The 
narrow age criteria (2–6 years) for disease may be an important phenotypic characteris-
tic, as heritability has been demonstrated to be higher for early-onset asthma.33
The method of case identification through national registries allowed us to define a 
specific and rare phenotype of repeated acute hospitalizations in young children from 
2 to 6 years of age, which, to our knowledge, has not previously been done in a GWAS. 
One limitation of this study is that we had relatively poor genome-wide coverage (ap-
proximately 125,000 SNPs).
in conclusion, our results demonstrate the strength of specific phenotyping in genetic 
studies of asthma. Future research focusing on understanding the role of CDHR3 variants 
in the development of asthma and severe exacerbations may increase understanding 
and improve treatment of this clinically important disease entity.
metHods
coPsAcexacerbation cohort (gwAs)
This is a register-based cohort of children with asthma who were identified and charac-
terized from national health registries. The study was approved by the Ethics Committee 
for Copenhagen (H-B-2998 -103) and the Danish Data Protection Agency (2008-41-2622). 
According to Danish law, research ethics committees can grant exemption from obtain-
ing informed consent for research projects based on biobank material under certain 
circumstances. For this study, such an exemption was granted (H-B-2998-103).
case selection
Children with repeated acute hospitalizations (cases) were identified in the Danish 
National Patient Register covering all diagnoses of discharges from Danish hospitals.34 
Information on birth-related events was obtained from the national birth register. Inclu-
sion criteria were at least two acute hospitalizations for asthma (ICD8-codes 493, ICD- 10 
codes J45-46) from 2 to 6 years of age (both years included). Duration of hospitalization 
had to be more than 1 day, and two hospitalizations had to be separated by at least 6 
months. Exclusion criteria were side diagnosis during hospitalization, registered chronic 
diagnosis considered to affect risk of hospitalization for asthma, low birth weight (<2.5 
kg) or gestational age of under 36 weeks at birth. Cases were further characterized with 
respect to the number of hospitalizations from asthma and acute bronchitis and for 
concurrent atopy.
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dnA sampling and genotyping of cases
DNA was obtained from blood spots sampled as part of the Danish neonatal screening 
program and stored in the Danish Neonatal Screening Biobank.35 Two disks, each 3.2 mm 
in diameter, were punched from each blood spot. DNA was extracted, and the whole ge-
nome for each individual sample was amplified in triplicate as previously described.15, 16 
Cases were genotyped on the Affymetrix Axiom CEU array (567,090 SNPs). Top SNPs 
from the five genome -wide significant loci were re-genotyped with the PCR KASPar 
genotyping system (KBiosciences) to validate the results (Supplementary Table 3). Two 
additional SNPs in the proximity of the newly discovered CDHR3 variant were genotyped 
for further exploration of the region encompassing it.
controls
The control population was randomly drawn from two large Danish cohorts: the Danish 
National Birth Cohort (females) and the Copenhagen draft board examinations (males). 
Individuals who indicated in a questionnaire that they had physician-diagnosed asthma 
were excluded. Genome-wide genotyping had previously been performed as part of the 
Genomics of Overweight in Young Adults (GOYA) study 36 on the Illumina Human610-
Quad v1.0 BeadChip (545,350 SNPs). Potential bias introduced by differences in chemis-
try between the different platforms used for cases and controls (Affymetrix and Illumina, 
respectively) was investigated by also using control data from the Wellcome Trust Case 
Control Consortium 2 (WTCCC2) project that performed genotyping on an Affymetrix 
platform (Affymetrix 6.0) (S-Table 4.1.4).
replication in a previously published gwAs
Replication of the five genome-wide significant loci from the discovery analysis was 
sought in publically available data from a GWAS performed by the GABRIEL Consortium. 
This replication included 19 studies of childhood-onset asthma (onset before 16 years of 
age) with a total of 6,783 cases and 7,720 controls.
replication in birth cohorts for the cdHr3 top snP
The COPSAC2000 replication cohort
Replication and phenotypic characterization of the CDHR3 risk locus were sought in the 
COPSAC2000 cohort, a prospective clinical study of a birth cohort of 411 children. This 
cohort is not overlapping with the COPSACexacerbation discovery study. The COPSAC2000 
cohort study was approved by the Ethics Committee for Copenhagen (KF 01-289/96) 
and the Danish Data Protection Agency (2008-41-1754), and informed consent was ob-
tained from both parents of each child. All mothers had a history of a doc-tor’s diagnosis 
of asthma after 7 years of age. Newborns were enrolled in the first month of life, as previ-
A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations
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ously described in detail.37-39 This cohort is characterized by deep phenotyping during 
close clinical follow-up. Doctors employed in the clinical research unit were acting pri-
mary physicians for the children from the cohort and diagnosed and treated respiratory 
and skin symptoms, and asthmatic symptoms were recorded in daily diaries.40 Acute, 
severe exacerbations from birth to 6 years of age were defined as requiring the use of 
oral prednisolone or high-dose inhaled corticosteroid for wheezy symptoms, prescribed 
at the discretion of the doctor in the clinical research unit, or by acute hospitalization at 
a local hospital for such  symptoms.41 Asthma from birth to 7 years of age was diagnosed 
on the basis of predefined algorithms of symptoms and response to treatment, as previ-
ously described.39
Neonatal spirometry and analysis of neonatal bronchial responsiveness to metha-
choline were carried out by 4 weeks of age, applying the raised volume, rapid thoracic 
compression technique. Lung function was measured by spirometry in the child’s sev-
enth year of life. Specific airway resistance (sRaw) was measured at 4 and 6 years by 
whole-body plethysmography. Bronchial responsiveness at ages 4 and 6 years was 
determined as the relative change in sRaw after hyperventilation of cold, dry air. Allergic 
sensitization against common inhalant allergens was determined at 6 years of age by 
measurement of serum-specific IgE levels. Atopic dermatitis was diagnosed using the 
Hanifin-Rajka criteria 42 from birth to 7 years of age.
High- throughput genome-wide SNP genotyping was performed using the Illumina 
Infinium II HumanHap550 v1, v3 or Quad BeadChip platform at the Children’s Hospital 
of Philadelphia’s Center for Applied Genomics. We excluded SNPs with call rate of <95%, 
minor allele frequency (MAF) of <1% or Hardy-Weinberg equilibrium P value of <1 × 
10−5. rs6967330 was a genotyped SNP on this array.
MAAS replication cohort
The Manchester Asthma and Allergy Study is a population-based birth cohort described 
in detail elsewhere.43 Subjects were recruited prenatally and were followed prospective-
ly. The study was approved by the local research ethics committee (South Manchester, 
reference 03/SM/400). Parents gave written informed consent. Participants attended 
follow-up at ages 1, 3 and 5 years of age.
For asthma, validated questionnaires were administered by interviewers to collect 
information on parentally reported symptoms, physician-diagnosed asthma and 
treatments received. ‘Current wheeze and asthma treatment’ was defined as parentally 
reported wheeze in the past 12 months. ‘Asthma ever’ was defined as positive if, at any 
given time point, two of three responses were positive to the following questions: “Has 
your child wheezed within the past 12 months?”, “Does your child currently take asthma 
medication?” or “Has a doctor ever told you that your child has asthma?” Controls were 
defined as children with none of these symptoms.
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For exacerbations, a pediatrician extracted data from primary-care medical records, 
including information on diagnosis with wheeze and/or asthma, all prescriptions (in-
cluding inhaled corticosteroids (ICS) and β2 agonists), unscheduled visits and hospital 
admissions for asthma and/or wheeze during the first 8 years of life. Following American 
Thoracic Society guidelines, we defined asthma exacerbations by either admission to a 
hospital or an emergency department visit and/or by receipt of oral corticosteroids for 
at least 3 days.44
DNA samples were genotyped on the Illumina Human610-Quad BeadChip. Genotypes 
were called using the Illumina GenCall application, following the manufacturer’s instruc-
tions. Quality control criteria for samples included call rate of greater than 97%, exclusion 
of samples with outlier autosomal heterozygosity and sex validation. We excluded SNPs 
with call rate of <95%, Hardy-Weinberg equilibrium P value of >5.9 × 10−7 and MAF of 
<0.005. We then performed a look -up for SNP rs6967330, which showed a genotyping 
success rate of 100% and a Hardy-Weinberg equilibrium P value of 0.4164.
Generation R replication cohort
The Generation R Study is a population-based prospective cohort study of pregnant 
women and their children from fetal life onward in Rotterdam, The Netherlands.45 The 
study protocol was approved by the Medical Ethical Committee of the Erasmus Medi-
cal Center, Rotterdam (MEC 217.595/2002/20). Written informed consent was obtained 
from all mothers and biological fathers or legal guardians. Information on wheezing, 
asthma and eczema was collected for the children by questionnaires at the ages of 1 to 
4 and 6 years.46 Questions about wheezing included: “Has your child had problems with 
a wheezing chest during the last year? (never, 1–3 times, >4 times) (age 1 to 4 years)” 
and “Did your child ever suffer from chest wheezing? (never, 1–3 times, >4 times) (age 6 
years) .” Questions about asthma included: “Has a doctor diagnosed your child as having 
asthma during the past year? (yes, no) (age 2 and 4 years)” and “Was your child ever 
diagnosed with asthma by a doctor? (yes, no) (age 3 and 6 years).” On the basis of the last 
obtained questionnaire, we grouped children as having ‘asthma ever before 6 years of 
age’. Reported asthma at 2, 3 or 4 years of age was used to reclassify children included in 
this group where appropriate. We then re-categorized children as those with an asthma 
diagnosis before 3 years of age and at 3 years of age or older. Reported numbers of 
wheezing episodes at 1 and 2 years of age and at 3 to 6 years of age, respectively, were 
used to reclassify asthma diagnosis before and at 3 years of age into ‘asthma diagnosis or 
≥3 episodes of wheezing before 3 years of age’. Questions about eczema included: “Has a 
doctor diagnosed your child as having eczema during the past year? (yes, no) (age 1 to 4 
years)” and “Was your child ever diagnosed with eczema by a doctor? (yes, no) (6 years).” 
As with asthma, we grouped children into those with ‘eczema ever before 6 years of age’ 
A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations
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on the basis of the last obtained questionnaire and used reported eczema at 1 or 4 years 
of age to reclassify children included in this group where appropriate.
Samples were genotyped using Illumina Infinium II HumanHap610 Quad arrays, 
following standard manufacturer’s protocols. Intensity files were ana-lyzed using Bead-
Studio Genotyping Module software v.3.2.32, and genotypes were called using default 
cluster files. Any sample with a call rate of less than 97.5%, excess autosomal heterozy-
gosity (F < mean – 4 s.d.) or mismatch between called and phenotypic sex was excluded. 
rs6967330 was a genotyped SNP in this set. Individuals identified as genetic outliers by 
identity-by -state (IBS) clustering analysis (>3 s.d. away from the mean for the HapMap 
CEU population (Utah residents of Northern and Western European ancestry)) were 
considered to have non-European ancestry. Ancestry determination analysis included 
genomic data from all Generation R individuals merged with data for three reference 
panels from Phase 2 of the HapMap Project (YRI (Yoruba from Ibadan, Nigeria), CHB + 
JPT (Han Chinese in Beijing, China, and Japanese in Tokyo, Japan) and CEU). Analysis of 
association between an asthma or eczema phenotype and GWAS SNPs was carried out 
using a regression frame-work, adjusting for population stratification in the Generation 
R cohort using MACH2QTL, as implemented in GRIMP. Ten genomic principal compo-
nents obtained after the application of SNP quality exclusion criteria and LD pruning 
were used to adjust for population substructure in the combined population, four 
principal components were used for the European subpopulation and eight principal 
components were used for the non- European subpopulation. Individuals were grouped 
as having European (n = 1,962; 64.5%) or non-European (n = 1,078; 35.5%) ancestry on 
the basis of genetic ancestry. On the basis of information on the country of birth of 
parents and grandparents obtained by questionnaires, the largest non-European ances-
try groups included individuals of Turkish (5.4%), Surinamese (4.6%), Dutch Antillean 
(4.0%), Moroccan (2.9%) and Cape Verdean (2.3%) origin.
genome-wide association analysis
Quality control was carried out separately on cases and controls. This included filtering 
on SNP call rate (>99%) and sample call rate (>98%) and tests for excess heterozygosity, 
deviation from Hardy-Weinberg equilibrium, sex mismatch and familial relatedness. 
Non-European individuals were excluded on the basis of deviation from the HapMap 
CEU reference panel (release 22). Indication of population stratification or genotyping 
bias was tested by multidimensional scaling (MDS) after quality control. This analysis 
showed evidence of association with disease status for the first seven MDS components, 
and these were therefore included as covariates in the association analysis. Additional 
analyses including the first 100 MDS components did not materially alter the results. 
Merged data for SNPs present on both arrays after quality control were used for associa-
tion testing with PLINK (v. 1.07) using a logistic additive model, adjusting for the first 
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seven MDS components. Additional quality control was performed for genome-wide 
significant SNPs after association analysis, including a test for genotyping batch effects, 
resulting in the removal of one genome-wide significant SNP with strong evidence of 
batch-related genotyping error.
Functional annotation for the SNPs in LD (r2 > 0.5) with the CDHR3 top SNP (rs6967330) 
was obtained from the RefSeq track downloaded from the UCSC Genome Browser. SNPs 
were associated with regulatory elements by HaploReg 47 in terms of predicted ENCODE 
chromatin state (promoter and enhancer histone modification signals) and DNase I 
hyper sensitivity (S-Table 4.1.8).
Regional imputation was performed to describe the identified loci from the discovery 
analysis (S-Figure 4.1.3) as well as reported loci from the previous largest published GWAS 
(GABRIEL) (S-Table 4.1.11).11 We used two- step genotype imputation as described.48 We 
used the SHAPEIT algorithm to pre-phase the haplotypes 49 and then used IMPUEv2 
software for the imputation of unknown genotypes 50 separately in case and controls. 
We used the 1000 Genomes Project reference panel 51 (April 2012 version). We used a 
strict cutoff (info of 0.88), which, according to our analyses, pro-vides an allelic dosage 
R2 correlation between real and imputed genotypes of greater than 0.8 and shows an 
optimal balance between sufficient accuracy and power.52 We then compared the result-
ing allelic frequencies using SNPTEST 2.4.1.53
cdHr3 protein expression in experimental models
The top SNP at the CDHR3 locus is a nonsynonymous SNP (encoding p.Cys529Tyr). To 
determine the functional consequences of the p.Cys529Tyr variant, we generated ex-
pression constructs encoding tagged human CDHR3 protein, and the mutation encod-
ing the p.Cys529Tyr alteration was introduced by site-directed mutagenesis. Plasmids 
encoding wild- type or mutant CDHR3 or empty vector were transfected into 293T cells, 
and cells were monitored for surface and intra-cellular expression of CDHR3 by flow 
cytometry. 293T cells were from the American Type Culture Collection (ATCC), catalog 
number CRL-3216. They were recently tested for mycoplasma contamination but were 
not authenticated. For protein blotting, cells expressing CDHR3 proteins were lysed, and 
whole-cell lysates were separated by SDS-PAGE under reducing or non-reducing condi-
tions, transferred to PVDF membranes and blotted for Flag (anti-Flag antibody, clone 
M2 (Agilent Technologies, 200470-21) at a dilution of 1:2,000). For immunofluorescence 
and confocal microscopy, 293T cells were grown on glass coverslips in DMEM with 3 
mM glutamine and 10% heat-inactivated FBS at 37 °C and 5% CO2 before and for 2 
d after transfection with expres-sion constructs for Flag-tagged wild-type CDHR3 and 
CDHR3 Cys529Tyr using TransIT 2020 reagent according to a standard protocol (Mirus 
Bio). Cells were obtained and used at a low passage from ATCC and had recently been 
tested for mycoplasma. Cells were incubated in 10% serum-containing culture medium 
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plus primary anti-Flag mouse antibodies (F3165, Sigma; 1:300 dilution) for 1 h at 37 °C 
before being washed briefly with culture medium. Cells were then stained with second-
ary rabbit anti-mouse antibodies (F0261, Daco; 1:600 dilution) conjugated with fluores-
cein isothiocyanate (FITC) with incubation at 37 °C for 30 min and washed with culture 
medium before PBS. Afterward, cells were fixed in 2% paraformaldehyde for 15 min, 
washed with PBS and permeabilized in 0.2% Triton X-100 in PBS for 5 min, washed and 
incubated with Cy3-conjugated mouse anti-Flag antibody (Cy3-labeled F3165, Sigma; 
1:300 dilution). Finally, cells were mounted with ProLong Gold antifade reagent with 
DAPI (Invitrogen). Images were acquired using a Leica DMI 6000-B confocal microscope 
(Leica Microsystems) with 40× magnifica-tion and were processed in Photoshop (Adobe 
Systems). Experiments were performed in triplicate (independent transfections) for 
both flow cytometry and immunofluorescence staining. Data presented (S-Figures 4.1.8 
and 4.1.9) were chosen as being representative of the repeated experiments.
CDHR3 protein structure modeling
A homology model of CDHR3 domains 2–6 (residues 141–681) was generated using 
the HHpred server.54 The model was based on the structure of mouse N-cadherin (PDB 
3Q2W) domains 1–5. A disulfide bridge was manually introduced in the final model 
between the structurally adjacent residues Cys566 and Cys592, as this corresponds to a 
disulfide bridge commonly observed in cadherin domains.
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AbstrAct
Folate is vital for fetal development. Periconceptional folic acid supplementation 
and food fortification are recommended to prevent neural tube defects. Mechanisms 
whereby periconceptional folate influences normal development and disease are 
poorly understood: epigenetics may be involved. We examined the association between 
maternal plasma folate during pregnancy and epigenome-wide DNA methylation using 
Illumina’s HumanMethyl450 Beadchip in 1,988 newborns from two European cohorts. 
Here we report the combined covariate-adjusted results using meta-analysis and em-
ploy pathway and gene expression analyses. Four-hundred forty-three CpGs (320 genes) 
are significantly associated with maternal plasma folate levels during pregnancy (false 
discovery rate 5%); 48 are significant after Bonferroni correction. Most genes are not 
known for folate biology, including APC2, GRM8, SLC16A12, OPCML, PRPH, LHX1, KLK4 
and PRSS21. Some relate to birth defects other than neural tube defects, neurological 
functions or varied aspects of embryonic development. These findings may inform how 
maternal folate impacts the developing epigenome and health outcomes in offspring.
Maternal plasma folate impacts differential DNA methylation in an epigenome-wide meta-analysis of newborns
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introdUction
Folate (vitamin B9) is vital for fetal development. Folic acid supplementation at 0.4 mg 
per day or higher is recommended worldwide before and in the very early stages of 
pregnancy to reduce the incidence of neural tube defects (NTDs). Over 50 countries 
have introduced programs to fortify the food supply with folic acid to increase folate 
levels in women of childbearing age.1 Rates of NTDs have clearly decreased following 
fortification2 and there is increasing interest in the possibility that higher maternal folate 
prevents additional birth defects including oral clefts, cardiac defects and others.3 A 
large international trial has been launched of supplementation with 4 mg versus the 
standard 0.4 mg to attempt to address these questions.3
Other beneficial effects of higher maternal folate levels have been reported in humans. 
These include reduced risk of low birth weight, pre-term delivery, language delay, leu-
kaemia, childhood brain tumours and autism, although the evidence is inconsistent.4,5 In 
the United States, food fortification has led to an increase in folate intake twice as large 
as anticipated6, and therefore concern has been raised about possible adverse effects, 
such as cancer in adults, as a result of this population-wide intervention.1 Furthermore, 
higher folic acid intake during pregnancy has been associated with an increased risk of 
childhood retinoblastoma and early respiratory illness.4
The mechanisms whereby folic acid prevents NTDs and potentially other birth defects 
and later health outcomes are poorly understood7 but could involve epigenetic changes. 
Folate is a critical component in the one-carbon metabolism pathway providing methyl 
groups for a range of biochemical reactions, including methylation of DNA.8 DNA meth-
ylation is an important epigenetic determinant of gene expression, and differential 
methylation has been associated with multiple diseases.9 Periconceptional maternal 
folate levels may alter methylation patterns established in utero that are vital for fetal 
development, which could impact later health outcomes in the offspring.
In mouse models, in utero dietary methyl donor supplementation has been associ-
ated with altered methylation patterns and disease phenotypes.4 The brains of human 
fetuses with NTDs had lower global methylation compared with controls, which was 
positively correlated with maternal folate levels.10 With respect to gene-specific differen-
tial methylation, perinatal folate has also been associated with differential methylation 
in specific imprinted genes, such as IGF2 and H19, in offspring, but reported results are 
inconsistent.11 The only published study using a platform with reasonable genome-wide 
coverage, the Illlumina HumanMethyl450 Beadchip (450 K), investigated 23 subjects and 
reported that folic acid supplementation during pregnancy was related to differential 
methylation upstream of the gene ZFP57, which plays a central role in the regulation and 
maintenance of imprinting.12
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Some countries, such as Norway and the Netherlands, do not fortify the food supply 
with folic acid. These populations may be particularly useful for examining the biologi-
cal implications of periconceptional folic acid supplementation on offspring health, as 
greater variability in the dose and the source of folate may exist compared with fortified 
populations.
To better understand the biological implications of folate status on the developing 
fetus, we examine the association between maternal plasma folate during pregnancy 
and epigenome-wide differential DNA methylation in newborn cord blood using the 
Illumina HumanMethyl450 (450 K) Beadchip. We include 1,988 newborns from two 
European pregnancy cohorts of Caucasian ancestry, the Norwegian Mother and Child 
Cohort Study (MoBa), and the Generation R Study (Generation R). We combine results 
using meta-analysis. Secondary pathway analyses and gene expression analyses are also 
explored.
metHods
study populations
This analysis included participants of the Norwegian Mother and Child Cohort Study 
(MoBa)13,14 and participants of the Generation R Study from the Netherlands. The study 
populations and cohort-specific methods described below are more extensively detailed 
in the Supplementary Information. The MoBa participants were mother–offspring pairs 
from a sub-study measuring maternal plasma folate during pregnancy.15 The Generation 
R Study is a population-based prospective cohort study from fetal life onwards.16,17 For 
this analysis, information on plasma folate and DNA methylation was available for 1,289 
mothers and their children from the MoBa study (1,275 with complete covariate data) 
and 790 Caucasian mothers, and their children from the Generation R Study (713 with 
complete covariate data). The MoBa study was approved by the Regional Committee 
for Ethics in Medical Research, the Norwegian Data Inspectorate and the Institutional 
Review Board of the National Institute of Environmental Health Sciences, USA, and writ-
ten informed consent was provided by all mothers participating. The Generation R Study 
has been approved by the Medical Ethical Committee of the Erasmus MC, University 
Medical Center Rotterdam, Netherlands and written consent was obtained from partici-
pating parents of their children.
maternal plasma folate measurements
Both cohorts measured maternal plasma folate during pregnancy. For MoBa, maternal 
blood samples were drawn during pregnancy (median weeks gestation=18 weeks, 
25–75th percentile=16–21 weeks) in EDTA-lined tubes, centrifuged within 30 min after 
Maternal plasma folate impacts differential DNA methylation in an epigenome-wide meta-analysis of newborns
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collection and stored at 4 °C in the hospital where they were collected. Samples were 
then shipped overnight to the Biobank of MoBa at the Norwegian Institute of Public 
Health in Oslo. Upon receipt (1–2 days after blood collection), plasma was aliquoted 
onto polypropylene microtiter plates, sealed with heat-sealing foil sheets and stored 
at −80 °C. Plasma folate concentration was measured at Bevital AS (www.bevital.no) by 
microbiological assay, using a chloramphenicol-resistant strain of Lactobacillus casei18, 
which measures biologically active folate species, predominantly 5-methyl-tetrahydro-
folate. The coefficient of variation (CV) for this assay corresponds to 4% within day and 
5% between days, at population median.
For the Generation R cohort, venous blood samples were drawn at enrolment of the 
mothers in early pregnancy (median weeks gestation=12.9 weeks; 25–75th percen-
tile=12.1–13.9 weeks) and stored at room temperature for a maximum of 3 h. Samples 
were transported to a laboratory facility of the regional laboratory in Rotterdam, Nether-
lands (Star-Medisch Diagnostisch Centrum) for additional processing and storage at −80 
°C. The samples were analysed at the Department of Clinical Chemistry at the Erasmus 
MC, University Medical Center Rotterdam, Netherlands. After thawing, folate concentra-
tions were analysed using an immunoelectrochemoluminence assay on the Architect 
System (Abbott Diagnostics BV). Between-run CVs for plasma measurements were 8.9% 
at 5.6 nmol /l, 2.5% at 16.6 nmol/ l and 1.5% at 33.6 nmol/ l with an analytic range of 
1.8–45.3 nmol/ l for plasma folate.
covariates
Each cohort had information on maternal age, education and parity from questionnaires 
completed by the mother or from birth registry records. Maternal smoking during preg-
nancy was ascertained with questionnaires (both cohorts) and cotinine levels (MoBa). 
Plasma levels of vitamin B12, vitamin D and total homocysteine from samples taken dur-
ing pregnancy were available for both cohorts. Mothers in both cohorts were genotyped 
for two SNPs in the (NAD(P)H) MTHFR gene, rs1801131 and rs1801133. Additional detail 
on these measurements is in the Supplementary Information.
dnA methylation measurements
DNA was extracted from cord blood and bisulfite conversion performed (EZ-96 DNA 
Methylation kit, Zymo Research Corporation, Irvine, USA). Samples were processed with 
Illumina’s Infinium HumanMethylation450 BeadChip (Illumina Inc., San Diego, USA) fol-
lowed by cohort-specific laboratory quality control. Each cohort calculated the methyla-
tion betas, and normalized the betas using a published method.19,20
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estimation of cell-type proportions
Both the MoBa and Generation R studies estimated cell-type proportion with the House-
man method21 as implemented in the R minfi package22 using the Reinius et al. data set 
for reference.23 Cell-type correction was applied by including the six estimated cell-type 
proportions as covariates in cohort-specific statistical models.
cohort-specific statistical analyses
The cohort-specific statistical models were run independently. For each cohort, we used 
robust linear regression models in R24 to evaluate the association between natural log-
transformed maternal plasma folate and cord blood DNA methylation for each probe 
while accounting for potential heteroskedasticity and/or influential outliers. Models 
were adjusted for maternal age, education, smoking during pregnancy, parity and for 
batch effects (adjustment for plate in Generation R, correction using ComBat19 in MoBa). 
Additional correction for study design was done in MoBa (whether the participant was 
in the MoBa1 or MoBa2 data set). Sex of the child was not expected to be associated with 
maternal plasma folate and was therefore not included as a covariate in the analyses. 
The adjustment variables were selected on a priori considerations and because they 
were also associated with maternal plasma folate levels at P<0.05.
meta-analysis
The probe-specific quality control resulted in 473,731 CpGs in the MoBa cohort and 
436,013 CpGs in the Generation R cohort. The meta-analysis was limited to the 425,749 
CpGs common to both cohorts. An additional 5,844 CpGs were excluded for having a 
SNP mapping to the last five nucleotides of the probe sequence and with a minor allele 
frequency ≥5% in the CEU (Utah residents with North and Western European ancestry) 
population, curated by 1000G projects (http://www.1000genomes.org/, 06/2011 
release, 87 individuals), HapMap project (http://hapmap.ncbi.nlm.nih.gov/, release 28, 
8/2010, 174 individuals) and dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/, build 
134, 8/2011, 116 individuals). This left 419,905 CpGs for the final meta-analyses.
Fixed-effect meta-analysis weighted by the inverse of the variance was completed 
using METAL.25 Multiple testing was accounted for by using the FDR procedure by 
Benjamini and Hochberg (BH).26 For each CpG, the resulting BH corrected P values 
are denoted by PBH. CpGs with PBH<0.05 were considered statistically significant. CpGs 
that were statistically significant based on the more stringent Bonferroni correction 
(uncorrected P<1.19 × 10−7 to account for 419,905 tests) were noted. We present the 
covariate-adjusted model without cell-type adjustment as the primary results. In the 
Supplementary Information, we present results additionally adjusted for cell type and 
results without covariate adjustment.
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sensitivity analyses
We performed sensitivity analyses to assess whether the associations observed between 
folate and methylation might be explained by levels of vitamin B12, a dietary co-factor 
involved in regulating carbon unit bioavailability. Vitamin B12 is generally present in 
multivitamins that pregnant women in our studies may have taken in addition to, or in 
lieu of, separate folic acid supplements. Multivitamin supplements containing B12 typi-
cally contain other B vitamins including vitamin B6, which is also involved in one-carbon 
metabolism. Because mothers with higher folate levels may have higher intakes of other 
vitamin supplements not involved in the one-carbon metabolism pathway, or healthier 
diets in general, we also performed separate analyses adjusting for maternal plasma 
vitamin D levels during pregnancy. We also examined two SNPs in MTHFR involved in 
modulation of one-carbon metabolism: rs1801131 and rs1801133.27,28 We evaluated 
the impact of adjustment for total homocysteine on the association between maternal 
plasma folate and DNA methylation in newborns. Finally, we examined whether the 
associations with methylation seen for maternal folate levels are also seen for newborn 
folate levels in a subset of 572 subjects in Generation R.
Pathway analysis
To better understand the functional relationships between differentially methylated 
CpGs, we evaluated the FDR-significant CpGs with pathway analysis using three inde-
pendent software programs. First, gene ontology analysis was performed using the 
IPA (www.ingenuity.com) based on the content version of 21249400 (release date: 22 
September 2014). For a given category in IPA, Fisher’s exact test was used to measure the 
probability that the category was randomly associated (P<0.05 defined as significantly 
enriched). Second, the NIAID’s DAVID Bioinformatics Resources 6.729 was used to analyse 
enrichments in main categories: biological process, cellular component, molecular 
function and KEGG pathway. Third, we used gene ontology enrichment analysis and 
visualization tool30 to identify the most informative terms that are significantly enriched.
methylation expression analysis
We evaluated the association between methylation and quantitative levels of gene ex-
pression for our top CpGs. We used messenger RNA gene expression and 450 K methyla-
tion data both from white blood cells from adults over 45 years of age in the Rotterdam 
Study, a population-based prospective cohort study in Rotterdam, the Netherlands. 
Among the 443 FDR-significant CpGs associated with folate, we were able to match 365 
CpGs to a gene transcript in our gene expression data set within a region of 250-kb 
upstream or downstream of the CpG (total region 500 kb). We analysed the associations 
of these CpGs with expression levels of the corresponding gene transcripts.
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study characteristics
In MoBa participants (N=1,275), maternal plasma folate levels ranged from 1.6 to 53.2 
nmol/ l (mean=11.9). The maternal plasma folate levels in Generation R (N=713) ranged 
from 4.1 to 45.3 nmol/ l (mean=20.3; Table 4.3.1). The mean maternal age was ~30 years 
for both cohorts. Approximately, 15% of MoBa mothers and 25% of Generation R moth-
ers smoked during the pregnancy and over 60% obtained college or more advanced 
levels of education in both studies (Table 4.3.1).
meta-analysis
Our meta-analysis of the association between maternal plasma folate levels during preg-
nancy and differential DNA methylation in newborn cord blood, adjusted for covariates, 
resulted in 443 false discovery rate (FDR)-significant CpGs (Benjamini and Hochberg 
FDR-corrected P (PBH)<0.05; Figure 4.3.1). Genes with two or more FDR-significant CpGs, 
where at least one CpG was within the gene, were prioritized for further discussion (Table 
4.3.2). Results for all FDR-significant CpGs are shown in Supplementary Data 1 (sorted by 
the uncorrected P value) and Supplementary Data 2 (sorted by chromosome and posi-
tion). The vast majority of the FDR-significant CpGs were robust to covariate adjustment 
as well as adjustment for cell type; coefficients from the unadjusted, covariate-adjusted, 
and covariate- and cell-type-adjusted models were in the same direction and had a simi-
lar magnitude of effect (Supplementary Data 1 and 2). More detailed gene information is 
provided in S-Table 1. The genomic inflation factor (lambda)31 values for the unadjusted, 
covariate-adjusted, and covariate- and cell-type-adjusted models were 0.96, 1.07 and 
1.16, respectively (Supplementary Figures 1–3). Among the 443 FDR-significant CpGs 
in the covariate-adjusted meta-analysis model, increasing levels of maternal plasma 
folate during pregnancy were associated with decreased methylation of 416 (94%) and 
increased methylation of 27 (6%) CpGs. There were 48 CpGs that also met the strict 
Bonferroni threshold for statistical significance (P<1.19 × 10−7, correcting for 419,905 
tests). The direction of effects for the statistically significant CpGs was largely consistent 
in the MoBa and Generation R populations (Table 4.3.2; Supplementary Data 1 and 2).
sensitivity analyses
We considered whether vitamin B12, a co-factor with folate in one-carbon metabolism, 
contained in most multivitamins, along with other B vitamins such as B6 and riboflavin, 
might confound associations between folate and methylation. Vitamin B12 and folate 
levels were modestly positively correlated (Spearman correlation 0.11 in MoBa, 0.14 in 
Generation R, P<0.001 for both). When we adjusted for vitamin B12, the coefficients for 
folate in relation to methylation changed only minimally (median change 4.9%, 25–75th 
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percentile 2.3–8.2%, N=1,933 subjects). In addition to the consistency of effect estimates 
after adjustment, results remained statistically significant for 376 (85%) at Bonferroni 
correction for 443 tests, P<1.13 × 10−4, and all 443 CpGs had P<9 × 10−4 (Supplementary 
Data 3). Thus, vitamin B12 does not confound the folate–methylation associations we 
observed.
Women with higher folate levels, which largely reflect supplement use, might be 
more likely to take multivitamins and/or separate supplements such as cod liver or fish 
oils that are common in Norway. However, vitamin D (total of D2 and D3) levels were 
modestly correlated with folate levels (Spearman correlation coefficient=0.14 in MoBa, 
0.23 in Generation R, P<0.001 for both cohorts). Adjustment for vitamin D only minimally 
altered effect estimates for folate in relation to methylation (median absolute value of 
table 4.3.1. Descriptive Characteristics of the MoBa and Generation R Study Populations.
Variable category moba 
n (%)
generation r 
n (%)
Maternal plasma folate (nmol l−1) Min–max 1.6–53.2 4.1–45.3
Mean 11.9 20.3
Median 9.1 19.6
25–75th percentile 6.2–16.0 13.3–26.4
Log-transformed maternal plasma folate Min–max 0.48–4.0 1.4–3.8
Mean 2.3 2.9
Median 2.2 3.0
25–75th percentile 1.8–2.8 2.6–3.3
Maternal age (years) Mean (s.d.) 29.9 (4.3) 31.5 (4.1)
Maternal education level Less than secondary school 96 (7.5) 14 (1.8)
Secondary school completion 415 (32.3) 267 (34.3)
Some college or university 566 (44.1) 203 (26.0)
4 Years or more of college/university 206 (16.1) 296 (37.9)
Missing 6 10
Parity* 0 537 (41.7) 479 (60.7)
1 511 (39.6) 240 (30.4)
2 179 (13.9) 63 (8.0)
3+ 62 (4.8) 7 (0.9)
Missing 0 1
Maternal smoking during pregnancy No 1098 (85.2) 541 (75.6)
Yes 191 (14.8) 175 (24.5)
Missing 0 74
N=1,289 MoBa and N=790 Generation R participants with maternal plasma folate and newborn DNA meth-
ylation data. N=1,275 MoBa and N=713 Generation R participants with complete data were included in the 
adjusted models.
*Parity was categorized as ≥1 versus 0 in the statistical models for the Generation R study.
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change 7.3%, 25–75th percentile 3.3–12.3%). Despite the reduction in power due to the 
smaller sample size for these adjusted analyses (N=1,664), 70% of CpGs significantly 
related to folate in the main model remained Bonferroni significant after adjustment for 
vitamin D (308 with P<1.13 × 10−4; Supplementary Data 3).
We performed additional analyses adjusting for two single-nucleotide polymorphisms 
(SNPs) in the MTHFR gene that influence one-carbon metabolism and are correlated 
with plasma folate: rs1801133 and rs1801131.27,28 These SNPs are in moderate linkage 
disequilibrium with each other (r2=0.20–21 in the two studies). Adjustment for these 
two SNPs made little difference in the effect estimates compared with the main model; 
median change in coefficient=3.8% (25–75th percentile=2.0–6.9%) and 85% of CpGs re-
mained statistically significant despite reduction in sample size to 1,880 (P<1.13 × 10−4, 
correction for 443 tests). Thus, these genetic variants do not confound the relationship 
between folate and methylation.
Homocysteine, unlike folate or vitamin B12, is not a nutrient that plays a role as a methyl 
donor or carrier, but is a product formed during transmethylation in the one-carbon 
metabolism cycle. It could be regarded as an intermediate on the causal pathway be-
tween folate and methylation. In addition, like plasma folate, it is an excellent marker 
of folate status. Homocysteine was strongly correlated with maternal plasma folate in 
MoBa (Spearman correlation=−0.49, P<0.001) and moderately correlated in Generation 
figure 4.3.1. Association between Maternal Plasma Folate and DNA-methylation in Newborn Cord Blood: 
Meta-analysis Results for MoBa (n = 1,275) and Generation R (n = 713) Cohorts.
The uncorrected –log10(P values) are plotted by CpG genomic position. Multiple testing was accounted for 
using the false discovery rate (FDR) procedure by Benjamini and Hochberg. A total of 443 CpGs were consid-
ered FDR significant (solid horizontal line); 48 CpGs were also Bonferroni significant (dashed horizontal line)
Maternal plasma folate impacts differential DNA methylation in an epigenome-wide meta-analysis of newborns
237
Ch
ap
te
r 4
.3
table 4.3.2. Selected Loci with Differential Methylation in Cord Blood in Relation to Maternal Folate.
cHr Position cpg gene gene group meta-analysis
coef s.e. P
7 126698829 cg15908975 GRM8 Body −0.012 0.002 6.76E−07
7 126889015 cg18574254 GRM8 5′-UTR −0.011 0.002 3.27E−09
10 91296252 cg22591480 SLC16A12 TSS1500 −0.008 0.002 1.34E−05
10 91296311 cg14920044 SLC16A12 TSS1500 −0.011 0.003 4.31E−06
11 132951838 cg24829292 OPCML Body 0.010 0.002 6.60E−06
11 132951861 cg22629528 OPCML Body 0.019 0.005 2.91E−05
11 132951950 cg26283170 OPCML Body 0.009 0.002 1.30E−05
12 49689685 cg24804179 PRPH Body −0.007 0.002 8.05E−06
12 49690254 cg05775627 PRPH Body −0.007 0.002 1.01E−05
12 49692283 cg16010628 PRPH 3′-UTR −0.005 0.001 1.73E−05
16 2866901 cg05635274 PRSS21 TSS1500 0.009 0.002 4.77E−06
16 2867051 cg02296564 PRSS21 TSS200 0.011 0.003 6.21E−06
16 2867434 cg22730830 PRSS21 Body 0.013 0.003 3.99E−06
16 2867446 cg01232511 PRSS21 Body 0.014 0.003 1.23E−05
17 35285205 cg10612259 LHX1 −0.011 0.002 9.10E−08
17 35285295 cg01965477 LHX1 −0.002 0.001 2.09E−05
19 1453909 cg11775595 APC2 Body −0.015 0.003 1.64E−07
19 1456246 cg14907738 APC2 Body −0.006 0.001 8.57E−06
19 1456337 cg27150178 APC2 Body −0.009 0.002 5.81E−07
19 1456886 cg03165176 APC2 Body −0.012 0.003 1.44E−05
19 1457211 cg14559388 APC2 Body −0.003 0.001 4.98E−06
19 1465207 cg04624885 APC2 Body −0.010 0.002 1.56E−05
19 1472936 cg19870717 APC2 3′-UTR −0.009 0.002 4.64E−09
19 1473042 cg16613938 APC2 3′-UTR −0.016 0.003 3.05E−08
19 1473179 cg23291200 APC2 3′-UTR −0.010 0.002 1.72E−09
19 51415450 cg13793157 KLK4 −0.009 0.002 4.00E−05
19 51415452 cg10078829 KLK4 −0.007 0.002 1.84E−05
CHR, chromosome; Coef, regression coefficient from statistical model; gene, mapped or nearest gene 
(within 10 Mb) symbol using the UCSC database and Snipper software; gene group, gene region feature 
category (UCSC with verification); P, uncorrected P value from statistical model; UTR, untranslated region. 
Selection limited to genes with at least two CpGs at FDR significance that were prioritized for discussion. 
Meta-analysis of results for 1,275 MoBa participants and 713 Generation R participants. Robust linear re-
gression models adjusted for maternal age, maternal education, maternal sustained smoking during 
pregnancy, parity and batch. Results sorted by the chromosome and position of the CpG sites listed. For 
complete list of CpGs differentially methylated in relation to maternal folate and for results from meta-
analysis models unadjusted for covariates and adjusted for covariates and cell type see Supplementary 
Data 1 (sorted by P value) and 2 (sorted by chromosome, position). Supplementary Data include columns 
for mapped and nearest gene for each CpG.
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R (Spearman correlation=−0.24, P<0.001), making it challenging to estimate indepen-
dent effects. Given these various factors, inclusion of homocysteine in the model led 
to a moderate change in the coefficients for folate in relation to methylation (median 
change 10.7%, 25–75th percentile 5.8–17.2%. N=1,931 subjects) and only 137 (31%) 
CpGs remained statistically significant (P<1.13 × 10−4, correction for 443 tests).
We also examined whether the associations with methylation seen for maternal folate 
levels are also seen for newborn folate levels in a subset of 572 subjects in Generation R. 
Thus, this analysis is not well powered compared with our maternal folate analysis with 
1,988 subjects. However, of the 443 FDR-significant findings for maternal folate in the 
meta-analysis there were 60 (14%) with nominal Pvalues<0.05 for newborn folate which 
is higher than the 5% expected by chance alone (Kolmogorov P<1.2 × 10−13). This sup-
ports the interpretation that some similar loci are differentially methylated in response 
to infant folate, although we were severely underpowered to address this properly.
Pathway analysis
Pathway analysis with the FDR-significant CpGs showed strong and consistent enrich-
ment of fundamental development pathways and of neurodevelopmental pathways 
(Supplementary Tables 2–4). The biological processes implicated from the DAVID 
pathway analysis included cell development, embryonic morphogenesis, develop-
ment, regulation of multicellular organismal processes, cell–cell signalling, embryonic 
development, forebrain development and, notably, neural tube development (Supple-
mentary Table 2). Ingenuity Pathway Analysis (IPA) results indicated pathways related to 
nervous system development and function, cell–cell signalling and basic developmental 
processes (Supplementary Table 3). Gene ontology enrichment analysis and visualiza-
tion tool results included pathways related to the synaptic signalling, cell–cell signalling, 
regulation of cAMP biosynthetic process, single-organism behaviour, single-organism 
signalling, signalling, regulation of gastrulation and the regulation of nervous system 
development (Supplementary Table 4).
methylation expression analysis
Of the 365 CpGs associated with folate that we were able to match to a gene transcript 
(±250 kb), 43 CpGs were significantly associated with altered expression of nearby genes 
(PBH<0.1). For most CpGs, increased methylation was associated with decreased gene 
expression (Supplementary Table 5).
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discUssion
Our study is the largest to date using the Illumina 450 K epigenome-wide platform 
to evaluate the impact of maternal plasma folate levels during pregnancy on DNA 
methylation in newborns. We meta-analysed results from two population-based birth 
cohort studies in Northern Europeans that measured DNA methylation using the same 
platform. We observed epigenome-wide FDR-significant associations between maternal 
plasma folate and DNA methylation in cord blood at 443 CpGs.
It is notable that many of the implicated genes have functional relevance to various 
developmental pathways. Some are relevant to NTDs, the indication for maternal folic 
acid supplementation, and others to distinct developmental conditions that have not 
been previously associated with maternal folate levels. Additional genes we identified 
have been implicated in conditions where there is some concern about possible adverse 
effects of higher folate levels, such as breast cancer progression.32 Due to the large num-
ber of genes significantly differentially methylated in relation to folate (Supplementary 
Data 1 and 2), we focus this discussion primarily on genes with two or more CpGs at 
genome-wide significance after FDR correction (PBH<0.05) where at least one CpG is 
within the gene (Table 4.3.2).
We observed the largest number (nine) of statistically significant CpGs mapping to 
the gene adenomatosis polyposis coli 2 gene (APC2). APC2 is expressed in both human 
fetal and adult brain17 and in the peripheral nervous system.33 It plays a critical role in 
the brain development in several model systems.34APC2 may also play a role in cancer 
aetiology. A homologue of the tumour suppressor gene APC, APC2, is involved in the 
regulation of the Wnt signalling pathway, which impacts both normal development and 
tumorigenesis.35 Studies in mice have reported associations between periconceptional 
maternal folate and methylation of APC genes.36 In two human breast cancer lines, folate 
leads to methylation-mediated silencing of APC and other tumour suppressor genes, 
raising concern about the risk of tumour progression.37 Thus, folate-related methylation 
of APC2 during fetal development could impact both pathways of neurodevelopment 
and carcinogenesis.
GRM8 encodes a glutamate receptor that interacts with L-glutamate, the major excit-
atory neurotransmitter in the central nervous system. Glutamatergic neurotransmission 
is ubiquitous in normal brain function38 and is perturbed in various neuropathologies. 
In humans, copy-number variations of GRM8 have been associated with neurodevelop-
mental disorders such as attention-deficit hyperactivity disorder39 and autism spectrum 
disorder.40
A number of genes we identified as differentially methylated in newborns in relation 
to maternal folate are known to harbour mutations that have been causally implicated 
in various developmental abnormalities other than NTDs, the indication for folic acid 
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supplementation in pregnancy. These include several with two or more statistically 
significant CpGs (Table 4.3.2) such as SLC16A12, implicated in juvenile cataracts with 
microcornea and renal glucosuria41; and KLK4, implicated in the dental malformation 
amelogenesis imperfecta42. Mutations in LHX1 have been associated with abnormalities 
in uterine development43, and recent evidence suggests an important role in retinal 
development44. Several genes with one CpG at genome-wide statistical significance 
(Supplementary Data 1 and 2) also harbour mutations that are causal for various devel-
opment malformations. These include IHH involved in skeletal malformations, ROBO3 
involved in horizontal gaze palsy with progressive scoliosis, PCSK9 involved in familial 
hypercholesterolemia, FAM83H related to amelogenesis imperfecta type 3 and GJA3 
associated with congenital cataracts. Taken together, these findings suggest a role for 
periconceptional folate levels in birth defects not previously known to be related to this 
nutrient.
Our agnostic evaluation of maternal folate levels and DNA methylation in newborns 
also identified genes related to various neurologic diseases. Genetic variation in OPCML 
and PRPH has been associated with the neurodegenerative disease amyotrophic lat-
eral sclerosis.45,46 In genome-wide association studies, CSMD1 has been associated with 
schizophrenia and autism.47
Some previous studies of folate and methylation have examined the H19 imprinted 
region.11,34 We identified three significant CpGs located 45–48-Kb upstream of H19 
among 77 CpGs on the platform that are within 48 up- or downstream of H19. The largest 
number of statistically significant associations at any locus, 31, are on chromosome 12 
and, based on our extended annotation, are nearest to ALG10. Two CpGs are 262–573-kb 
upstream; the other 29 CpGs are 261–573-kb downstream. None are in ALG10. Most are 
in a CpG island near the centromere and there are no features that suggest functional 
impact.
In the only previous study using the 450 K platform, Amarasekera et al12 reported dif-
ferential methylation in relation to maternal folate in a 923-bp region on chromosome 6, 
3-kb upstream of ZFP57. Our studies differ in sample sizes, design and analysis methods. 
However, when we evaluate the 20 CpGs that map to ZFP57, we find 5 with uncorrected 
P values of 0.05 or smaller—more than would be expected by chance alone. Thus, our 
data provide support for association at this locus.
From correlation analysis of 450 K methylation data and gene expression in white 
blood cells in adults, after correction for multiple testing, 43 CpGs that we implicated 
in relation to maternal folate were also related to expression of nearby genes (Supple-
mentary Table 5). Although correlation of 450 K methylation with gene expression in 
the same newborn samples would have been preferable, we were only able to examine 
correlations in a population of Dutch adults. The most statistically significant correlation 
between methylation and gene expression was observed for the gene PRSS21 (protease 
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serine 21 (testisin)); four CpGs were both significantly associated with maternal folate 
(Table 2) and expression of this gene (Supplementary Table 5). PRSS21 is a tumour sup-
pressor gene silenced by aberrant methylation in testicular germ cell tumours.48 Testicu-
lar germ cell tumours are diagnosed in early adulthood and can manifest as early as 15 
years of age. Prenatal origin of this tumour has been proposed49; perhaps, methylation in 
utero, influenced by maternal folate levels, could play a role in this pathogenesis.
Because other important factors in one-carbon metabolism could potentially explain 
associations between folate levels and DNA methylation in cord blood, we performed 
various sensitivity analyses (Supplementary Data 3). On the basis of these analyses, vita-
min B12 does not confound the folate–methylation association. This lack of confounding 
by B12 should extend to other B vitamins such as B6 and riboflavin that are present in mul-
tivitamins along with B12. We did not have data in both studies on choline, a nutrient that 
can serve as a source of one-carbon units. However, in MoBa, where choline was mea-
sured, there was no correlation with folate levels (Spearman correlation=−0.034, P=0.23) 
and thus choline should not confound associations between folate and methylation. 
Vitamin D is not part of the one-carbon metabolism cycle but might impact methylation 
by other mechanisms.50 We performed analyses in a subsample taking vitamin D into 
account as proxy for intake of other supplements or possibly healthy dietary patterns 
and observed no major differences in results. Adjustment of the folate–methylation 
association for homocysteine, a product formed in one-carbon metabolism that is itself 
an excellent marker of folate status, resulted in a substantial reduction in the number of 
statistically significant findings. Although caution is required, both because folate and 
homocysteine are correlated, and because they operate together in a cycle rather than a 
clear unidirectional pathway, this attenuation could be interpreted as homocysteine, at 
least in part, mediating some of the associations between folate and methylation.
Given the role of folate as a major provider of methyl groups in the one-carbon me-
tabolism pathway, our finding of reduced methylation with higher folate at the majority 
of the implicated CpGs may seem counterintuitive. However, methyl groups from the 
one-carbon metabolism pathway are used in a range of biological processes and the 
complex interactions of these systems may not necessarily result in linear relationships. 
Indeed, there is evidence that effects of folate on folate-dependent enzymes may switch 
directions at the higher intracellular concentrations that may accompany folic acid 
supplementation.38 Folic acid, in vitamin supplements or food fortification, is a synthetic 
folate with possible effects that differ from those of natural occurring folate species. 
There is recent evidence that folic acid interferes with the inhibitory effect of S-adenosyl-
methionine (SAM) on methylenetetrahydrofolate reductase (MTHFR)51 and may inhibit 
MTHFR activity, thereby reducing the amount of 5-methyl-tetrahydrofolate, SAM and 
the SAM/S-adenosylhomocysteine (SAH) ratio.52 The SAM/SAH ratio has been referred to 
as the methylation potential; low SAM/SAH ratio may decrease DNA methylation. This 
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may explain the inverse relationship we observe in our study but additional research is 
needed to more fully explain the complex biochemistry behind these observations. Of 
note, inverse correlations between prenatal folate status and DNA methylation at differ-
entially methylated loci have been identified in the other population studies including 
Hoyo et al53 and Amarasekera et al.12
Although the health outcomes that have been related to folic acid supplementation 
involve target tissues such as the nervous system, we only had cord blood available 
for assessment of methylation. We do not know whether differential methylation at 
the sites that we observed in cord blood would be observed in relevant target tissues. 
While divergence in epigenetic patterns is critical for cell-type regulation, there is also 
evidence of similarities in patterns among some tissues.54-56 We do not have data on 
methylation at older ages and thus the question of whether the differential methylation 
at these loci seen at birth in relation to maternal folate persists to later childhood would 
need to be addressed in future studies.
We measured folate using two different platforms in the two studies. Both are valid 
methods for the measurements of folate. Levels were reasonably similar although slightly 
higher in Generation R, which could reflect a difference in the platforms, differences in 
folate intake or the earlier timing of measurements in Generation R (~12-week gestation 
in Generation R versus ~18-week gestation in MoBa). Nonetheless, the top findings were 
consistent in both cohorts and thus robust to differences in measurement platforms. 
This may increase their generalizability to other populations.
One-carbon metabolism is a complex pathway with influences from multiple genetic, 
hormonal and environmental factors. Despite our attempt to account for other impor-
tant dietary intake involved in one-carbon metabolism, other supplementation and 
genetic variants, residual confounding could still be present and influence the observed 
associations of folate levels in pregnancy with methylation at birth.
The MoBa and Generation R cohorts offer a unique opportunity to study the epigen-
etic effect of folic acid supplementation in the absence of food supply fortification. It is 
possible that results may differ in populations exposed to fortification.
in conclusion, we identified multiple novel genes not previously implicated in 
biological responses to folate. Many of the implicated genes have functional relevance 
to various developmental pathways, including the nervous system. Some of these are 
relevant not only to NTDs, the indication for maternal folic acid supplementation, but 
also to other developmental abnormalities that have not been previously associated 
with maternal folate levels. The associations between periconceptional folate and these 
conditions are difficult to study because the abnormalities are rare and both supple-
mentation and fortification are now widespread. Other genes identified are implicated 
in conditions where concern exists about possible adverse effects of higher folate levels, 
such as breast cancer progression16. These findings may provide new insights into 
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mechanisms for the associations between maternal folate status and health outcomes 
in the offspring. Given that food fortification programs have greatly increased the folate 
status of the population, greater understanding of the biological effects of this nutri-
ent is important. The large number of novel genes identified using our genome-wide 
methylation approach may shed light on the protean effects of folate on human health.
Detailed acknowledgements and Supplementary Data can be found in the published 
article online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749955/
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introdUction
Early life factors are suggested to have an important role in the development of diseases 
in later life.1, 2 A classic example is low birth weight, which has been associated with a 
wide range of adult morbidities, including chronic obstructive respiratory diseases.2-4 
These observations have resulted in the “Developmental Origins of Health and Disease“ 
hypothesis, which proposes that the development of an organism is partly depending 
on the environment it is exposed to.2 Adverse exposures may result in specific adapta-
tions that benefit short term development and survival, but eventually lead to diseases 
in later life.
The main objective for this thesis was to identify early growth characteristics, envi-
ronmental exposures in early life, and genetic and epigenetic variants that affect lung 
function and predispose the individual for chronic obstructive respiratory diseases in 
childhood and adulthood. The main results, merits and limitations of the studies pre-
sented in this thesis have been discussed in the previous chapters. This chapter provides 
a general overview and interpretation of the main findings presented in this thesis, 
considers general methodological issues in epidemiological studies, and suggests direc-
tions for further studies.
interPretAtion of mAin findings
growth
Previous studies suggested that children born extremely preterm or with a low birth 
weight have high rates of neonatal respiratory diseases.5 Furthermore, children born 
preterm, with a small size for gestational age at birth, or with accelerated weight growth 
in the first months of infancy have increased risks of childhood wheezing and asthma.6 
Not much is known about the longitudinal foetal and infant growth patterns predispos-
ing to chronic obstructive respiratory diseases.
In this thesis, we examined the associations between early growth characteristics 
and childhood asthma using the individual data of 25,000 children participating in 
24 European cohort studies. We observed that a younger gestational age, smaller size 
for gestational age and greater infant weight gain across the full ranges were associ-
ated with lower childhood lung function (Table 5.1). Mediation analyses suggested that 
lower lung function explained up to 45% of the associations between early growth 
characteristics and childhood asthma. Studies that examined the combined effects of 
growth in both fetal life and infancy are scarce, but suggest that increased infant growth 
is associated with lower lung function and an increased risk of wheezing and asthma 
in childhood.7-9 In studies assessing weight gain from birth onwards, increased weight 
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growth between birth and 3 months was most consistently associated with lower FEV1/
FVC and an increased risk of asthma.10 We assessed combined fetal and infant growth 
patterns and showed that smaller weight growth in late fetal life and greater weight 
growth in early infancy were independently associated with lower lung function mea-
sures and an increased risk of asthma in childhood. Both our and other studies support 
the hypothesis that early growth characteristics affect the development of the lungs and 
airways, and that adverse growth characteristics lead to relatively small airways, a reduc-
tion in expiratory flows reflected by lower lung function values, and an increased risk of 
childhood asthma.11 The highest rate of airway and alveolar development occurs in early 
life.12 Adaptations related to fetal and infant growth could affect lung function and the 
risk of respiratory diseases.13 Other potential explanations include underdeveloped ana-
tomical or immunological mechanisms, or interaction with environmental factors, such 
as tobacco smoke exposure, or genetic factors.11 Further studies are needed to identify 
whether early developmental adaptations of the lungs and immune system explain the 
associations of fetal and infant growth characteristics with childhood asthma.
Next we examined the associations of detailed measured body fat composition with 
childhood lung function and asthma. We observed that a higher body mass index in 
children aged 6 years was associated with a higher respiratory resistance (Rint) and an 
increased risk of wheezing (Table 5.1). Detailed assessment of total body fat mass distri-
bution showed that a higher fat mass index was associated with a higher Rint, whereas 
a higher android/gynoid fat mass ratio was associated with a lower Fractional exhaled 
Nitric Oxide (FeNO). A higher pre-peritoneal fat mass, a measure of visceral abdominal 
fat, was associated with a higher FeNO, whereas subcutaneous fat mass was not associ-
ated with any outcome. In a recent case-control study of asthma in 678 Puerto Rican 
children, waist circumference and percentage body fat were associated with a larger 
increased risk of exercise-induced asthma symptoms, lower FEV1/FVC, higher total IgE 
levels and diagnosis of allergic rhinitis than BMI with these outcomes.14 Similarly, the 
association of central obesity with asthma showed larger effect estimates than BMI with 
asthma in a survey of Taiwanese schoolchildren.15 These and our findings suggest that 
specific adipose tissue distribution patterns are linked to pathways underlying the ef-
fect of obesity on asthma in childhood. One of these pathways could be the metabolic 
complications of obesity, rather than obesity itself, which might affect lung function and 
asthma risk in children.16, 17
Thus, preterm birth, low birth weight, infant growth, obesity and specific body fat 
mass distribution measures were associated with development of childhood lung func-
tion and asthma-related symptoms, and are potential targets for early prevention of 
impaired childhood lung function.
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environmental exposures
Various common environmental exposures have been linked to respiratory health.11, 18 
We focused on tobacco smoke exposure, which is the most important adverse exposure 
for the development of chronic obstructive lung diseases. Furthermore, our interested 
was on the use of folic acid supplements during pregnancy, which is highly recommend-
ed by the World Health Organization to prevent congenital anomalies. Intake of high 
dosages of folic acid supplements have been associated with increased risks of allergic 
airway diseases in animals, but results in human studies are scarce and conflicting.19-22 
Last, we focused on the role of breastfeeding on respiratory health. Breastfeeding dura-
table 5.1. Overview of the results of studies presented in this thesis on early growth and childhood lung 
function and asthma.
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birth characteristics
Gestational age (weeks) n.s. n.s. ↑ ↑ ↑ ↑ ↑ n.s. ↓
Preterm birth (<37 weeks) n.s. n.s. ↓ ↓ ↓ ↓ ↓ n.s. ↑
Birth weight (SDS) n.s. n.s. ↑ ↑ ↑ ↑ ↑ n.s. ↓
Low birth weight (<2500 gram) n.s. n.s. ↓ ↓ ↓ ↓ ↓ n.s. ↑
growth
Fetal weight growth (SDS) n.s. n.s. ↑ ↑ = = = n.s. =
Infant weight growth (SDS) n.s. n.s. = ↑ ↓ = ↓ n.s. =
Adiposity
BMI (SDS) ↑ = n.s. n.s. n.s. n.s. n.s. ↑ =
Fat mass index = = n.s. n.s. n.s. n.s. n.s. = =
Android/gynoid fat mass ratio = ↓ n.s. n.s. n.s. n.s. n.s. = =
Subcutaneous area (SDS) = = n.s. n.s. n.s. n.s. n.s. = =
Pre-peritoneal area ↓ ↑ n.s. n.s. n.s. n.s. n.s. = =
Lung function was measured at age 6 (Respiratory resistance (Rint), Fractional exhaled Nitric Oxide (FeNO)) 
and 10 years (lung function measures by spirometry), and symptoms and diseases until 6 years (wheezing) 
and at 6 or 10 years (ever/current physician diagnosed asthma). FEV1: Forced Expiratory Volume in 1 sec-
ond; FVC: Forced Vital Capacity; FEF25-75: Forced Expiratory Flow between 25 and 75% of FVC; FEF75: Forced 
Expiratory Flow at 75% of FVC. Arrows represent directions of associations per increase of early growth 
measure. Up going arrows represent a positive association, down going arrows represent a negative asso-
ciation. The “=” sign represents that no association was observed. “n.s.”: not studied in this thesis.
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tion and exclusiveness is known to be associated with a lower risk of asthma symptoms 
in early childhood, but its effect on respiratory health at older ages is unclear.  
Maternal smoking during pregnancy has been associated with an up to 1.7 times 
increased risk of wheezing until age 2 years.23 We observed that continued maternal 
smoking during pregnancy was associated with increased risks of wheezing and asthma 
up to age 6 years, but not with Rint or FeNO.24 Gestational age and birth weight did 
not explain these associations (Table 5.2). In mice, nicotine exposure during pregnancy 
reduces forced expiratory flows, and increases airway reactivity in offspring, which 
suggests a direct intrauterine effect of tobacco smoke on respiratory morbidity in 
childhood.25 Tobacco smoke exposure might also affect lung development through 
DNA-methylation. Maternal tobacco smoking during pregnancy has been associated 
with differential DNA-methylation of >6,000 loci across the newborn genome.26 Further 
research is needed to identify the pathophysiologic mechanisms of intrauterine tobacco 
smoke exposure on childhood respiratory health. Additionally, prevention strategies 
such as smoke legislation programs should be further implemented.27
Maternal folic acid supplement use during pregnancy is strongly recommended to 
prevent congenital anomalies 28, while high dosages of folic acid supplement use are 
suggested to have adverse effects on respiratory health. We observed that maternal folic 
acid supplement use during pregnancy was associated with lower lung function mea-
sures in children, but only among mothers carryingMTHFR-C677T variants (Table 5.2). 
A higher vitamin B12 level at birth was associated with a lower FEV1 and FVC, but only 
among children carrying MTHFR-C677T wildtype. MTHFR produces an enzyme that af-
fects the one-carbon metabolism, a process that converts the amino acid homocysteine 
to methionine, which is an important methyl donor.29, 30 The variant C677T is known to 
affect the activity of the MTHFR enzyme, leading to lower circulating folate and higher 
homocysteine concentrations.31 Also, folate and vitamin B12 are important cofactors 
in the one-carbon metabolism.32 Elevated folic acid exposure during pregnancy has 
been linked to cellular modifications associated with asthma and allergic diseases.33 
In animal models, maternal diet enriched with folic acid and vitamin B12 was associ-
ated with epigenetic changes in offspring, including immune functioning.33, 34 Further 
research on the interactions between folic acid and genetic predisposition is needed to 
provide insight into mechanisms leading to chronic obstructive respiratory diseases.35 
The results of the first study examining associations of maternal plasma folate levels 
during pregnancy and epigenetic changes in neonatal cord blood are presented below. 
Because of the importance of folic acid supplement use during pregnancy to prevent 
congenital anomalies, the potential adverse effects of folic acid supplement use on 
childhood respiratory health need to be carefully evaluated before any changes in the 
current recommendations are considered.
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Prolonged and exclusive breastfeeding has been associated with a decreased risk 
of asthma symptoms up to age 2 years.36 We observed that children who were never 
breastfed had a lower FeNO and an increased risk of wheezing until age 6 years (Table 
5.2). Among breastfed children, a shorter duration and less exclusive breastfeeding were 
associated with an increased risk of wheezing in early life, and a breastfeeding duration 
less than 2 months was associated with a 2.2 times increased risk of asthma. The associa-
tions partly attenuated when lower respiratory tract infections in early life were taken 
into account. This suggests that the associations between breastfeeding and childhood 
asthma are partly explained by the protective effect of breastfeeding on lower respira-
table 5.2. Overview of the results of studies presented in this thesis on environmental exposures in early 
life and childhood lung function and asthma.
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tobacco smoke exposure = = n.s. n.s. n.s. n.s. n.s. ↑ ↑
folic acid supplement use during pregnancy
Maternal MTHFR-C677T wildtype n.s. n.s. ↑ ↑ = ↑ = n.s. =
Maternal MTHFR-C677T variants n.s. n.s. = = ↓ ↓ = n.s. =
Vitamin b12 levels at birth
Child MTHFR-C677T wildtype n.s. n.s. ↓ ↓ = = = n.s. =
Child MTHFR-C677T variants n.s. n.s. = = = = = n.s. =
folate, vitamin b12 and homocysteine 
levels in early pregnancy
n.s. n.s. = = = = = n.s. =
folate and homocysteine levels at birth n.s. n.s. = = = = = n.s. =
breastfeeding
Never = ↓ n.s. n.s. n.s. n.s. n.s. ↑ =
Shorter duration = = n.s. n.s. n.s. n.s. n.s. ↑ ↑
Less exclusive = = n.s. n.s. n.s. n.s. n.s. ↑ =
Lung function was measured at age 6 (Respiratory resistance (Rint), Fractional exhaled Nitric Oxide (FeNO)) 
and 10 years (lung function measures by spirometry), and symptoms and diseases until 6 years (wheezing) 
and at 6 or 10 years (ever/current physician diagnosed asthma). FEV1: Forced Expiratory Volume in 1 sec-
ond; FVC: Forced Vital Capacity; FEF25-75: Forced Expiratory Flow between 25 and 75% of FVC; FEF75: Forced 
Expiratory Flow at 75% of FVC. Arrows represent directions of associations for each exposure. Up going 
arrows represent a positive association, down going arrows represent a negative association. The “=” sign 
represents that no association was observed. “n.s.”: not studied in this thesis.
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tory tract infections. Breastfeeding might contain secretory factors in breastmilk that 
stimulate the developing immune system and protect for childhood asthma.37-39 Also, a 
longer duration of breastfeeding has been associated with a lower methylation status 
of Leptin, a gene implicated in appetite regulation and fat metabolism.40 Interestingly, 
a shorter duration of breastfeeding has been associated with higher central fat mass in 
early childhood.41 Therefore, a shorter duration or less exclusive breastfeeding might 
lead to genome-wide or Leptin-specific epigenetic changes, resulting in specific adverse 
adipose tissue distributions, which subsequently affect childhood lung function and 
asthma.
In summary, we identified adverse effects of maternal smoking during pregnancy, 
of maternal folic acid supplements use during pregnancy when carrying MTHFR-C677T 
variants, and of shorter and less exclusive breastfeeding on childhood lung function, 
wheezing or asthma. Further research is needed to identify underlying mechanisms, 
including epigenetics changes. 
genetic and epigenetic studies
Genome-wide association (GWA) studies enable to examine the associations of millions 
of common genetic variants, known as Single Nucleotide Polymorphisms (SNPs). With 
recent advances in genetic technologies, currently the associations of >10 million SNPs 
with any phenotype can be explored. Only a limited number of loci associated with asth-
ma have been verified in GWA studies, any many variants have not been replicated.42-47
We increased the understanding of the genetic background of early childhood asthma 
with severe exacerbations by conducting a GWA study of this specific asthma pheno-
type.48 We identified 5 loci, 4 of which were previously associated with asthma. We also 
identified a new susceptibility gene, CDHR3, which encodes the gene cadherin-related 
family member 3 (Table 5.3). The detailed biological function of CDHR3 is unknown. 
Variants in CDHR3 may increase the risk of severe asthma exacerbations by altering 
the structural integrity of airway epithelium, thus promoting infection by respiratory 
microbes. The pathophysiologic mechanisms of variants in CDHR3 in childhood asthma 
need to be further explored, which could potentially lead to prevention strategies and 
targeted therapies of the malfunctioning protein.
Three meta-analyses of GWA studies from population-based studies previously identi-
fied 35 SNPs associated with lung function in European adults.49-52 We now showed that 
2 genetic risk scores composed of SNPs associated with adult lung function were also 
associated with childhood lung function, but not with childhood asthma (Table 5.3). Ex-
posure to maternal smoking and gestational age at birth modified some of the observed 
associations. These results suggest that SNPs associated with adult lung function already 
affect lung function in early life. Identification of abnormal lung function development 
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in early childhood life may help identify individuals at risk for chronic airflow obstruction 
in adulthood.53, 54
Genetics are unlikely to explain the quickly altering prevalence of asthma in the past 
decades, because any mutation would require multiple generations to occur on popula-
tion level.55 Epigenetic changes are influenced by environmental exposures and could 
exert population effects much more rapidly than genetic mutations.56 DNA-methylation 
is currently the best understood epigenetic mechanism, and techniques have been 
developed to assess epigenome-wide DNA-methylation patterns in large population-
based studies.
DNA-methylation affects fetal development through effects on gene transcription 
and expression.57 The methyl groups required for DNA-methylation are mostly provided 
by the one-carbon metabolism.32, 58
table 5.3. Overview of the results of studies presented in this thesis on genetic susceptibility and epigen-
etic factors associated with childhood lung function and asthma, and COPD in adults.
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genome-wide association study
CDHR3 n.s. n.s. n.s. n.s. n.s. n.s. + n.s.
genetic risk scores
Based on SNPs associated with adult FEV1 ↓ = ↓ = ↓ = n.s. n.s.
Based on SNPs associated with adult FEV1/FVC ↓ = ↓ = ↓ = n.s. n.s.
differentially methylated regions
in cord blood*
+ n.s. + n.s. + + n.s. +
Lung function was measured at age 10 years (lung function measures by spirometry), and symptoms and 
diseases until 6 years (asthma exacerbations), at 10 years (current physician diagnosed asthma) and in 
adulthood (COPD; mean age 65 years). FEV1: Forced Expiratory Volume in 1 second; FVC: Forced Vital Capac-
ity; FEF25-75: Forced Expiratory Flow between 25 and 75% of FVC; FEF75: Forced Expiratory Flow at 75% of 
FVC. Arrows represent directions of associations for each genetic or epigenetic variant. Up going arrows 
represent a positive association, down going arrows represent a negative association. The “+” sign repre-
sents that significant associations were observed, in which the direction of the association is depending on 
the direction of the genetic variant or methylation of the specific differentially methylated region. The “=” 
sign represents that no association was observed. “n.s.”: not studied in this thesis. *Of all 59 identified differ-
entially methylated regions related with childhood lung function, 18 (31%) were associated with childhood 
asthma, and 9 (15%) were associated with COPD.
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Folate is an essential cofactor in this biological pathway. In this thesis, we presented a 
meta-analysis in which we observed that maternal plasma folate levels during pregnancy 
were associated with differential methylation of 443 CpGs located near 320 genes of the 
child at birth (Table 5.3). Most genes were not known for folate biology. Some were 
related to birth defects other than neural tube defects, neurological functions or varied 
aspects of embryonic development. These findings provide additional evidence that 
maternal folate impacts the developing epigenome of the child, which subsequently 
could affect the occurrence of chronic non-communicable diseases in later life.
We additionally reported the identification of 22, 15 and 22 differentially methyl-
ated regions of the child at birth to be associated with childhood FEV1, FEV1/FVC and 
FEF75, respectively. Differentially methylated regions are genomic regions containing 
multiple correlated CpGs within a close distance, usually defined as 500 to 1000 base-
pairs. Multiple of the identified differentially methylated regions were also associated 
with childhood asthma, adolescent and adult lung function, and adult COPD. Further 
analyses showed that the identified differentially methylated regions were related with 
differential expression of >100 genes, of which many have previously been related to 
lung function and chronic obstructive respiratory diseases. Also, genes related to the 
identified differentially methylated regions were expressed in adult lung tissue, and 
associated with respiratory developmental or pathogenic pathways. This supports the 
hypothesis that adverse exposures in fetal life impact DNA-methylation at birth, gene 
expression and subsequent respiratory development, predisposing individuals for 
obstructive airway diseases. Further studies on the identified differentially methylated 
regions and annotated genes might benefit strategies in early life to improve lung func-
tion and respiratory health in later life.
metHodologicAl considerAtions
Most studies presented in this thesis were performed within the Generation R Study, 
a prospective population-based cohort study with follow-up from fetal life onwards 
located in Rotterdam, The Netherlands. For meta-analyses on the associations of early 
growth characteristics with childhood lung function and asthma, and a genome wide 
association study on childhood asthma with severe exacerbations we used individual 
participant or effect estimate data from 24 and 23, respectively, European birth cohorts. 
For epigenome-wide studies on maternal folate levels during pregnancy and lung func-
tion and respiratory health across the life course, we used effect estimate data from 2 
European birth cohorts, and 4 European and 2 American birth cohorts, respectively.
Specific methodological considerations of the presented studies have been discussed 
in the studies presented in this thesis. In the following paragraphs, some general meth-
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odological issues with respect to the internal and external validity, and genetic and 
epigenetic methodological issues of epidemiological studies are discussed.
selection bias
Selection bias could occur if the association between the exposure and outcome of inter-
est is different in study participants and those who did not participate in the study, but 
were eligible for the study. The results obtained are thereby not representative for the 
population intended to be analyzed. Of all children eligible at birth, the overall response 
to participate in the Generation R Study was 61%.59 This non-response at baseline is not 
likely at random. Non-participating parents and children more frequently were of non-
Caucasian origin, had a lower socio-economic status, and more adverse birth outcomes, 
such as low birth weight, compared to mothers and children who did participate in the 
study, suggesting a selection toward a relative more healthy study population.60
Another source of selection bias is selective loss to follow-up, which occurs when the 
association between the exposure and outcome of interest is different between those 
participating in the studies described in this thesis and those lost to follow-up. Of all 
children (n = 9,901) originally included in the Generation R study, 85.2% (n = 8,305) 
participated in the follow-up studies at age 6 years, and 83.1% (n = 6,899) of them had 
information on airway resistance, airway inflammation, wheezing or asthma.59 At age 10 
years, 74.7% of all children (n = 7,393) originally participating in Generation R still par-
ticipated, and 77.4% (n = 5,721) of them had information on lung function or physician-
diagnosed asthma. Non-response and loss to follow-up may reduce statistical power, 
due to lower prevalence rates of exposures and outcomes. We performed non-response 
analyses to determine differences between participants and non-participating families. 
Overall, mothers from children who did not answer questionnaires related to r specific 
research questions or did not visit the research center for lung function measures of 
their child were more often of non-Caucasian origin, more frequently lower educated 
and smoked more during pregnancy, and their children were more often born with a 
low birth weight. Selection towards a relatively healthy population may have biased 
the observed effect estimates, despite its difficulty to quantify. Therefore, we applied 
multiple imputation, which limits the risk of selection bias due to missing values in 
covariates.61, 62
information bias
Information bias is a systematic error due to misclassification of participant data. 
Misclassification is differential (non-random) when the misclassification is different 
for those with and without the exposure or outcome of interest. Misclassification is 
non-differential (random) when it is unrelated to the occurrence or the presence of 
the exposure or outcome of the study. Differential misclassification may lead to either 
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over- or underestimated effect estimates, whereas non-differential misclassification usu-
ally results in an underestimation of the true effect estimates. Data used in the studies 
presented in this thesis, including fetal and childhood length and weight at different 
time points, tobacco smoke exposure during pregnancy, maternal folic acid supplement 
use and breastfeeding, and genetic and epigenetic samples, were collected before as-
sessment of the outcomes. All parents and researchers involved in data collection were 
unaware of specific research questions, which limits differential misclassification of 
the exposures. Lifestyle factors with potential adverse health effects, such as maternal 
smoking during pregnancy, are known to be underreported in epidemiologic studies. 
Differential misclassification may have therefore occur, because the difference in the 
risk of the outcome between those who smoke and those who do not smoke becomes 
smaller due to underreporting of mainly those who smoke, leading to an underesti-
mation of effect estimates. Similarly, overreporting of lifestyle factors with potential 
beneficial effects could have influenced the observed associations. Mothers are likely 
to have overreported the use of folic acid supplements during pregnancy, and might 
have exaggerated the duration of breastfeeding. This would again lead to differential 
misclassification of the exposure, resulting in underestimations of effect sizes.
Lung function and asthma were the two main outcomes examined in this thesis. Lung 
function was measured by Rint, FeNO or spirometry. The quality and reliability of lung 
function measures mainly depend on optimal performance of the study participant.63 
It seems unlikely that lung function measurements were influenced by differential 
misclassification, because the researchers involved in data collection were unaware of 
the lung function or asthma-status of the participant. Asthma is a difficult diagnosis 
in young children. Both wheezing patterns and asthma were self-reported outcome 
measures. Underreporting or over-reporting might have occurred despite the use of 
validated questionnaires based on international guidelines 64, and this might have led to 
misclassification of respiratory disease diagnosis resulting in either overestimations or 
underestimations of the true associations.
confounding
A confounding factor is a factor associated with both the exposure and the outcome, 
but not located in the causal pathway. If not taken into account, confounding may lead 
to biased effect estimates. We took well-known confounding variables as previously 
reported by literature into account, and examined the confounding effect of potential 
variables in our statistical models. Although we adjusted for many potential confound-
ers in all studies presented in this thesis, we cannot exclude that results were affected by 
unmeasured variables or by variables not known to be confounders in specific analyses, 
such as specific viral or bacterial respiratory infections and antibiotic use in early life, the 
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pulmonary and gastro-intestinal microbiome, and interactions between the environ-
ment and genetic susceptibility.65-68
external validity
External validity is the extent to which results of a study can be applied to other popu-
lations. The Generation R study is based on the general population in Rotterdam, the 
Netherlands. The largest ethnic groups are from Dutch, Surinamese, Turkish and Moroc-
can origins, and is comparable to the general ethnic distribution of the population in 
the Rotterdam region.60 Both household income and highest followed educational level 
in parents participating in the study suggest a selection towards a population with a 
higher socioeconomic status than the average in the whole study area. This pattern was 
similar in the follow-up assessments until age 10 years, and in line with other large scale 
prospective cohort studies. Although there is a selection towards a population with a 
higher socio-economic status in the general Generation R cohort, the population that 
was under study for the projects presented in this thesis contained representative eth-
nic and socio-economic subgroups of the general population. The results of this thesis 
could therefore presumably be applied to western populations with mixed ethnicities. 
The meta-analysis examining the associations of early growth characteristics and child-
hood lung function and asthma was based on individual participant data of 24 birth 
cohort studies from countries throughout Europe. Although countries from Eastern 
Europe were somewhat underrepresented, we assume that the overall study popula-
tion was a good representation of the average European population. The genetic and 
epigenetic studies were performed in populations of mainly Caucasian origin. Genetic 
variants might have differential effects across different ethnic populations.69 Replication 
of the associations of the identified genetic variants in non-Caucasian populations is 
needed before conclusions can be drawn on the global generalizability of these results.
methodological issues in genetic and epigenetic studies
In the past decade, GWA studies have been the main approach to identify genetic vari-
ants associated with common non-communicable diseases.70 Despite the potential of 
GWA-studies to examine the associations of a large number (currently >10 million) of 
genetic variants in a hypothesis-free manner, some methodological issues need to be 
considered. GWA studies will primarily detect small effect sizes for outcomes in relation 
to common SNPs, because the currently available genotyping platforms and imputa-
tion technologies mainly include SNPs with ≥1% minor allele frequencies. Current GWA 
studies are underpowered to detect associations of SNPs with low (<1%) minor allele 
frequencies to be associated with an outcome. We observed that the risk alleles associ-
ated with lung function, asthma and COPD by GWA studies accounted for small propor-
tions of the variance explained by genetic susceptibility. Combined non-identified rare 
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variants might potentially have larger effects than common variants on disease risk.71 
Furthermore, outcome assessment might differ between different study populations in 
GWA meta-analyses. This could potentially lead to non-differential (random) misclassifi-
cation, because the outcome assessment is unlikely to be related to the genotype of the 
examined individuals within participating studies. This non-differential misclassification 
may reduce the statistical power to detect associations of SNPs with the phenotype of 
interest. Also, population stratification may arise when genotype and outcome distribu-
tion is different between different participating study populations, although the selec-
tion of children for genetic studies in population-based cohorts usually is unrelated to 
any outcome. Population stratification may lead to false positive results.72 To minimize 
this, we applied genomic control by using principal components in all genetic associa-
tion studies presented in this thesis. Last, in GWA studies associations of a large number 
of SNPs with an outcome are tested, which might lead to false-positive findings when 
conventional statistical significance thresholds are used. Therefore, the statistical signifi-
cance threshold of GWA studies has been set to 5x10-8, reflecting a Bonferroni correction 
of testing one million variants (0.05/1,000,000). Still, false-positive findings are likely to 
occur due to insufficient statistical power, because common genetic variants are likely 
to have small effects. Combining data from multiple study cohorts has increased power 
for identification of common genetic variants.
Epigenome-wide association (EWA) studies have the potential to examine associa-
tions of a large number (~485.000) of CpG-sites across the genome with exposures and 
outcomes. However, some limitations need to be addressed. The Infinium HumanMeth-
ylation450 BeadChip array currently provides the best coverage of the human genome 
and covers 96% of all known CpG-islands, but only about 1.6% of all CpGs located in 
the human genome.73 Furthermore, the Illumina BeadChip technology relies on hybrid-
ization of genomic fragments to probes on the chip. Certain genomic factors, such as 
SNPs, may compromise the ability to measure DNA-methylation.74 It is not known to 
what extend these genomic factors do impact association analyses of CpGs with any 
outcome. However, stringent exclusion of probes potentially containing these genomic 
factors would results in many false-negative results. Therefore, the exclusion of probes 
with potential irrelevant genomic variants should be applied as sensitivity analysis in 
any EWA study, and further research is needed to make any technical recommendations. 
Furthermore, knowledge about the methylation status of an individual CpG is usually 
of limited value unless it is contextualized by the methylation status of neighboring 
CpGs nearby. The use of differentially methylated regions increases power to identify 
regions of interest and is conceptually consistent with what is known about human DNA 
methylation patterns.75-77 EWA studies are subject to confounding, including environ-
mental, genetic and technical factors, which should be accounted for.73, 78 Blood is an 
easy accessible tissue in large cohort studies, however, in epigenetic studies concerns 
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arise regarding confounding by differential cell types and the biological relevance of 
the tissues assessed. DNA-methylation differences between blood samples are strongly 
influenced by cellular heterogeneity.79 Consequently, EWA studies need to adjust for 
cell type composition. The most common used reference dataset to estimate cell type 
composition is based on blood samples from adults and is not likely representative of 
the cell type composition in neonatal cord blood.80 Recently, two new reference sets for 
cell type adjustment in cord blood have been published and are currently being vali-
dated. Future studies are needed to shed light on the differences between the available 
reference panels.81, 82 Blood DNA-methylation does not necessarily reflect lung epithelial 
DNA-methylation but this is difficult to examine in living children. Asthma and COPD 
have systemic manifestations characterized by increased inflammatory blood markers, 
and therefore blood might be an appropriate proxy for the EWA studies presented in this 
thesis.83, 84 Furthermore, we used publicly available databases to examine expression of 
the genes identified by cord blood DNA-methylation in lung tissue. Last, multiple test-
ing correction in EWA studies is required similar to GWA studies to prevent false positive 
findings.
cAUsAlitY
We assessed associations but not causal effects of early growth, environmental expo-
sures, genetic susceptibility, and epigenetic mechanisms on childhood lung function 
and asthma due to the observational design of all studies reported in this thesis. The 
Bradford Hill criteria define specific criteria to determine the causality of observed 
associations between exposures and diseases.85 These criteria include the strength, 
consistency, specificity and temporality of the observed associations, and causality is 
further strengthened by the observation of a biological gradient, a biologically plau-
sibility, coherence with current knowledge of the biology, experimental evidence and 
analogy with comparable exposures. Taking the Bradford Hill criteria into account, we 
can conclude that the observed associations were in line with results reported by previ-
ous studies. Temporality indicates that the effect has to occur after the cause, which 
we observed in our studies assessing the associations of growth in early life, tobacco 
smoke exposure and folic acid supplement use during pregnancy, and breastfeeding in 
early life, with respiratory outcomes at ages 6 and 10 years. Additionally, we observed 
dose-response effects for tobacco smoke exposure during pregnancy and breastfeeding 
duration with respiratory outcomes. For all observed associations of early growth and 
environmental exposures, plausible underlying mechanisms with coherence in animal 
studies are available.85 We could not fulfill the experimental criterion as defined by the 
Bradford Hill criteria, such as the use of animal models to prove associations of early 
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growth and environmental factors with childhood lung function and asthma. Studies 
that assessed analogue factors for the environmental factors assessed in this thesis 
provide further evidence for the observed associations. For example, low physical activ-
ity and higher waist circumference, which could be considered analogues for high BMI 
and adverse body fat distribution, have been associated with asthma in children and 
adolescents.86, 87
The causality of early growth and environmental exposures on lower lung function 
and increased risk of asthma can theoretically be proven using randomized controlled 
trials. However, randomized exposure to externally regulated growth patterns or 
environmental chemicals with proven adverse or beneficial effects on health, such as 
respectively maternal smoking and folic acid supplement use during pregnancy and 
breastfeeding, is unethical. Instead, experimental interventions promoting smoke ces-
sation, the intake of folic acid and breastfeeding coherent to the current guidelines, 
might provide additional evidence for the causality of these exposures on childhood 
respiratory diseases. This is illustrated by the PROBIT-trial, in which children of mothers 
who were intensively promoted to breastfeed according to the newest WHO guidelines 
had decreased risks of gastrointestinal tract infections and atopic eczema in the first 
year of life, compared to children of mothers who were not promoted and continued 
usual infant feeding practices and policies.88 To further explore causal effects of early 
growth and environmental factors on lung function and asthma, results from further 
studies according to the Bradford Hill criteria provide the highest likelihood of causality 
of the identified factors.85
GWA studies most often do not directly identify the causal genetic variant. GWA stud-
ies rely on linkage disequilibrium between genotyped SNPs and causal variants, which 
are most often not genotyped. If the identified variant has an effect on gene expression 
in selected cell types, this could support the finding that the identified variant is within 
a causal gene. As presented in this thesis, we assessed the functional consequences of 
the CDHR3-variant in T-cells, and we observed that the wildtype protein was expressed 
at very low levels, whereas the mutated protein showed an increase in cell surface 
expression. Furthermore, we observed a high expression of CDHR3 in adult bronchial 
epithelium and in fetal lung tissue. Further evidence for causality could be derived from 
animal knockout models, in which the occurrence of the disease after removing the 
suspect gene suggests a causal effect. Last, Mendelian randomization offers a unique 
method to assess causality in observational studies.89 Mendelian randomization is based 
on the principle that if a genetic variant is associated with an environmental exposure, 
and the environmental exposure itself is associated with the risk of a disease, then 
that genetic variant should also be associated with the disease.89 A study that applied 
Mendelian randomization using a genetic risk score based on 32 SNPs associated with 
BMI and adiposity suggested a causal association between BMI and asthma up to age 
General discussion
323
Ch
ap
te
r 5
7 years.90 This is consistent with the observed associations of higher infant weight gain 
and obesity with childhood asthma, as presented in this thesis.
In contrast to GWA studies, EWA studies are subject to genetic, environmental and 
technical confounding. DNA-methylation is a dynamic biological process, with altering 
patterns across the human life course.91 Differential methylation of a differentially meth-
ylated region might cause the disease, but development of the disease might also affect 
methylation at the same differentially methylated region. Therefore, interpretation of 
the directionality and causality of effects from an observational EWA studies is challeng-
ing. In the studies presented in this thesis, we observed that maternal folic acid levels in 
early pregnancy were associated with newborn DNA-methylation in cord blood. We also 
reported associations of newborn DNA-methylation in cord blood with lung function 
and respiratory outcomes across the life course. Due to the longitudinal aspect between 
the assessment of the exposures and outcomes in both studies, it is unlikely that reverse 
causation could have affect the observed results. Additionally to multiple studies with 
single observations, longitudinal studies with epigenome-wide DNA-methylation, 
confounding variables and outcomes measured at multiple time points are needed.92-94 
Longitudinal studies enable the identification of the direction and possibly the causality 
of EWA findings. Also, twin studies provide an additional and unique opportunity to 
eliminate confounding in EWA studies, because twins are matched controls for nearly 
all genetic variants and many environmental exposures. Last, epigenetic Mendelian 
randomization could be applied.95 In this method, first associations of a genetic variant 
with an environmental exposure, which is known to associated with differential DNA-
methylation, are assessed. Second, associations of another genetic variant with DNA-
methylation, which is known to be associated with an outcome, are assessed. With this 
two-step method it could be examined whether DNA-methylation is within the causal 
pathway between the exposure and the disease.
clinicAl imPlicAtions
The research we presented in this thesis is mainly based on observational collected data. 
As discussed previously, this limits the identification of causality and application in clini-
cal situations. Still, our studies do have some important clinical implications:
– Our observations that children born with a younger gestational age, lower birth 
weight, and restricted or accelerated growth patterns in early life have lower lung 
function measures and risks of asthma-related symptoms in childhood could be 
used in clinical models to predict the probability of the development of childhood 
asthma 96. An early risk prediction for the development of lower lung function and 
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asthma in childhood will support early identification and prevention of respiratory 
health problems in later life, such as COPD.
– We observed that specific body fat mass distributions were associated with child-
hood lung function and asthma. Public intervention programs should be further 
developed, aiming to reduce specific obesity phenotypes in childhood.97
– Our findings on the associations between tobacco smoke exposure during preg-
nancy with lung function and asthma in childhood provide additional support for 
nation-wide smoke legislation programs, which have shown strong beneficial effects 
on a population level.27
– Our study on the protective effect of breastfeeding on childhood asthma supports 
the current WHO-guidelines for prolonged and exclusive breastfeeding.98
– Our identification of CDHR3 as a new asthma-susceptibility gene has increased 
understanding of severe childhood asthma, and has created a new potential target 
for therapy. Research focusing on understanding the role of CDHR3 variants in the 
development of asthma and severe exacerbations is currently ongoing.
The other main results presented in this thesis require replication, and future research 
needs to shed light on underlying pathophysiological mechanisms. 
fUtUre PersPectiVes
As discussed before, randomized controlled trials to assess the causal effects of the 
risk factors studied in this thesis have ethical limitations. Alternative designs, such as 
the PROBIT-trial described above, might provide additional evidence for causality of 
the observed associations.88 We observed that maternal folic acid supplement use was 
associated with lower childhood lung function when mothers were carrier of MTHFR-
C677T variants. Potential adverse effects of folate supplement use needs to be carefully 
evaluated before clinical implications can be determined and any changes in the current 
guidelines are considered. Our results on the associations between breastfeeding and 
childhood asthma suggest a mediating effect by lower respiratory tract infections. Ad-
ditionally, CDHR3 is a plausible candidate gene for asthma because of its high level of 
expression in the airway epithelium and the known role of cadherins in cell adhesion and 
interaction. There is an increasing focus on the role of the airway epithelium in asthma. 
Structural or functional abnormalities in the epithelium may increase susceptibility to 
environmental stimuli, such as respiratory viruses, by exaggerating immune responses 
and structural changes in underlying tissues.99 Therefore, further insight on potential 
pathophysiological mechanisms of respiratory tract infections on long term lung func-
tion and asthma is needed.
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Current results of GWA studies explain only a minor part of the heritability of chronic 
obstructive respiratory diseases.50, 51, 100, 101 The effects of rare variants have been pro-
posed as an explanation for the “missing genetic variance”. The identification of func-
tional rare variants is best carried out by DNA sequencing, since most rare variants will 
either not have been seen before or have such low allele frequencies that they are not 
included in genotyping arrays.102 Current advances in inexpensive whole-genome and 
whole-exome sequencing and rare variants genotyping arrays will enable studies for 
the effects of rare variants. In adults, the environmental influence of e.g. tobacco smoke 
exposure on lung function may be more important than genetic factors or interact with 
genetic factors. Therefore, some phenotypes are particularly interesting to study in 
children since environmental exposures have been present for a relatively short period. 
Although the number of subjects available for GWA studies is increasing and genotyping 
techniques advance quickly, other options to identify common genetic variants should 
be considered. Within one locus, multiple common genetic variants are independently 
associated with the phenotype. These secondary signals can be found by conditioning 
on the identified variants. Also, as shown in this thesis, a more detailed definition of the 
asthmatic phenotype will benefit identification of genetic variants.
Genetics in general are unlikely to explain the quickly altering prevalence of asthma 
and COPD over the past decades55, 103, 104 Therefore, it is likely that changes in environ-
mental exposures in the last decades interact with susceptible genes, thereby affecting 
development and health.56 The identification of environmental exposures that lead to 
specific changes in gene regulation has just recently been started. Functional studies 
including identification of functional elements in DNA using gene expression analysis, 
protein-protein interaction or RNA-methods should use the candidate genes identified 
by GWA- and EWA-studies, and aim to identify the underlying biological mechanisms. 
We need to determine whether epigenetics are an important underlying mechanism of 
the associations of environmental exposures and genetic susceptibility with respiratory 
health, and whether DNA-methylation acts differently on gene expression at various 
stages in human development. Future birth cohort studies should track DNA-methyla-
tion over time, and ideally over multiple generations. This will provide critical informa-
tion about developmental phases in life which are most suitable to prevent adverse 
DNA-methylation patterns, or enables interventions to normalize DNA-methylation.105 
Given that DNA-methylation patterns are heritable, future research will provide a unique 
opportunity to not only predict and treat chronic obstructive respiratory diseases in the 
current generation, but also prevent it for generations to come.
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conclUsion
We identified fetal and infant growth patterns, adverse environmental exposures, and 
genetic and epigenetic factors that are associated with changes in lung function and 
risk of chronic obstructive respiratory diseases across the life course. Functional studies 
are needed to evaluate the associations of the identified risk factors on lung function 
and asthma in later life, and potential underlying epigenetic mechanisms need to be 
further explored in detail. Ultimately, by identification of early life exposures, genetic 
susceptibility and their interactions, therapeutic and preventive strategies focused on 
pregnant women and young children could be developed to improve lung develop-
ment in early life, which would benefit respiratory health across the life course.
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In this thesis, we examined the hypothesis that early growth and adverse environmental 
exposures in fetal life and infancy, in combination with genetic susceptibility, lead to 
structural and functional adaptations in early lung development, with subsequently 
lower lung function and higher risk of chronic obstructive respiratory diseases in later 
life. Furthermore, we explored epigenetic mechanisms as a potential pathway explain-
ing environmental and genetic factors that influence the development of lower lung 
function and risk of respiratory diseases. By identification of early life growth and envi-
ronmental exposures, genetic variants, and DNA-methylation as underlying mechanism, 
we improve the understanding of the origins of chronic obstructive respiratory diseases 
in childhood and adulthood. Furthermore, we might be able to develop new preventive 
strategies and therapeutic interventions for pregnant women and young children, aim-
ing at reducing the burden of later life chronic obstructive respiratory diseases.
In chapter 1, the background and rationale of the studies presented in this thesis are 
given. We also provide the aims of the performed studies and describe the outline of 
this thesis.
chapter 2 describes the associations of early growth characteristics with childhood 
lung function and asthma. In Chapter 2.1, we report that a younger gestational age, 
smaller size for gestational age and greater infant weight gain across the full ranges 
were associated with lower childhood lung function. Mediation analyses suggested that 
lower lung function explains 7% to 45% of the associations between early growth char-
acteristics and childhood asthma. In Chapter 2.2, we report that smaller weight growth 
in late fetal life and greater weight growth in early infancy was associated with lower 
lung function and an up to 1.3-fold increased risk of childhood asthma. The results of 
Chapters 2.1 and 2.2 support the hypothesis that changes in early growth characteristics 
lead to developmental adaptations of the lungs and airways, resulting in relatively small 
airways, and potential risk of childhood asthma. In Chapter 2.3, we show that a higher 
BMI was associated with higher respiratory resistance and increased risk of wheezing in 
school-age children. We also report that higher fat mass index was associated with higher 
respiratory resistance, and higher android/gynoid fat mass ratio and pre-peritoneal fat 
mass, a measure of visceral abdominal fat, with higher Fractional exhaled Nitric Oxide. 
These findings suggests that detailed body fat distribution measures might be better 
measures than BMI only to understand the obesity-asthma paradigm.
In conclusion, preterm birth, low birth weight, infant growth, obesity, and specific 
body fat distribution measures are associated with changes in lung function and risk of 
asthma in childhood, and could be used as potential targets for early prevention.
chapter 3 describes the associations of adverse environmental exposures with 
childhood lung function and asthma. In Chapter 3.1, we report that continued maternal 
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smoking during pregnancy was associated with increased risks of early and persistent 
wheezing and asthma, but not with Rint or FeNO in children aged 6 years. Gestational 
age and birth weight did not explain these associations. In Chapter 3.2, we show that 
folic acid supplement use during pregnancy was associated with lower lung function 
measures, but only among mothers carrying variants of the MTHFR-C677T gene. A higher 
vitamin B12 level at birth was associated with a lower FEV1 and FVC among children car-
rying MTHFR-C677T wildtype. In Chapter 3.3, we show that a shorter duration and less 
exclusive breastfeeding was associated with an increased risk of wheezing in early life, 
and that a breastfeeding duration less than 2 months was associated with a 2.2-fold 
increased risk of asthma up to age 6 years.
In conclusion, maternal smoking during pregnancy, the use of folic acid supplements 
in pregnancy in mothers carrying the MTHFR-C677T variants, and breastfeeding are sug-
gested to affect lung function and the risk of asthma in childhood.
chapter 4 describes the identification of genetic loci related to childhood lung func-
tion and asthma, and of epigenetic loci related to an adverse environmental exposures 
and chronic obstructive respiratory disease outcomes across the life course. In Chapter 
4.1, we report the identification a new asthma-susceptibility gene, CDHR3. Variants in 
CDHR3 may increase the risk of severe asthma exacerbations by altering the integrity 
of airway epithelium, thus promoting entry and replication of respiratory viruses. In 
Chapter 4.2, we show that genetic variants associated with adult lung function were also 
associated with childhood lung function, but not with childhood asthma. This suggests 
that genetic variants associated with adult lung function already affect lung function 
in early life. In Chapter 4.3, results of our meta-analysis showed an association between 
maternal plasma folate levels during pregnancy with differential methylation of 443 
CpGs located near 320 genes across the human genome. These findings provide new 
insights in the impact of maternal folate levels during pregnancy on the developing 
epigenome of the newborn. We report the identification of 59 differentially methylated 
regions (DMRs) associated with childhood lung function in Chapter 4.4. Multiple of these 
DMRs were also associated with childhood asthma, adolescent and adult lung function, 
and COPD. This study supports the hypothesis that DNA-methylation at birth has impact 
on gene expression and subsequent respiratory development, predisposing individuals 
for obstructive airway diseases.
In conclusion, genetic variants affect lung function and respiratory health from early 
life onwards, maternal folate levels in pregnancy have a genome-wide impact on neona-
tal DNA-methylation, and neonatal DNA-methylation has impact on lung function and 
respiratory health across the life course.
Finally, in chapter 5 we provide a general overview and interpretation of the results of 
the studies presented in this thesis. Furthermore, methodological issues of the studies, 
causality of the observed associations, and directions for future research are discussed.
Samenvatting
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In dit proefschrift hebben we de hypothese onderzocht dat groei in het vroege leven 
en blootstelling aan nadelige omgevingsfactoren tijdens de zwangerschap en op de 
vroege kindertijd, in combinatie met genetische predispositie, leiden tot een lagere 
longfunctie en een hoger risico op chronisch obstructieve respiratoire aandoeningen 
op oudere leeftijd. Daarnaast onderzochten we epigenetische mechanismen als een 
mogelijke verklaring voor de interacties tussen omgevingsfactoren en genetische 
predispositie. Door het identificeren van nadelige blootstellingen in het vroege leven, 
genetische predispositie en DNA-methylatie als mogelijk onderliggend mechanisme, 
kunnen nieuwe preventie-strategieën en therapeutische interventies worden ontwik-
keld die toegepast kunnen worden tijdens de zwangerschap en op de kinderleeftijd. 
Dit kan uiteindelijk resulteren in een betere preventie en behandeling van chronisch 
obstructief longlijden op de oudere leeftijd.
In Hoofdstuk 1 bespreken we de achtergrond en rationale van de studies die worden 
gepresenteerd in dit proefschrift. Ook geven we in dit hoofdstuk een overzicht van de 
onderzoeksdoelen van de verrichte studies, en wordt de indeling van dit proefschrift 
toegelicht.
Hoofdstuk 2 beschrijft de associaties van groei in het vroege leven met longfunctie 
en astma op de kinderleeftijd. In Hoofdstuk 2.1 tonen we aan dat een kortere zwanger-
schapsduur, een lager geboortegewicht voor de zwangerschapsduur, en een grotere 
gewichtstoename in het eerste levensjaar geassocieerd zijn met een lagere longfunctie 
bij kinderen. Een mediatie-analyse toonde dat een lagere longfunctie 7% tot 45% van 
de associaties tussen vroege groei en astma op de kinderleeftijd verklaard. In Hoofstuk 
2.2 laten we zien dat een kleinere gewichtstoename tijdens de foetale periode, en een 
grotere gewichtstoename op de vroege kinderleeftijd zijn geassocieerd met een lagere 
longfunctie en een 1.3 maal verhoogd risico op astma. De resultaten van Hoofdstukken 
2.1 en 2.2 ondersteunen de hypothese dat veranderingen in vroege groei leiden tot aan-
passingen in de ontwikkeling van de longen en luchtwegen, wat leidt tot relatief kleine 
luchtwegen, en een verhoogd risico op astma. In Hoofstuk 2.3 tonen we aan dat een 
hogere BMI is geassocieerd met een hogere luchtwegweerstand en een hogere kans op 
een piepende ademhaling bij kinderen op de schoolgaande leeftijd. Ook tonen we aan 
dat een grotere vet massa is geassocieerd met een hogere luchtwegweerstand, en een 
hogere androïde/gynoide ratio en meer preperitoneaal vet, een maat van visceraal vet, 
met een hoger stikstofoxide in de uitademingslucht. Deze resultaten suggereren dat 
gedetailleerde metingen van lichaamsvet mogelijk betere maten zijn dan BMI om de 
complexe relatie tussen obesitas en astma te verklaren.
Samenvattend tonen wij dat vroeggeboorte, een laag geboortegewicht, obesitas, en 
vetmassa’s op specifieke locaties in het lichaam zijn gerelateerd aan veranderingen in 
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longfunctie en het risico op astma op de kinderleeftijd. Deze factoren vormen dan ook 
potentiële aangrijpingspunten voor de preventie van astma.
In Hoofdstuk 3 beschrijven we de associaties tussen blootstellingen in het vroege le-
ven met longfunctie en astma in kinderen. In Hoofdstuk 3.1 tonen we aan dat roken van 
de moeder tijdens de gehele zwangerschap is geassocieerd met een verhoogd risico op 
een piepende ademhaling en astma, maar niet met luchtwegweerstand of stikstofoxide 
in de uitademingslucht, bij 6-jarige kinderen. Deze associaties werden niet verklaard 
door de zwangerschapsduur of geboortegewicht. In Hoofdstuk 3.2 beschrijven we dat 
het gebruik van foliumzuursupplementen tijdens de zwangerschap is geassocieerd met 
lagere longfunctie bij kinderen, maar alleen als moeder drager is van variant C677T in het 
MTHFR -gen. Een hogere bloedwaarde van vitamine B12 is geassocieerd met een lagere 
longfunctie bij kinderen die drager waren van het reguliere MTHFR-gen. In Hoofdstuk 
3.3 tonen we aan dat een kortere periode van borstvoeding en het eerder starten van 
kunstvoeding is geassocieerd met een verhoogde kans op een piepende ademhaling 
tot de leeftijd van 3 jaar, en dat een borstvoedingsduur korter dan 2 maanden is geas-
socieerd met een 2.2 maal verhoogd risico op astma tot de leeftijd van 6 jaar.
Samenvattend tonen wij in deze studies aan dat roken van de moeder tijdens de 
zwangerschap, het gebruik van foliumzuursupplementen tijdens de zwangerschap 
als moeder drager is van variant C677T in het MTHFR-gen, en borstvoedingspatronen 
geassocieerd zijn met veranderingen in longfunctie en het risico op astma op de kin-
derleeftijd.
Hoofdstuk 4 beschrijft de identificatie van een gen geassocieerd met long functie 
en astma op de kinderleeftijd, en van locaties in het DNA waar epigenetische factoren 
gerelateerd zijn aan omgevingsblootstellingen en chronisch obstructieve respiratoire 
aandoeningen gedurende het leven. In hoofdstuk 4.1 beschrijven we de identificatie van 
een nieuw gen, CDHR3, dat geassocieerd is met astma. Varianten in het CDHR3-gen ge-
ven veranderingen in de integriteit van de luchtwegepitheelcellen, waardoor deze meer 
vatbaar worden voor virale infecties, en de kans op ernstige astma-aanvallen mogelijk 
verhoogd. In hoofdstuk 4.2 tonen we aan dat genen die geassocieerd zijn met longfunc-
tie in volwassenen ook geassocieerd zijn met longfunctie van kinderen. Dit suggereert 
dat deze genen al op de kinderleeftijd invloed hebben op longfunctie. In hoofdstuk 4.3 
tonen de resultaten van een meta-analyse de associaties van foliumzuurwaarden van de 
moeder tijdens de zwangerschap met verschillen in DNA-methylatie van het kind bij de 
geboorte, namelijk in 443 CpGs die gelokaliseerd zijn bij 320 verschillende menselijke 
genen. Deze resultaten leveren nieuw inzicht in de invloed van foliumzuurwaarden 
tijdens de zwangerschap op het ontwikkelende epigenoom van het kind. In Hoofdstuk 
4.4.beschrijven we de identificatie van 59 regio’s waarin verschillen in DNA-methylatie 
bij de geboorte zijn geassocieerd met longfunctie op de kinderleeftijd. Meerdere van 
deze regio’s waren ook geassocieerd met astma op de kinderleeftijd, longfunctie op de 
Samenvatting
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adolescente en volwassen leeftijd, en met COPD op de volwassen leeftijd. Dit onderzoek 
ondersteunt de hypothese dat DNA-methylatie patronen bij de geboorte invloed heb-
ben op gen-expressie en daaropvolgende longontwikkeling, die de kans op chronische 
obstructieve respiratoire aandoeningen vergroot.
Samenvattend hebben wij aangetoond dat genetische varianten vanaf het vroege 
leven invloed hebben op longfunctie en de kans op respiratoire aandoeningen, dat 
foliumzuurwaarden tijdens de zwangerschap invloed hebben op DNA-methylatie ver-
anderingen van het kind bij geboorte, en dat DNA-methylatie veranderingen van het 
kind bij de geboorte geassocieerd zijn met longfunctie en respiratoire aandoeningen 
gedurende het leven.
In Hoofdstuk 5 geven een samenvatting en interpretatie van de bevindingen gerap-
porteerd in dit proefschrift. Ook bespreken we methodologische aspecten, causale 
verbanden van de gevonden associaties, en geven we suggesties voor toekomstig on-
derzoek.
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moeite heeft willen nemen plaats te nemen in de kleine commissie.  Ook dank aan prof. 
dr. de Hoog, prof. dr. Postma, prof. dr. steegers en dr. turner, de leden van de grote 
354
Chapter 7
commissie, voor de bereidheid met mij van gedachten te willen wisselen tijdens mijn 
verdediging.
Zoe en willem, mijn paranimfen. Dank dat jullie bij mijn verdediging naast me willen 
staan. Zoe, heel veel dank voor alle gezelligheid en je zieke gevoel voor humor. Je 
bent in staat om elke werkdag voor de eerste slok koffie al meerdere vieze verhalen 
te vertellen. En ook om mijn vertrouwen zo te beschamen dat ik na een vakantie 4000 
met water gevulde bekertjes in mijn huis vind. Maar naast de gezelligheid en plagerijen 
hebben we ook serieuze gesprekken kunnen voeren, en gaf je me na veel zeuren de eer 
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etentjes ben ik jullie echter ook steeds meer als goeie vrienden van mezelf gaan beschou-
wen. Dank voor jullie vriendschap, interesse en kookkunsten. kristin, vakantiemaatje. 
We hebben samen een aantal hele mooie reizen mogen maken. Je was zelfs gek genoeg 
om me te komen opzoeken in Australië. Ik hoop ooit nog een keer die walvishaai te 
kunnen spotten met je!  kitty en robin, wat zijn jullie toch twee geweldige vrienden! 
We hebben samen de Gavia en de Stelvio beklommen, en Lotte en ik hebben genoten 
van jullie bruiloft. Nieuw Zeeland ligt helaas wel wat verder weg dan Leidschendam, 
maar de afstand Zuid-Amerika – Australië is ook nooit een probleem geweest voor ons. 
De voetbaltafel-mannen; ronald, ryan, Philip, gerard, tim, gijs, strahinja. Wat heb ik 
een geweldige tijd met jullie gehad, met het weekend in Servië als absoluut hoogtepunt. 
We zijn een hechte groep geworden, en ik hoop dat er nog heel veel rib-nights volgen! 
ronald, of het nu met de eerste verbouwing van mijn huis was, de fiets-ergometer, of 
de meest duurzame voetbaltafel, je staat altijd klaar om te helpen. Dank! ryan, na al die 
jaren vertik ik het je nu nog in het Engels aan te spreken. Ik heb heel veel respect voor hoe 
je het met ons “knuckleheads” hebt uitgehouden, en zelfs hebt besloten om nog langer 
in Nederland te blijven. Laten we nog heel veel Fantasy Football competities spelen; 
misschien leer je het ooit nog wel een keer. Philip, je hebt volgens mij nog nooit een 
vrijmibo overgeslagen, en nog nooit een potje aan de voetbaltafel gewonnen. Je hebt 
heel indrukwekkende analyses verricht, en ik ben benieuwd naar je resultaten. gerard, 
onze superman en mister gadget. Ik begrijp nog steeds niet hoe je in dat kleine tasje 
alle kleding voor Servië kon meenemen. Ik hoop dat je de eervolle titel “pussy for life”, 
die je eerlijk hebt gewonnen aan de voetbaltafel, met trots zal blijven dragen. Inverse 
U-shaped tim. Ik ga het sparren, je eeuwig kritische blik en cynisme missen op kantoor. 
En vooral je reacties op weer een schuin balletje dat ook volgens je eigen regels telde. 
gijs, wat was het mooi dat jij in -20°C in Philadelphia zat, en ik in 40°C in Perth. En dat je 
de Vredesloop hebt gedaan op een krat bier en een kapsalon. Dank voor je gezelligheid 
en altijd sportieve reacties op alle grappen die we met je hebben uitgehaald. De baby-
shower vond ik een hoogtepunt! strahinja, wat heb ik een respect voor hoe snel jij je 
hebt aangepast aan Nederland. Nadat je in je eerste jaar nog mijn wasmachine sloopte 
en mijn handdoeken meenam, was je twee jaar later eigenaar van je eigen Servische 
sportschool inclusief zwembad en sauna. En zelfs de flauwe Servië-grappen ben je gaan 
waarderen. Het is heel mooi om te zien hoe je je plek in Nederland hebt gevonden. Ik 
hoop ooit nog een keer bij je in de tandartsstoel te durven liggen.    
Lieve John, lienet, Anne en Pieter, dank voor jullie oprechte belangstelling, humor, 
zorg en gezelligheid, en de geweldige bootreisjes en skivakanties. Ik ben enorm blij met 
jullie als schoonfamilie!  
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Lieve Jolinde, gert Jan, chantal, erik, diandra, niels, daphne en renske. Mijn broers 
en (schoon)zussen, allemaal met een onbegrensd relativeringsvermogen en een (boeren)
nuchterheid. Mijn promotie-periode werd gezien als stage, wonen in Rotterdam was bij 
voorbaat een grove fout en mijn eerste publicatie in Nature Genetics was makkelijker te 
onthouden als dat stukje in de Naturisten Gids. Ik heb altijd op jullie kunnen bouwen, en 
jullie staan klaar op elk moment dat nodig is. We vormen een bijzonder stel met z’n allen, 
en ik ben blij dat ik daar deel van uit maak. 
Lieve pa en ma. Heel veel dank voor jullie oneindige vertrouwen, onvoorwaardelijke 
steun en grenzeloze hulp. Jullie laten me mijn eigen richting bepalen, maar staan altijd 
en overal als vangnet achter mij. De basis die jullie me hebben meegegeven, met de 
nodige duwtjes in de rug op latere leeftijd, hebben er toe geleid dat ik hier vandaag kan 
staan.
Lieve lotte, jij bent halverwege dit proefschrift in mijn leven gekomen, en bent sinds-
dien mijn hulp, steun, luisterend oor en mede-avonturier geweest. Je zal dat ook zijn bij 
alles wat nog komen gaat. Ik kijk uit naar wat de toekomst ons brengen zal! Ik hou van je!
